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A b s t r a c t
Background
Audits o f  service provision for people with epilepsy in the UK have shown care to be 
substandard. People with epilepsy may die prematurely, and substandard care may contribute 
to this.
Methods
The Chiltem  audit is a records audit o f people taking anti-epileptic drugs in 12 general 
practices in Buckingham shire. The National Sentinel Clinical Audit o f Epilepsy-related 
death is an audit o f  deaths certified as being epilepsy-related in one year in the UK; the 
prim ary and specialist care sections were further explored in this thesis. In both audits 
docum ented care w as com pared with published standards.
Data from an incident cohort o f  people with epilepsy were examined to investigate which 
details predicted inclusion o f  epilepsy on the death certificate. The standardised m ortality 
ratio (SM R) for epilepsy in England and W ales was calculated from death certificates 
including epilepsy. A re-analysis o f  a previously published meta-analysis o f  suicide in 
epilepsy was perform ed.
Results
The prim ary care audits found evidence o f recent epilepsy review in fewer than two thirds o f 
people with epilepsy. These audits suffered from lack o f evidence in the clinical records.
The overall standard o f  specialist care was adequate in under half, but there was no evidence 
o f  different standards o f  care in people with and without learning disability.
Epilepsy is indicated in seven percent o f death certificates o f people with epilepsy, 
confirm ing that they do not provide appropriate case ascertainment for studying death in 
people w ith epilepsy. The investigation o f suicide in England and W ales shows that they are 
sim ilarly unsuitable for investigating deaths from suicide in people with epilepsy. The SMR 
for suicide in epilepsy is significantly increased.
Conclusion
Poor record keeping hampers assessment o f  care by audit. Epilepsy care may often be 
substandard, but death as outcome is far removed from delivery o f  care; other outcomes are 
considered.
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P e r s o n a l  c o n t r ib u t io n
The inspiration behind most of the work in this audit was Prof Ley Sander
1. The Chiltem audit
The audit was designed by Mrs Annette Russell, Prof Ley Sander and Prof John 
Duncan. The data were extracted from the primary case records by Annette Russell, 
Anita March and Alison Nixon. The original data entry into Microsoft Excel was 
designed by the author and performed by Annette Russell. Further data entry and 
checking were performed by the author. The author performed all the analyses and is 
responsible for writing up the study.
2. The National Sentinel Clinical Audit of epilepsy-related death
The National Sentinel Clinical Audit of epilepsy-related death was instigated by the 
charity Epilepsy Bereaved and the Royal Colleges. Audit record development was by 
the steering committee o f the project. Data extraction was performed by five audit 
officers who also entered the data into Microsoft Excel.
The author researched the standards against which to assess care. The author prepared 
summaries o f the primary, specialist and pathology audit records for the specialist care 
panel and recorded the decisions. She checked all the data entry and designed and 
performed the analysis for the adult specialist care section of the report and for both 
sections presented in this thesis.
3. Use of death certificates as case ascertainment for epilepsy
The National General Practice Study of Epilepsy was set up over 20 years ago. The 
author and Dr Thanasis Gaitatzis hand searched the records for details of death 
certificates and the author hand searched them for all clinical details and for the details 
of the physician who certified death. The author designed and performed the analysis, 
with advice from Dr Tony Johnson of the MRC Biostatistics Unit in Cambridge. The 
author was responsible for the publication of this study.
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4. Suicide in England and Wales
This study was designed by the author, Prof Ley Sander and Dr Thanasis Gaitatzis. 
The author and Dr Gaitatzis independently reviewed the death certificates in which 
epilepsy was recorded and sought deaths by suicide. Dr Gaitatzis calculated the 
Standardised Mortality Ratios (SMRs). This calculation was checked by the author 
who also calculated the confidence intervals. The author and Dr Gaitatzis were 
responsible for writing up the study.
5. Meta-analysis o f suicide in epilepsy
The author was responsible for all aspects of this study. She and Dr Andrew Bell 
independently reviewed all the studies in the original paper to ascertain the number of 
suicides and patient-years at risk. The author extracted the national rates of suicides 
from the relevant data sets and calculated the SMRs. She performed all the analyses 
with advice from Dr Tony Johnson and is responsible for writing up the study.
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In t r o d u c t io n
This thesis concerns the provision o f services for people with epilepsy in the UK and 
its relationship to standards of care and the implications, particularly for mortality. It 
starts by providing a snapshot o f the provision of services for people with epilepsy in 
the world and then reviews services for people with epilepsy in the United Kingdom 
(UK).
Epilepsy is one o f the most common serious neurological conditions, affecting 
between five and ten people per thousand. It can be defined as “the occurrence of 
transient paroxysms o f excessive or uncontrolled discharges of neurons, which may be 
caused by a number of different aetiologies, leading to epileptic seizures” (Sander and 
Hart, 1997). There are many causes of epilepsy, and in many ways seizures can be 
regarded as a symptom of many diseases rather than as a single disease (Sander and 
Hart, 1997). Epileptic seizures represent the clinical manifestations that result from 
excessive, synchronous, abnormal firing patterns of cerebral neurons.
People with epilepsy have increased morbidity from other causes (Gaitatzis et al., 
2004a), as well as an increase in mortality rate. Substandard care could contribute to 
this. Work carried out for this thesis is an initial assessment to look into these 
concerns. It comprises an assessment of mortality, and of some of the methodological 
problems in the study o f this. It looks into the standard of care in two ways; a national 
audit carried out to determine the role of care in people who died from a cause related 
to epilepsy and a thorough audit of the provision of services in 12 general practices.
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S e c t io n  1. R e v ie w  o f  t h e  l it e r a t u r e
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1.1. P r o v i s i o n  o f  c l i n i c a l  s e r v i c e s  f o r  p e o p l e  w i t h  e p i l e p s y  a r o u n d  t h e
WORLD -  A SNAPSHOT OF CARE
People’s expectations for health vary from country to country and from culture to 
culture (Gumnit, 1997a). While expectations may indeed vary, this may be related far 
more to lack o f health facilities than to the basic desire for good health. Unless 
knowledge o f facilities for epilepsy care and accurate figures for both morbidity and 
mortality around the world are available, it will not be possible to ascertain how the two 
relate. In terms o f health provision in general, studies are beginning to evaluate the 
impact o f reforms on health. A discussion paper from the Global Programme on 
Evidence for Health Policy (Evans et al., 2006) compared the efficiency of national 
health systems delivery. Using total health expenditure per capita as a surrogate for 
physical inputs to the health system, and Disability Adjusted Life Expectancy (DALE) 
as outcome, the authors established the expected positive correlation between the two 
(ie as expenditure on health increases, so does the DALE). Income per capita is highly 
collinear with health expenditure per capita (Evans et al., 2006); thus it is not possible to 
consider the impact o f services for health independently of the financial resources of the 
country and the way in which they are allocated.
In 2000 almost 200 nations committed, in the United Nations Millennium Declaration, 
to rid the human race o f want. To help track progress, a set of time-bound and 
measurable goals and targets was established- the Millennium Development Goals. The 
first of these is to halve, between 1990 and 2015, the proportion of people whose 
income is less than one US dollar (US$) a day (United Nations Statistics Division,
2005).
In resource-poor countries, much of the focus of healthcare is on the prevention, 
management and control of communicable diseases (Gourie-Devi et al., 2003).
This chapter provides a snapshot overview of services for people with epilepsy in a 
small number o f countries around the world. Countries were not chosen at random, but 
were selected to provide a broad spectrum in terms of geographical distribution, as well
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as population size and wealth. Wherever possible bona fide  texts have been used, from 
government sources, the World Health Organisation (WHO) and the International 
League Against Epilepsy (ILAE). For many countries, however, it was extremely 
difficult to find such information. Thus, occasionally, less reliable sources have been 
used, such as newspaper articles or web-sites biased towards a particular viewpoint (for 
example, the ‘50 years is enough’ campaign (US Network for global economic justice, 
2005)). The information provided is as up-to-date as possible; nevertheless, some older 
sources have been used where more recent material is not available.
Countries are grouped according to the WHO regions. For most countries the infant 
mortality rate (IMR) and the life expectancy at birth are provided, usually from data 
from the US Central Intelligence Agency (CIA, 2006). These are given in an attempt to 
assess the general state of health of the population. It should be noted that in some 
countries, particularly those in Africa, life expectancy has been reduced by up to 20 
years by the Human Immunodeficiency Virus (HIV) (Mathers et al., 2001). For the less 
developed countries the Human Development Index (HDI) rank has also been given. 
The HDI is a composite index of human well-being, and is calculated as a function of 
life expectancy at birth, adult literacy rate (and amount of schooling) and per capita 
gross domestic product (GDP) (United Nations Development Programme, 2005).
The section on Africa includes some information on the Bamako Initiative, as this is 
central to some o f the problems and proposed solutions in Africa.
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1.1.1. Africa
In most African countries, fees are charged for health services, reducing accessibility of 
services for the poor. Even in systems o f ‘free’ public healthcare, it is rarely free in 
reality. Additionally, the distribution of services is unequal in Africa, favouring urban 
areas. Many African countries are very poor; the percentage of the population of 
Lesotho described as indigent in 1985 was 50% in cities and 55% in the rural areas 
(World Bank 1994, quoted in Stierle et al., 1999). Figures show that the percentage 
living on or below one US$ per day, when most recently estimated (between 1990 and 
2003) was 11% in South Africa, 23% in Kenya, 26% in Senegal, 36% in Lesotho, 70% 
in Nigeria, (United Nations Development Programme, 2005) and 69% in Uganda 
(World Bank, 1999). Recently the percentage of people living in absolute poverty in 
Sub-Saharan Africa has risen from 42% to 47%, while in the world as a whole the 
percentage has dropped. O f the countries discussed here, only Uganda and South Africa 
are on track to halve the number o f people living on less than one USS per day by 2015 
(United Nations Industrial Development Organisation, 2004).
Some African countries have introduced measures to protect the poor from charges for 
health services. In Senegal, indigent people are exempt from some fees, and this is 
administered locally. In Lesotho, there is a national policy to exempt the ‘poor without 
means’ although, in practice, few are exempt. Nigeria and Uganda each have various 
policies throughout the country, but Burkina Faso has no such system (Stierle et al., 
1999).
Another mechanism which can improve access to healthcare by vulnerable groups is 
price differentiation, based on demographic, geographical or socio-economic factors, 
health status, or a mixture. Subsidies are recommended for various health-related 
activities, but in many cases funds intended for subsidies are, in fact, spent on urban 
health facilities providing secondary and tertiary care and mainly benefiting the richer 
segments o f society (Stierle et al., 1999).
Some countries have introduced prepayment and health insurance to overcome problems 
in financing healthcare. In general they require the existence of some form of individual
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or collective saving capacity, mutual confidence between members, and the presence of 
functioning and credible healthcare services. One advantage of these schemes is that 
payment does not occur at the time of need. They are, however, difficult to design and 
implement in low-income countries and rural areas. Additionally, indigent people may 
not be able to afford to pay at all, and may miss out on the benefits. Excluding public 
servants (whose health services may be provided by the state), under five percent of the 
population o f Burkina Faso was covered by such insurances in 1989 (Stierle et al.,
1999).
The exacerbation in the 1980s of many o f the problems of healthcare in Africa has been 
blamed on the World Bank (Samba, 2004). A combination of natural and manmade 
factors, together with general worldwide economic depression, left many African 
countries with increasing debts. These countries turned for loans to the World Bank and 
the International Monetary Fund, who, in return, demanded stringent conditions, 
including cuts to health, education and housing programmes. Before this time many 
African countries provided medical services and essential drugs free o f charge, but by 
the end o f the 1990s, the health systems in most sub-Saharan countries had virtually 
collapsed (Samba, 2004). A different view is that user-fees were introduced in the 
1980s as an alternative way of financing healthcare on the assumption that they would 
extend the coverage o f services and promote the appropriate use of care (International 
Labour Organisation, 2000).
1.1.1.1. The Bamako Initiative
In September 1987, at a meeting in Bamako, Mali, the United Nations Children’s Fund 
proposed a scheme to help solve the drug supply and maternal and child health problems 
of sub-Saharan Africa. This involved supplying patients with essential drugs at two to 
three times the cost price, and using the funds so raised to improve public health 
services (Anonymous, 1988). The African Health Ministers agreed with the proposal, 
which is based on eight principles:
• Improving primary healthcare services for all
• Decentralising the management of primary health services to district level
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• Decentralising the management o f locally collected patient fees to community 
level
• Ensuring consistent fees are charged at all levels for health services -  whether in 
hospitals, clinics or health centres
• High commitment from governments to maintain and, if possible, expand 
primary healthcare services
• National policies on essential drugs should be complementary to primary 
healthcare
• Ensuring the poorest have access to primary healthcare
• Monitoring clear objectives for curative health services (McPake et al, quoted in 
Tearfund International learning zone, 2005).
Many people had misgivings about the initiative (Chabot, 1988; Gamer, 1989), and 
countries varied considerably in the ways they tried to put these principles into action 
(McPake et al, quoted in Tearfund International learning zone, 2005). A study 
published in 2000 suggested that, although there were initial gains in some countries, 
these were not sustained over time. Additionally, none of the countries studied had 
effective exemption mechanisms to protect the poorest from the burden of payment 
(Gilson et al., 2000). Others, however, see the advantages o f the Bamako Initiative, 
seeing it as an example o f ‘user-fees that work’ (Vandemooretele et al., 1997). For 
example, phenobarbital and phenytoin are available in most healthcare establishments in 
Africa via the Bamako Initiative drug supply system (Stierle et al., 1999).
1.1.1.2. Burkina Faso
Burkina Faso (population 13 million) is one of the world’s poorest countries, with 
literacy rates o f less than one in three males and one in eight females. Education is free, 
but not compulsory, and less than one third of children receive basic education (Family 
Heath & AIDS, 1994). Life expectancy is 48 years, and the IMR is 92 per thousand live 
births (CIA, 2006).
Healthcare is organised into several tiers. The primary health posts, staffed by 
paramedical workers, provide small communities with essential treatment (Family
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Heath & AIDS, 1994; Laafi, 2000). The second level, the centre of health and social 
promotion, treats more severe cases, and care is provided by nurses. Medical centres 
cater for small towns, usually having a physician and often an attached operating theatre. 
Hospitals are found in larger towns.
In theory, patients are referred to the next level according to the severity of their 
condition (Laafi, 2000). In practice, however, very few communities have a working 
primary health post, as these require the voluntary work of community health workers, 
and essential drugs are often not available. The nearest medical centre is often far away, 
and costs prohibitive.
Burkina Faso has only one neurologist (WHO, 2001a), but essential anti-epileptic drugs 
(AEDs) are available, as is Computerised Tomographic (CT) scanning. Primary care 
workers are responsible for follow-up and for education (Dua, personal 
communication). Many people with epilepsy are treated by traditional healers, although 
phenobarbital costs less than most traditional treatments (Millogo et al., 2004).
1.1.1.3. Kenya
Kenya (population 33 million) has a life expectancy of 47 years, and IMR of 61 per 
thousand live births (CIA, 2006). Since independence in 1963, Kenya has attempted to 
promote coverage and access to healthcare by the population (Owino, 1997). Non- 
Govemment Organisations (NGOs), mostly located in rural and underserved areas, 
provide services, helped by partial government grants, donations and user-fees. Private 
practitioners provide treatment to those who can afford it, and local government 
provides primary and preventative healthcare. There is a pyramid system of care, with 
dispensaries and health posts at the bottom o f the pyramid, through health centres and 
subdistrict hospitals, eventually to Kenyatta National Hospital in Nairobi at the top 
(Owino, 1997).
Initially the government committed itself to free health services and, in 1964, abolished 
user-fees. Many services were free to unemployed people; employers met the expenses 
of those in employment. This proved unsustainable, however, and in 1989 cost-sharing
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was introduced. This was supposed to generate additional revenue, strengthen the 
referral system and improve equity and access to health (Institute of Policy Analysis and 
Research, 2003). The scheme included a system of waivers and exceptions to cushion 
the poor and other vulnerable groups. The cost-sharing programme was decentralised, 
however, and this led to an arbitrary and uncoordinated fee structure (Owino W et al., 
2000).
The National Hospital Insurance Fund (NHIF) was established in 1968. Contributions 
were compulsory for those earning above a certain limit, and aimed to assist workers to 
gain access to private hospitals and to relieve congestion in public hospitals (Owino,
1997). A study in 2005 found that the fund covered only 20-30% of the population, and 
that it was inaccessible to many (Institute of Policy Analysis and Research, 2005). 
Although the monthly premiums are low, many are not able to join NHIF due to high 
poverty levels.
Studies in Kenya have shown that patients with convulsive epilepsy can be identified 
and treated by primary healthcare workers, and that over half can be rendered seizure- 
free with the use o f AEDs (Feksi et al., 1991). An NGO, the Kenya Association for the 
Welfare o f Epileptics (KAWE) was established in 1982. Its work includes providing 
clinics, but also publicity to educate the population that epilepsy is a treatable, medical 
condition (Dekker, 2002). It depends on local and international donations (Dua, 
personal communication). Despite this, in 2002 it was reported that only one percent of 
people with epilepsy in Kenya were receiving medical care (Epilepsy Action, 2002). 
Basic AEDs are available, as are electroencephalography (EEG) and Magnetic 
Resonance Imaging (MRI). Primary care workers are involved with diagnosis, 
treatment and follow-up, maintenance of AED supply and education (Dua, personal 
communication).
1.1.1.4. Lesotho
Almost all o f the two million people in Lesotho are poor (Wiskin and Torbe, 2001).
The IMR is 88 per thousand live births, and life expectancy is only 34 years (CIA,
2006).
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The country is divided into nine different health service areas, each covered by a 
hospital, most of which have satellite clinics. There is one national referral hospital to 
which patients are transferred if necessary (Wiskin and Torbe, 2001). Further transfer to 
hospitals in South Africa is sometimes necessary. At a local level, health centres have a 
catchment population of 6,000 to 10,000 people (World Bank, 1995). The most basic 
level o f services is provided at the village level, through a network of village health 
workers. Traditional practitioners are the most common medical practitioners in 
Lesotho, mostly providing herbal remedies. Flying Doctors serve remote clinics (World 
Bank, 1995).
Poor people do not have the same access to basic services and good healthcare as those 
better off, and the life expectancy in the richer urban areas is almost seven years longer 
than in rural areas, with a similar inequity in the infant mortality rate. This may be, in 
part, a result o f the policy to enforce user-fees (World Bank, 1995).
There is little information available on the care for people with epilepsy in Lesotho. In 
2002 the country received a loan and grant to finance support to the health sector 
reforms programme. Part of this was intended to strengthen the mental care system, and 
to create standards o f care and develop clinical protocols for epilepsy (Strategis, 2002). 
There is one neurologist in Lesotho, and the basic AEDs are available at primary care 
level (WHO, 2001a). Primary care workers are responsible for the initial detection of 
symptoms, o f encouraging the patient to attend the clinic, and then for follow-up and 
education (Dua, personal communication).
1.1.1.5. Nigeria
Nigeria has a large population (128 million), with life expectancy of only 46 years, and a 
very high IMR o f 98 per thousand live births (CIA, 2006). Primary healthcare in 
villages is provided by the village health service (manned by volunteer village health 
workers) and district health centres (manned by community health officers) 
(Adamolekun, 1997). Recently new health centres have been built, and a basic package 
of minimum health services has been established (Management Sciences for Health,
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2002). The National Primary Health Care Development Agency, formed in 1992, is 
responsible for the delivery of primary healthcare services and the construction of the 
new health centres (Adamolekun, 1997).
Many public health institutions lack basic facilities such as medicines and dressings.
The population per physician ratio is better than many in Africa, although the spread is 
not uniform throughout the country. In 1995, there were as many Nigerian hospital 
specialists practising in the US as in Nigeria (Africa Recovery, 1999).
Traditional medicine is the indigenous healthcare system in Nigeria. People with 
epilepsy have a strong preference for traditional herbal medicine over conventional 
medicine, particularly in rural areas. In a survey, of 101 patients with epilepsy, all had 
been treated with herbal remedies while only four were receiving conventional AEDs. 
The village surveyed had good primary healthcare facilities. Most patients with epilepsy 
seen for the first time in a conventional hospital facility have spent up to five years in 
traditional therapy (Adamolekun, 1997).
People with epilepsy must be referred to health centres and thence to the general 
hospitals, as the health centres may only use paraldehyde or diazepam as treatment. The 
hospitals usually have a full range of AEDs available, as well as EEG and CT scanning 
(Adamolekun, 1997).
1.1.1.6. Senegal
Senegal has a population of 11 million, an IMR of 54 per thousand live births, and a life 
expectancy o f 58 years (CIA, 2006). In Senegal, micro-health organisations, which are 
non-profit, mutual, community-based health insurance schemes, have been formed. 
Several such schemes exist in and around Dakar (Organisation for Economic Co­
operation and Development, 2001). Here, the health insurance organisations cooperate 
closely with the local regional hospital. The health insurance organisations pay for 
100% of hospital costs for two weeks, while the hospital offers the organisations and 
their members the services at reduced cost (Novartis Foundation, 2004). Each scheme 
has around 500 members, but does not include all members of the community; in
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particular, the very poorest still cannot afford to pay regular membership contributions. 
The schemes do not provide primary healthcare (Organisation for Economic Co­
operation and Development, 2001).
Senegal has a chapter o f the ILAE, and has been the site of a WHO epilepsy 
demonstration project. This found the prevalence of epilepsy to be 14 per thousand, 
with only 23% either not treated or treated only by traditional healers (Ndoye et al.,
2005). The authors report that the prevalence appears to have increased since a similar 
study in 1989 and postulate that this increase may be accounted for by population 
changes due to the establishment in nearby Dakar of the Senegalese League against 
Epilepsy, which has provided people with information about epilepsy, and attracted 
people with epilepsy from rural areas to the suburbs of Dakar. Carbamazepine, 
phenobarbital and sodium valproate are generally available at primary healthcare level 
in Senegal (WHO, 2001a). There are epilepsy specialists in Dakar, but only limited 
investigations available (EEG and CT scanning). Most epilepsy care is paid for out-of- 
pocket. Primary care workers are responsible for follow-up and education of people 
with epilepsy (Dua, personal communication).
1.1.1.7. South Africa
Before the abolition of apartheid, there was no real attempt to deliver primary healthcare 
to the majority of the 44 million people in South Africa (International Marketing 
Council for South Africa, 2001). With the end of apartheid in 1994, the healthcare 
system in South Africa underwent changes to erase inequities in service and access, and 
to fund a higher level of healthcare. The aim is to provide a decentralised system that 
offers an equally accessible and free basic package of primary healthcare to all 
(Connolly, 2002). The IMR is 61 per thousand live births, and life expectancy is only 
43 years (CIA, 2006).
The public sector is under-resourced and over-used, while the fast-growing private 
sector has most of the resources, yet cares for only 20% of the population. Many of the 
nation’s health professionals work in the private hospitals (International Marketing 
Council for South Africa, 2001).
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Mental health is part o f the primary healthcare system in South Africa (WHO, 2001a).
A study o f the management of non-communicable diseases found that 80% o f people 
with epilepsy achieved ‘acceptable’ control (as defined by the patient or carer) when 
treated by doctors at primary care clinics (Coleman et al., 1998). Investigations are 
available in the major cities, and AEDs are available on general practitioner (GP) 
prescription. The major roles of primary care include diagnosis and treatment, as well 
as education (Dua, personal communication).
1.1.1.8. Uganda
The population o f Uganda (27 million) has a life expectancy of 51 years, and an IMR of 
67 per thousand live births (CIA, 2006). Healthcare is beyond the reach of over half the 
households in Uganda (WHO, 200 le). In 1989 there were 79 hospitals, and in 1990 
about 700 doctors, in the country. A little over half the hospitals were provided by the 
government (Federal Research Division o f the Library o f Congress, 1990). In the north 
of the country the facilities were poorer, and people needed to travel further to reach 
them. There is a structure to the health services provided, with minimal facilities at 
village level to meet immediate needs (WHO, 200le).
In 1993, after years o f indecision, user-fees were introduced in Uganda as a condition of 
a World Bank loan (Okuonzi, 2004); they were abolished in 2001 (Kajula et al., 2004). 
User-fees were expected to generate resources and improve quality and equity of health 
services. They generated less than five percent of total expenditure, and were associated 
with a dramatic drop in the uptake o f health services. Although the system included 
decentralisation of delivery of services, the earmarking o f many funds dictated that the 
district health authorities were not able to deploy them to meet local needs; hence 
specific local priorities frequently were not addressed (Okuonzi, 2004).
The Epilepsy Support Association of Uganda provides training for people with epilepsy 
as volunteers to raise awareness of the condition. They also become community-based 
counsellors for individuals with epilepsy and their families.
36
Section 1
There is a shortage of basic drugs for epilepsy in Uganda (International Bureau for 
Epilepsy, 2002), and the cost o f those that exist is prohibitive for many people (Warf, 
2004). In areas of Uganda people use traditional medicine, and this seems to be 
particularly the case for epilepsy (Tabuti et al., 2003). Most epilepsy care is paid for 
out-of-pocket. Primary care is responsible for referring and counselling patients, 
distributing AEDs and providing education (Dua, personal communication).
Paediatric neurosurgery is available in Mbale. In 2004 there were plans to develop an 
epilepsy surgery programme in 2005, which would make it the only comprehensive 
epilepsy centre in east or central Africa (Warf, 2004).
1.1.2. Eastern Mediterranean
This WHO region mostly covers the Muslim third world. The countries described here, 
with the exception o f Saudi Arabia (position 77 of 177), come in the lower half o f the 
world in human development rank (United Nations Development Programme, 2005). 
The data for the percentage of the population surviving on less than one USS per day are 
not available for Saudi Arabia or Sudan, but fewer than two percent of the population 
does so in Iran and Morocco, compared with 13% in Pakistan, and 16% in Yemen 
(United Nations Development Programme, 2005). IMRs are higher than those in the 
western world, and life expectancy somewhat shorter (CIA, 2006).
1.1.2.1. Islamic Republic o f  Iran
The population of Iran is 68 million, and life expectancy is 69 years (CIA, 2006). Over 
the last twenty years the rural health system has been transformed by the introduction of 
a primary healthcare system; the IMR in 1974 was 120 per thousand live births in rural 
areas and 62 in urban areas and it decreased to 30 in rural areas and 28 in the cities by 
2000 (World Bank, 2005).
The basis of the primary health system is the establishment of health houses in villages 
with each designed to cover about 1500 people. The health house is run by health 
workers, whose role includes record keeping, public health education, antenatal, 
perinatal, and postnatal care, care of children, family planning, immunisation and
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disease control. There is backup for the health houses with diagnostic and treatment 
services, and those needing more specialised care can be referred to district health 
centres or hospitals. There is a similar setup in urban areas, and the system is funded 
entirely by the national government (World Bank, 2005).
Mental healthcare (including epilepsy care) became integrated into the primary 
healthcare system in the late 1980s, and now covers the whole country. There are four 
neurologists per million inhabitants. Carbamazepine, ethosuximide, phenobarbital, 
phenytoin and sodium valproate are all generally available at primary healthcare level 
(WHO, 2001a). At least some care is available for people with epilepsy in hospital 
outpatient clinics (Baker et al., 2005). A pilot study o f mental health activities in the 
late 1980s found that, at the point o f identification, the duration of illness in 70% o f 
people with epilepsy was more than ten years, and that most were not on regular 
treatment (WHO, 2001b). Epilepsy investigations are available, but there are no 
epilepsy specialists. Epilepsy care is paid for directly or by social or private insurance 
(Dua, personal communication).
1.1.2.2. Morocco
The literacy rate in Morocco (population 33 million) is under 50% (WHO, 2001c), and 
the IMR is high at 42 per thousand live births. Life expectancy is 71 years (CIA, 2006).
The national health system is organised in three sectors. The public sector aims to 
implement prevention, promotion of health and treatment strategies. Within the public 
sector the primary healthcare network consists of dispensaries, community health 
centres, local hospitals and urban health centres. Specialised and general hospitals 
consist o f public health polyclinics, regional hospitals and academic hospitals (WHO, 
2001c). There is also a private (profit making) sector and a private, non-profit sector. 
The health system has done much to improve the health standards in Morocco. 
However, there is uneven distribution of health cover and insufficient manpower and 
practical resources (Archane, 1994).
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There are three neurologists per million population, and in 1999 there were 80 
neurosurgeons in Morocco (El, 1999). Epilepsy is covered by the mental health 
programme. Some AEDs are available at primary healthcare level (WHO, 2001a) and 
there are epilepsy specialists, and epilepsy investigations. The roles of primary 
healthcare workers include diagnosis, maintenance of AEDs and education o f patients 
(Dua, personal communication).
/. 1.2.3. Saudi Arabia
The 26 million people of Saudi Arabia have a life expectancy at birth of 75 years, and 
the IMR is 13 per thousand live births (CIA, 2006).
Primary healthcare centres were established in the early 1980s (Al-Yousuf et al., 2002). 
They are distributed throughout the country and are the patient’s first point of contact 
with the health system. The centres refer to general hospitals, which provide secondary 
care and are linked to tertiary care services. Each health centre provides preventive, 
curative and rehabilitative functions, as well as the provision of drugs, environmental 
health and health education.
Saudi Arabia is a welfare state. Healthcare, including drugs, is free (Abduljabbar et al.,
1998), and most drugs can be prescribed by primary care physicians (WHO, 2001a). 
Most healthcare is provided from government revenues; the remaining health services 
are financed through private sources and through occupational health insurance 
premiums. There is also a pilgrimage health service which provides care for both acute 
and chronic illnesses o f pilgrims performing the Haj (Al-Yousuf et al., 2002). There is 
an essential drugs list within primary care which reduces expenditure on 
pharmaceuticals.
Epilepsy is the second most common neurological disorder in Saudi Arabia. Specialised 
neurological services with modem investigations are found at some hospitals. There is 
less than one neurologist per million population, although there are five neurosurgeons 
per million (WHO, 2001a). Primary care workers are responsible for arranging tertiary
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care, follow-up o f patients and prescription of AEDs, education of patients and pre­
marital counselling (Dua, personal communication).
1.1.2.4. Sudan
The 40 million people in Sudan have a life expectancy of 58 years, and an IMR of 62 
per thousand live births (CIA, 2006). In the 1960s, medical care was free (Abdu et al., 
2004), but civil war for most of the time since 1956 has caused the healthcare system to 
disintegrate. Healthcare facilities have been drastically reduced in the south by the war, 
and in the north by the economic situation, as Sudan lacks the hard currency to buy 
drugs and equipment (Federal Research Division of the Library of Congress, 1991).
In the 1970s, the Ministry of Health began a national programme to provide primary 
care, with emphasis on preventative medicine. The primary healthcare centre was to be 
staffed by community health workers, who would receive a few months of training 
(Federal Research Division of the Library of Congress, 1991). The programme had 
virtually disappeared by 1991. In 1992 a user fee system was introduced, meaning that 
uninsured patients had to pay the full cost of every consultation, laboratory service and 
treatment. No exemption policy was developed to protect poor or vulnerable groups; 
over 60% of the population is estimated to live below the poverty line. Despite an 
increase in gross domestic product (GDP) since 1990, government spending on health 
has steadily declined (Abdu et al., 2004).
A survey amongst school children in Khartoum in the 1980s found that most children 
with epilepsy were receiving treatment (Younis, 1983). There is little other information 
available. The ILAE proposed to integrate epilepsy services into the primary healthcare 
services in Sudan (Newsletter of the Global Campaign against Epilepsy, 2004), but this 
has not been followed up.
1.1.2.5. Yemen
Yemen is one o f the poorest Middle Eastern countries, with a large disparity between 
urban areas (47% poor) and rural areas (82% poor) (Yemeni development foundation,
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2002). The people of Yemen (20 million) have a life expectancy at birth of 61 years, 
and an IMR of 61 per thousand live births (CIA, 2006).
The government aims to improve the health status of the population and to reduce 
regional disparities in access to healthcare (Al-Ghabiry, 2002); in 2001, only 45% of the 
population had access to primary healthcare (Yemeni development foundation, 2002). 
Nonetheless, the public health facilities have increased since the 1970s, when only ten 
percent o f the population had access to basic healthcare (Al-Ghabiry, 2002). There is a 
large public health sector as well as a private health sector. The public health sector has 
three tiers: the primary tier has healthcare units, staffed by primary healthcare workers, 
and healthcare centres staffed with one or two physicians and some nurses; secondary 
care is provided by district hospitals; tertiary care is provided in specialised and 
university hospitals in two cities (WHO, 200Id). Many primary healthcare facilities in 
rural areas are short o f qualified staff and o f drugs, whereas the secondary and tertiary 
levels, largely in urban areas, are better financed and better equipped. Therefore the 
majority of hospital patients are self-referred (Al-Ghabiry, 2002). Out-of-pocket 
expenses are high, and may be an important disincentive to accessing healthcare (United 
Nations Development Programme, 2001).
There is little information available on the care for people with epilepsy in Yemen. 
Commonly used AEDs are available on GP prescription, and EEG and CT are available, 
but not MRI. Most epilepsy care is paid for out-of-pocket (Dua, personal 
communication).
1.1.3. Europe
Most countries in Western Europe are well-developed, with low IMRs (between 3.7 and 
5.9 per thousand live births in the countries studied here) and relatively long life 
expectancies (between 76 and 79 years). Conversely, those in the Russian Federation 
have shorter life expectancy (67 years) and relatively high IMR (15 per thousand live 
births) (CIA, 2006). None, however, counts as a developing country in the United 
Nations Development Programme report.
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The western European countries investigated here have good healthcare provision, 
funded either through taxes or through compulsory insurance. In some countries there 
are out-of-pocket co-payments, but there is usually a ceiling above which patients need 
pay no more. Some countries use GPs as gatekeepers to the secondary care system, 
while others do not. All have at least reasonable epilepsy care. The Russian Federation 
attempted to provide compulsory health insurance, but this has not worked well in 
practice.
1.1.3.1. Denmark
Denmark, with 5.5 million residents, has a tax-based decentralised health system, with 
care free at the point of use (European Observatory on Health Care Systems, 2004). 
About 30% o f the population purchases voluntary health insurance to cover the costs of 
co-payments for physiotherapy, pharmaceuticals etc. Primary care is provided by self- 
employed GPs. Residents choose between two options: in the first option they may 
access a GP free o f charge, but the GP will act as gatekeeper to specialist care; in the 
second option they may visit any GP or specialist without referral, but will have to pay 
part of the cost.
The 30 to 40 thousand people with epilepsy in Denmark are treated by the 
approximately 250 neurologists and 300 paediatricians in that country (Gram, 1997). 
Paediatric neurology is not recognised as a specialty, but some paediatricians have 
particular interest in epilepsy. There is easy access to specialists. Any GP can request 
an EEG, but only hospitals can request CT scans. GPs may write repeat prescriptions 
for people with epilepsy. Patients are reimbursed for 75% of the costs of AEDs, but if 
drugs are expensive the patient can apply for additional reimbursements, so that there is 
a ceiling for drug costs to an individual.
Denmark has a National Epilepsy Centre, but access to the centre is limited, as referrals 
outside the local area need to be funded. Although GPs can refer patients to the 
Epilepsy Centre, traditionally those referred have intractable epilepsy, and most will 
have been seen by specialists in the regional neurological or paediatric wards (Schubart 
and Jensen, 2003).
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1.1.3.2. France
Healthcare for the 60 million people in France is based on a national social insurance 
system complemented by voluntary insurance (European Observatory on Health Care 
Systems, 2004). There are three main schemes within the statutory health insurance 
system; the general scheme covers 84% of the population, the agricultural scheme seven 
percent and the self-employed scheme five percent. At the end of the last century 
universal health insurance coverage was established; anyone who is legally living in 
France and not covered by insurance has medical expenses (including any co-payments) 
covered (Elkan, 2003).
People can see a specialist without being referred (Elkan, 2003), and changing physician 
is easy. France has more physicians per thousand population than Britain, but fewer 
than most countries in Europe (European Observatory on Health Care Systems, 2004). 
Patients pay to consult a physician, but 75% is refunded by the National Sickness 
Insurance Funds. Most of the population takes out supplementary insurance to cover the 
co-payments. Some chronic diseases, such as tuberculosis, psychosis and severe 
learning disability, are covered fully by the state insurance, and no co-payments are 
required (Dulac and Jallon, 1997). Although most people with epilepsy are not exempt 
from co-payments, those with associated handicaps and with cognitive impairments may 
be exempt.
People with new onset of seizures are often seen in A&E; however, epilepsy care is 
often initiated by the GP and followed-up by a neurologist (Dulac and Jallon, 1997). 
Almost all people with new onset seizures will have an EEG and a CT scan. Although 
patients may choose their own physician, they are only reimbursed at the rate for their 
local physician unless the local physician refers them further, when reimbursement will 
be provided by the national insurance. About half of neurologists have specialised 
training in epilepsy care. In 1997 six centres in France performed epilepsy surgery. The 
national insurance covers all costs for this (Dulac and Jallon, 1997).
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1.1.3.3. Germany
Over eighty million people live in Germany (CIA, 2006), 90% of whom are covered by 
insurance through the Statutory Health Insurance Scheme (HIS), which is based on 
income (European Observatory on Health Care Systems, 2004; Pforzheim University, 
2004). Most of the rest are covered by private health insurance, as it is obligatory to 
have adequate health insurance. The HIS pays doctors’ fees, and also for hospital 
treatment and medication; in the Statutory HIS, the patients pay a small fee.
Ambulatory healthcare is mainly delivered by GPs; patients have free choice of 
physicians. There is no formal gatekeeping system by GPs and therefore referral is not 
necessary for visiting a specialist. In 2004 co-payments were introduced for outpatient 
visits.
After a first seizure, the patient is usually referred by the GP to a neurologist. Over ten 
percent of neurologists have additional training in epilepsy (Pfafflin and Thorbecke,
1997). If control is good, the patient will be followed-up by the GP, but can be referred 
back if there are further seizures or complications. Those with refractory epilepsy will 
receive care from a specialist at an epilepsy centre, although access to these centres is 
restricted. In 1993 there were over 80 epilepsy clinics for children and 39 for adults, 
and five comprehensive epilepsy centres (Pfafflin and Thorbecke, 1997). Surgery is 
carried out at 16 epilepsy centres, but (in 1997) limited to approximately 300 patients 
per year.
1.1.3.4. Italy
Italy has a population of around 58 million (CIA, 2006). In 1978, health insurance 
funds were abolished and the National Health Service (NHS) was established (European 
Observatory on Health Care Systems, 2001). Reorganisation in the late 1990s 
reinforced central state control over the NHS, but at local level, local health units are 
responsible for assessing needs and providing comprehensive care. In 1999 
approximately 30% of the population was covered by private health insurance.
Outpatient costs are paid by the patients, with a ceiling to prevent excessive costs. 
People with chronic diseases and disability, as well as some people on low income, are
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exempt. Private healthcare services and over-the-counter drugs also incur a cost to the 
user.
Primary healthcare is provided by GPs and paediatricians, who act as gatekeepers for 
access to secondary services. Secondary and tertiary care is provided either directly by 
the local health units or by contracted-out facilities. Once secondary care is authorised 
by the GP, the patient can choose a provider from those accredited. High co-payments, 
long waiting lists and low quality o f services lead many people to seek private care.
Italy has more neurologists per person than any other country in Europe (one neurologist 
for fewer than 9,000 people) (Humphrey et al., 2002). Despite this, a study in 1992 
showed that the healthcare of people with epilepsy involved a wide range of specialists, 
and that GPs were responsible for the diagnosis of epilepsy in 10% of patients and for 
its management in 22% (Giuliani et al., 1992). A more recent survey by the WHO 
suggests that the major task of primary care physicians in Italy is maintenance of drug 
therapy (Dua, personal communication).
1.1. S. 5. The Netherlands
The health service for the 16 million people in the Netherlands is based on health 
insurance (European Observatory on Health Care Systems, 2004). There is national 
health insurance for exceptional medical expenses associated with long-term care or 
high-cost treatment, financed by payroll deductions and government funds, and most 
people are covered by this. Standard medical care for anyone whose income is below a 
certain level is provided by insurance from sickness funds. Anyone with earnings above 
this level is insured by private health insurance, and a further scheme exists for public 
servants.
Patients enrol with a GP, who acts as gatekeeper for specialist and inpatient care. 
Referral rates are low. The Netherlands has 100 general hospitals, eight teaching 
hospitals and 28 specialist hospitals. Nearly all medical specialists work in hospitals; 
some are salaried, but most work on a fee-for-service basis (Scholten et al., 1998).
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There are three special epilepsy centres in the Netherlands, which together run 13 
outpatient clinics (De Boer and Muller, 2003). Around one quarter of people with 
epilepsy are referred to the epilepsy centres at some stage, by neurologists, paediatric 
neurologists or paediatricians, and occasionally by GPs. Most people are seen only in 
outpatient clinics, but short stay and long stay care facilities exist. Epilepsy surgery is 
carried out, where indicated, at Utrecht University Hospital.
The majority o f the population, with obligatory health insurance, needs to consult the 
GP for referral to an epilepsy specialist. The specialists tend to advise on treatment, but 
GPs can prescribe AEDs (Dua, personal communication).
1.1.3.6. Norway
In Norway (population four million) healthcare is predominantly provided by a tax- 
financed scheme, supplemented by out-of-pocket payments. The compulsory National 
Insurance Scheme (NIS) covers all residents. Hospital inpatient treatment is free, but 
most other forms o f treatment require co-payment. For example, patients are charged a 
small amount for each consultation and each investigation. However, there is an annual 
ceiling for cost-sharing, and once the ceiling is reached, free treatment and benefits are 
provided for the rest o f the calendar year (European Observatory on Health Care 
Systems, 2000).
Most GPs are either employed by the municipality or have a contract with the 
municipality which provides a basic grant and a fee-for-service from the NIS. Since 
2000, all patients have needed to register with a single GP (European Observatory on 
Health Care Systems, 1999). GPs refer patients for secondary care as, without the 
referral, the specialist cannot be paid thought the NIS (European Observatory on Health 
Care Systems, 2000). Norway has many small hospitals, at least in part owing to the 
dispersed population in the north of the country. There are a few private clinics in 
densely populated areas, and five private hospitals. Treatment in these hospitals is 
financed by the NIS and by user charges.
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An adult with newly suspected epilepsy will be referred to a neurologist, and followed 
up by either the neurologist or the GP. The most difficult cases are referred to the 
National Centre for Epilepsy; tertiary referral can only be made from a regional hospital. 
Most people with newly suspected epilepsy will have an EEG at onset, and most will 
have CT scanning and an MRI if the CT is normal. The epilepsy surgery service is 
small and centralised. Plans introduced in the 1990s may reduce referrals to the 
National Centre for epilepsy, and limit the availability of epilepsy surgery (Henriksen, 
1997).
1.1.3.7. Russian Federation
The population o f the Russian Federation, is 143 million, but declining. The IMR is 15 
per thousand live births and life expectancy is 67 years (CIA, 2006).
At the time of the break-up of the Soviet Union, spending on healthcare had declined to 
about three percent o f the budget, as more was spent on military and industrial 
development (Tragakes and Lessof, 2003). (Health expenditure in European countries is 
generally more than eight percent of GDP (Epidemiology Statistics and Health 
Information Unit, 1999)). Changes in policy in Russia aimed for equity in provision, 
and a system of compulsory health insurance was proposed to provide universal access 
and comprehensive cover, while giving patients freedom to choose both insurer and 
provider. This was to be financed by payroll contributions and was to supplement the 
budgetary provision. Additional voluntary insurance was to be permitted to cover 
services beyond those provided by the basic compulsory insurance, or people could pay 
directly for healthcare. In practice, health insurance financing has failed to be purely 
supplementary, as the budgetary provision has been reduced. In some areas no 
insurance companies have been set up, and in others the area is divided into sectors with 
insurance companies allocated to these sectors, eliminating the right to choose 
(Tragakes and Lessof, 2003).
In rural areas the first point of contact is a nurse-run health post. More complex 
problems are referred to a rural health centre, providing a mixture of primary and 
routine secondary care. More complex cases still are referred to polyclinics or hospitals.
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Each region also has a tertiary referral hospital. In urban areas the primary care givers 
are doctors working out of polyclinics. There is a failure to communicate between 
primary and secondary care, which encourages inappropriate referrals and lack of 
continuity of care. Patients are assigned to a primary care doctor and although they have 
a technical right to change their doctor, in practice this rarely happens. There is a lack 
o f confidence in the primary healthcare system and many self-referrals to secondary care 
are made; thus gatekeeping does not work in practice (Tragakes and Lessof, 2003).
There is little information available on care for people with epilepsy in Russia. The vast 
majority of any published information in the medical journals is in Russian, and 
abstracts are rarely available. The setting up of a regional epileptological centre has 
been described (Gromov et al., 1990). There is a Russian chapter of the ILAE. AEDs 
are available on specialist prescription. EEG, CT and MRI imaging are also available, 
and there are epilepsy specialists in the Russian Federation (Dua, personal 
communication).
1.1.3.8. Slovenia
The IMR in Slovenia (population two million) is low at four per thousand live births, 
and life expectancy is 76 years (CIA, 2006).
In 1899 a sickness fund was established, making Slovenia one of the first countries in 
Europe to establish compulsory health insurance. When Slovenia became part of the 
Socialist Federal Republic of Yugoslavia in 1945, healthcare was based on the 
principles of universal coverage. Private practice was prohibited and all physicians 
became salaried employees of the state. However, the country experienced periods of 
high inflation, and by 1990 the healthcare system was on the verge of financial collapse 
(European Observatory on Health Care Systems, 1996)
In 1991 Slovenia became independent. In early 1992 legislation was changed to 
introduce a compulsory and a voluntary health insurance system, and private practice 
was reintroduced. People are obliged to insure themselves against health risks, and 
virtually the entire population is covered. Those who are unemployed are covered by
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payments from the local authorities (European Observatory on Health Care Systems,
1996).
The compulsory plan covers a full range of basic benefits, either in total or with co­
payment; this includes treatment of epilepsy. To cover the difference between the share 
o f healthcare costs paid by compulsory insurance and the full price, people may take out 
voluntary supplementary health insurance (European Industrial Relations Observatory 
on-line, 2005).
At the primary level, healthcare centres provide healthcare to the local community. 
Specialist care at the secondary levels is organised in regional general hospitals. Tertiary 
care, generally organised at the national level, includes university hospitals and 
institutes, providing highly specialised services, education and research (European 
Observatory on Health Care Systems, 2002c).
Personal physicians generally refer patients with epilepsy to secondary care where 
necessary. Fees for AEDs are fully reimbursed, and most established AEDs (except 
ethosuximide) are available. There are some epilepsy specialists in Slovenia, but no 
postgraduate education. Primary care providers are responsible for fast-track referrals, 
prescription of drugs and follow-up of treatment (Dua, personal communication).
1.1.4. The Americas
The countries o f South America investigated here are all relatively poor; they are classed 
as resource-poor countries, but all appear in the upper half of the HDI ranks. Peru has 
18% of its population living on less than one US$ per day; the others have less than ten 
percent (United Nations Development Programme, 2005). Despite poverty, Peru and 
Panama appear to have fairly well-structured healthcare systems, while the other South 
American countries investigated have less successful schemes.
Canada and USA both have high human development indices. While Canada provides 
healthcare that is free at the point of use, the US has private health insurance and a
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variety of schemes for those who cannot afford healthcare; some people seem to have 
little access to healthcare.
1.1.4.1. Argentina
Almost one fifth of the 39 million people who live in Argentina live in a situation of 
poverty (International Development Research Centre, 1995). The IMR is 15 per 
thousand live births and life expectancy at birth is 75 years (CIA, 2006).
There are three main providers of healthcare; the public sector, social plans and the 
private sector (International Observatory on End of Life Care, 2002). The public sector, 
which supplies free clinical care for inpatients and outpatients, covers about 50% o f the 
population. Outpatients are charged for medicines. The private sector, where patients 
meet the total cost o f care, covers about five percent o f the population. The Social Plans 
are group insurance schemes based on occupation. Employers and employees each pay 
a fixed fee. The plans function as sickness insurance funds, financing healthcare 
services of employees and their families. The patient may need to provide the 
difference between the fixed fee and the actual cost of treatment (International 
Observatory on End o f Life Care, 2002).
In Argentina, patients can, without being referred, choose to see any GP or specialist. 
There has been very little use of gate keeping within the system (International 
Development Research Centre, 1995).
Mental health is part o f the primary healthcare system, but facilities are not uniform 
across the country. There are about 1.6 neurologists per million population (WHO, 
2001a). Basic AEDs are available at primary care level. MRI and EEG are available, as 
are epilepsy specialists. Primary care workers are responsible for monitoring treatment 
and provision of drugs (Dua, personal communication).
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1.1.4.2. Brazil
Brazil is one of the top ten world economies, but has huge social inequalities. The 
population is 186 million, IMR is 29 per thousand live births and life expectancy is 71 
years (CIA, 2006).
In 1990 the SUS (the Unified Health System) was created, theoretically offering total 
health coverage to the population (Guerreiro, 1997). This was in response to the 
constitution which states that health is the right of every citizen and the duty of the state 
to provide. There are problems with the SUS, particularly in the poorest parts, and in 
practice less than 80% of the population is covered. The SUS owns and runs most of 
the outpatient services in Brazil, but most of the hospitals are private (IHSD, 1999a). 
Most Brazilians, therefore, use private hospital services funded by the public sector, but 
with difficulties. Unofficial co-payments are common. The money the federal 
government disburses for services is frequently below the actual cost of those services 
(Guerreiro, 1997). There is unequal access to healthcare, and it is estimated that about 
ten million people in northern Brazil have no access (IHSD, 1999a).
The primary healthcare system in Brazil consists of home care, health clinics and 
diagnostic and therapeutic support services. Secondary healthcare includes specialist 
outpatient clinics and local and regional hospitals. Tertiary healthcare adds university 
hospitals. Over half of neurologists practise in the private sector. The higher income 
areas have more neurologists than the low-income areas. Most psychiatrists in Brazil 
will treat some patients with epilepsy, but a survey of Brazilian psychiatrists found that 
one third had no formal training in epilepsy, and most lacked knowledge on some 
aspects of epilepsy (Marchetti et al., 2004).
The cumulative prevalence of epilepsy in Brazil is estimated as between 12 and 21 per 
thousand population. The treatment gap (the percentage difference between the number 
o f people with active epilepsy and the number whose seizures are being appropriately 
treated (Meinardi et al., 2001)) for epilepsy is around 50%. A recent house-to-house 
survey of over 55,000 people in three areas of Brazil confirmed epilepsy in nine per 
thousand, of whom almost 60% had active epilepsy; the prevalence of active epilepsy
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was higher in poorer socio-economic groups. Almost two fifths of those with active 
epilepsy were on inadequate treatment, o f whom half were on no treatment (Li, personal 
communication).
1.1.4.3. Canada
Canada has a population of 32 million, with a life expectancy of 80 years, and with an 
IMR of four per thousand live births (CIA, 2006).
Healthcare is provided by Medicare, which is publicly financed, but privately run. Care 
is free at the point of use, and the healthcare system is based on five principles; care 
should be universal, portable, comprehensive, accessible and publicly administered 
(Irvine and Ferguson, 2002). Theoretically patients have free choice of physician and 
hospital. The healthcare system is funded by taxes; the federal government transfers 
cash to provinces, but the latter may levy their own taxes to supplement the money. 
Although Canadians may buy private health insurance, this is limited to services that are 
not available under the public health system.
Healthcare providers are predominantly private, but are publicly funded. Physicians are 
mostly in private practice, receiving fee-for-service payments, but a few opt out of the 
system. In order to limit the demand for expensive treatments, Canada introduced the 
Canadian Coordinating Office for Health Technology Assessment, similar to (but pre­
dating) the UK’s National Institute for Clinical Excellence Technology Assessments. 
Hospitals are also limited by budgets, and in 2002 waiting time for a cranial MRI scan 
was an average o f five months.
There are approximately 30,000 primary care physicians in Canada, providing basic 
medical treatments and preventative care. Patients have the right to choose their GP, 
and can change as often as they wish (Keene, 1997). Primary care physicians refer 
patients to specialists when required, and hospitals deal with these referrals as well as 
emergencies (Canadian Health Care, 2004).
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Family physicians in more isolated areas of Canada are likely to be more involved in the 
care of people with epilepsy than those in urban areas (Keene, 1997). There are 
neurologists located in larger Canadian urban centres, and centres of excellence for 
people with epilepsy in almost all provinces. Patients need to be referred to these 
centres o f excellence by their physicians. Most AEDs are available at primary 
healthcare level (WHO, 2001a), and EEG and MRI are available in the country. The 
major roles o f primary care in caring for people with epilepsy are referring to specialists, 
monitoring AEDs and their side-effects, and counselling (Dua, personal 
communication).
1.1.4.4. Chile
The population o f Chile is almost 16 million. The IMR is eight per thousand live births, 
and the life expectancy 76 years (CIA, 2006).
The National Health Service began in 1952, and provided care free of charge for people 
who had previously held accounts in various pension funds, to workers and their 
families in the social security system, and, for a fee, to the population at large (Federal 
Research Division of the Library of Congress, 1994). However, standards of care 
deteriorated, due to decreasing funding. Following decentralisation and privatisation a 
two-tier system resulted, with the wealthy and healthy in the private system and the poor 
and sick in the public system. The return to democracy resulted in public health 
expenditure more than doubling (Bailey, 2003).
Currently the mixed health system allows people in Chile to opt for their preferred 
system. About 30% opt for the private health insurance, and the rest are covered by the 
public system (the SNSS) (Bailey, 2003). The SNSS provides treatment free of charge 
to those whose income falls below a certain level, and up to 50% is payable by those 
with higher incomes. The private health insurance system requires that employees pay a 
premium in addition to that paid by employers. Medical services are then reimbursed to 
users at a percentage of the cost. The companies, however, may refuse to cover those at 
higher risk o f illness, and may drop those who become higher risk. Consequently, the
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SNSS covers the healthcare of most high-risk individuals (Federal Research Division of 
the Library of Congress, 1994).
There has been interest in epilepsy amongst professionals for many years, and epilepsy 
is well catered for. There are epilepsy specialists and post-graduate education in 
epilepsy, and there is an epilepsy surgery programme. Primary care includes the 
diagnosis, follow-up and education o f people with epilepsy (Dua, personal 
communication).
1.1.4.5. Panama
In 1995 it was estimated that 40% of the population of Panama (now three million) lived 
in poverty, and 18% lived in extreme poverty (Pan American Health Organisation,
2001). The IMR is 16 per thousand live births, and life expectancy is 75 years (CIA, 
2006).
The aim o f the current health policy is to offer universal access to comprehensive health 
programmes. The model emphasises primary healthcare and the use of family 
physicians, so that health problems can be solved at the appropriate level, with the result 
that national hospitals no longer have to deal with problems that could be solved at the 
local level (Latin America and Caribbean Regional Health Sector, 2001).
There are approximately three neurologists per million population (WHO, 2001a).
Basic AEDs are available at primary healthcare level, and there are facilities for EEG 
and MR imaging. The aims of primary care for epilepsy include follow-up of treatment, 
introducing a national policy for the treatment of epilepsy and promoting suitable 
environments for people with epilepsy (Dua, personal communication).
1.1.4.6. Peru
Peru is characterised by extreme inequalities in income distribution, with corresponding 
inequalities in life expectancy. About 50% live in poverty with some in extreme 
poverty (IDHS, 1999). The IMR is 31 per thousand live births, and overall life 
expectancy is 69 years. The current population is 27 million (CIA, 2006).
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Peru has a well-developed service infrastructure for health, with the Ministry of Health 
providing the largest hospitals and most primary healthcare establishments. The 
Peruvian Institute of Social Security, funded by employers and employees, delivers 
some hospital-based services, mostly in urban areas, and the private sector provides 
services to the wealthiest part of the population, either through insurance schemes or 
through direct fees for service. The government has attempted to improve primary care 
availability, particularly in areas previously under-served (IDHS, 1999).
In the mid 1990s it was found that although the number of primary care facilities had 
been increased, costs, inefficiencies and a weak information system meant that many 
primary care facilities were underused. The Ministry of Health therefore introduced 
Local Health Administration Committees, to transfer administrative responsibility for 
rural health services to communally owned and administered institutions. By 1998 there 
were over 500 such committees, as well as 650 minor health posts. The committee 
facilities have higher rates of community participation (Bowyer, 2004).
There is little information available on services for people with epilepsy. Basic AEDs 
are available, as are facilities for neuroimaging and EEG. Primary care is responsible 
for diagnosis, initial treatment and follow-up, and referral to specialists when needed 
(Dua, personal communication).
7.7.4.7. United States o f  America
There are 195 million people in the USA, with a life expectancy at birth of 77 years.
The IMR is 6.5 per thousand live births (CIA, 2006).
The health sector in the US is diverse, with a mix of public and private funding and 
provision (Irvine, 2002). The very poor have no health insurance (Gumnit, 1997b), and 
much healthcare is provided by Accident and Emergency (A&E) departments. As a 
consequence, many postpone seeking medical care, and are less likely to receive 
preventative care (Kaiser Commission, 2004). The major public health programme for 
people with low income is Medicaid (Kaiser Commission, 2004). To qualify for
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Medicaid an individual must meet financial criteria and must also fit into a category 
such as children, pregnant women, the elderly, people with disabilities and parents. 
Medicaid pays for a broad range o f services but pays a very low percentage of costs and 
therefore many practitioners will not accept its patients (Willmore, 1997).
People over 65 years old, and certain people with disabilities, are eligible for Medicare. 
One part of Medicare covers inpatient care, nursing and hospice care. Although there is 
no premium charge, there is a charge for most of these services. Another part of 
Medicare pays for doctors’ services and outpatient care and laboratory tests. There is a 
monthly premium to be paid, and also some co-payments required. From 2006 some 
outpatient prescription costs will be covered (Kaiser Foundation, 2005).
Many Americans are covered by private health insurance, often through employment- 
based health insurance (Irvine, 2002). Various managed care plans have appeared in an 
attempt to control costs; these put administrators and ‘gatekeepers’ in charge of guiding 
patients through the healthcare network, in order to manage costs. Patients are often 
required to check with their health plan for approval prior to visiting a physician. 
Examples of these managed care plans are Health Maintenance Organisations (HMOs) 
and Preferred Provider Organisations (PPOs). HMOs generally provide care through 
hospitals and clinics that the plans own, with physicians, nurses and other personnel 
employed by the HMO. It is in the best interest of the HMO to enrol healthy people and 
provide the least amount of care (Willmore, 1997). PPOs are networks of doctors and 
hospitals that have agreed to treat participants in these plans for reduced fees based on 
pre-negotiated contracts (Irvine, 2002).
Treatment of patients with epilepsy is influenced by their health insurance plan 
(Willmore, 1997). Those with low income will often use hospitals with open access to 
emergency departments. The emergency physician will assess the patient, and then 
select an AED. Treatment is thus often provided by the physician with the least 
education. Those people enrolled in HMOs may fare little better. There is a tendency 
not to refer to specialists (who might require expensive tests and prescribe expensive 
medication). The primary care provider is not allowed to make a referral to a
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neurologist until persistent demands are made or the patient develops complications 
(Willmore, 1997). Practice guidelines have been developed which offer a systematic 
process for treating patients (Montouris, 2000). Some managed care plans require 
practitioners to adhere to guidelines, while others offer incentives. The insistence of the 
insurance companies and managed care organisations that primary care practitioners 
manage all aspects of a patient’s health means that only 17% of patients with new onset 
epilepsy are seen by neurologists (Montouris, 2000). However, the National 
Association o f Epilepsy Centres recommends that, after three months of unsuccessful 
treatment at primary care level, the patient should be referred to a neurologist, and that 
after nine months of unsuccessful treatment by a neurologist, the patient should be 
referred for subspecialty evaluation (Montouris, 2000). In a study reported in 2003 of 
people who had epilepsy surgery, the average duration of epilepsy before being seen at 
the epilepsy referral centre was 18 years; 22 of 36 patients operated on were referred by 
neurologists, while 14 were self-referred (including five who had been specifically 
advised not to consider surgery) (Benbadis et al., 2003).
The A&E department is the source of initial, primary and ongoing care for many 
children (Clancy, 1997). When a child has a first seizure, the diagnostic evaluation will 
vary depending on the type o f health insurance, and there is no consensus for minimal 
diagnostic evaluation (Clancy, 1997). Children with epilepsy may be cared for by the 
family physician or a paediatrician; access to an epilepsy specialist is often dependent on 
insurance. There are relatively few comprehensive paediatric epilepsy centres.
Although EEGs can be ordered by any physician, there is variability in the quality of 
recordings and interpretation.
1.1.5. South-East Asia
In many parts o f the world, beliefs about epilepsy are based on myths and 
misconceptions. In parts of Asia, faith healers may be consulted in preference to 
medical doctors (Gourie-Devi et al., 2003).
Bangladesh, India and Nepal all occur in or near the bottom half of the HDI, with over 
one third of the population estimated to live on less than one USS per day (data from
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1990 to 2003) (United Nations Development Programme, 2005). Much of the 
population has access either to primary care only, or to no healthcare at all.
1.1.5.1. Bangladesh
The population of Bangladesh is large (143 million). Life expectancy is 62 years (CIA,
2006), and illiteracy is widespread. Less than 40% of the population has access to basic 
healthcare; many trained staff are unwilling to work in rural areas, hence access to 
services is inequitable (Pearson, 1999).
Primary health centres were established over 20 years ago, and initially included 
operating theatres and x-ray, pharmacy and inpatient facilities. An essential package of 
services has been defined for primary health centres, and includes reproductive 
healthcare, child healthcare, communicable disease control and limited curative care. 
The facilities in the health centres often deteriorated and many doctors are unwilling to 
work in them. The hospital system is overused, as many people bypass the primary 
health centres (Pearson M, 1999).
There are an estimated 1.5 million people with epilepsy in Bangladesh (Mannan, 2004). 
The Epilepsy Association of Bangladesh organises seminars and workshops about 
epilepsy for health professionals, and also runs free epilepsy clinics; however, only a 
small proportion o f people with epilepsy is treated. Many people have alternative 
beliefs which influence their attitudes towards epilepsy; only about 20% of people with 
epilepsy will seek medical advice. Even when advice is sought, drug supply is not 
satisfactory and many patients cannot afford the drugs (Mannan, 2004). Theoretically 
phenobarbital and phenytoin are available with a prescription from a GP, and 
carbamazepine and sodium valproate with a prescription from a specialist. The only 
source of funding for epilepsy treatment is out-of-pocket. Primary care workers are able 
to refer patients to higher levels within the health system, and sometimes follow-up the 
patients themselves. All investigations are available within the country. There are 
epilepsy specialists but there is no post-graduate education available (Dua, personal 
communication).
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1.1.5.2. India
Between the early 1950s and the 1980s healthcare facilities and personnel in India 
increased substantially, but the increase was outstripped by the growth in population 
(Indian Child, 2000). The IMR of the population (one billion) is estimated at 57 per 
thousand live births and life expectancy at about 66 years (WHO Regional Office for 
South-East Asia, 2000).
Primary healthcare is provided by subcentres manned by health workers, and by primary 
health centres (Gourie-Devi et al., 2003) staffed by primary care practitioners, supported 
by nurses and health assistants. Although 70% of the Indian population lives in villages, 
only 30% of medical personnel practises there (Mani and Subbakrishna, 2003). 
Complicated cases are referred from primary health centres to sub-district hospitals, and 
from there to district hospitals or to the large government hospitals (Mani and Rangan, 
1997). Tertiary care is provided by the hospitals of medical colleges and specialised 
centres (Gourie-Devi et al., 2003).
Healthcare in India is funded by both the federal and state governments (Mani and 
Rangan, 1997), but only a little over two percent of the government budget is given to 
healthcare. More recently a general health insurance system has been introduced; this 
covers only people between five and 70 years old and specifically excludes epilepsy 
from its cover. Some employees are entitled to free or reimbursable services in certain 
hospitals; private insurance companies barely exist.
Many people consult traditional or spiritual healers for their illnesses. The treatment 
gap for epilepsy in India is between 50 and 70% (Gourie-Devi et al., 2003). Various 
groups have attempted to improve care for people with epilepsy. Suggestions include 
teaching simple practical epilepsy-related medicine to primary healthcare physicians and 
also providing sufficient teaching to paramedical workers to enable them to be able to 
identify cases (Mani and Rangan, 1997). In 2003 there were fewer than 700 
neurologists in India, about one per 7,000 people with epilepsy (Gourie-Devi et al.,
2003). Epilepsy surgery is being developed in a few large centres (Mani and Rangan, 
1997).
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The main AEDs available are phenobarbital and phenytoin. MRI, CT scanning and 
EEG are available in the country. The primary method of paying for epilepsy care is 
out-of-pocket (Dua, personal communication).
1.1.5.3. Nepal
Nepal is one of the poorest countries in the world, and has a population of around 27 
million. There is one doctor per 20,000 population (Rajbhandari, 2004). Around 70% 
of the burden of disease is due to communicable diseases. Life expectancy is about 62 
years and the IMR is around 60 per thousand live births (WHO Regional Office for 
South-East Asia, 2000). Many rural communities are distant from health centres, and 
health services are fragmented. Governmental health facilities are more widespread 
than mission and private facilities. In government health facilities patients pay 
subsidised rates (Rajbhandari, 2004), whereas user-fees are commonplace in mission 
and private facilities (IHSD, 1999b).
The prevalence o f epilepsy is around seven per thousand population (Nepal et al, quoted 
in Rajbhandari, 2004). In one study almost half of new onset seizures were caused by 
neurocysticercosis (Rajbhandari, quoted in Rajbhandari, 2004). In 2003 there were 
seven neurologists in the country, and some investigations are available. Most basic 
AEDs are available in some situations. The treatment gap in rural areas is between 74 
and 80%. In Nepal, primary healthcare workers are involved in health education and 
referral, and treatment of people with uncomplicated epilepsy (Dua, personal 
communication).
Many Nepali people do not attribute seizures to a disease, but to evil spirits and 
weakness. As a result, the practice of traditional treatment of epilepsy is prevalent 
(Rajbhandari, 2004).
1.1.6. Western Pacific
There is a wide range of healthcare availability in the Western Pacific Region. Australia 
and New Zealand are both well-developed countries with good systems of health
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provision. GPs act as gatekeepers in both systems. Japan is one of the most developed 
countries, and has good access to healthcare with mandatory insurance cover, and 
thorough epilepsy care. China is a relatively poor country, with 17% living on less than 
one US$ per day (United Nations Development Programme, 2005) and access to 
medical care is limited. Samoa is a small nation with a poor economy; most tertiary 
care is provided in Australia or New Zealand.
1.1.6.1. Australia
The people o f Australia (20 million) have a long life expectancy at over 80 years and 
low IMR at four per thousand live births (CIA, 2006).
The healthcare system is financed through general taxation and a health insurance levy 
(European Observatory on Health Care Systems, 2002a). It offers universal access to 
healthcare through the government health insurance system, Medicare. Medical 
treatment is mainly free and its use is largely unlimited. Self-employed GPs provide 
most medical care. Patients are free to choose their GP, and may consult more than one, 
as there is no need to enrol with a practice. Most GPs ‘bulk-bill’ the health insurance 
commission so that their services effectively are free to patients. Alternatively the GP 
may charge the patient a higher amount and the patient may then reclaim an 85% rebate. 
GPs act as referral gatekeepers to the rest of the healthcare system. Medicare 
reimburses 85% of the schedule fee for outpatient appointments. There is also, 
however, a large private sector in the health service, as the government provides a 30% 
subsidy to individuals who acquire private health insurance (Australian government: 
Department o f Health and Ageing, 2005).
The GP is usually the first point of contact for a patient with a first seizure (Averis,
1997), and may refer the patient to a specialist neurologist where necessary; epilepsy is 
the second most common reason for referral to neurologists. People with epilepsy 
commonly see both the GP and the neurologist. Occasionally people with epilepsy may 
be referred to a comprehensive epilepsy centre for initial diagnostic evaluation, 
particularly if there are complications. GPs are responsible for the long-term follow-up
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of people with epilepsy, including monitoring of seizure control and side-effects of 
medication.
Most GPs will initiate AEDs on occasions, and more than half of these do so frequently. 
Patients with refractory epilepsy or with complex problems may be reviewed at the 
comprehensive epilepsy centre, but a recent questionnaire showed that very few GPs 
knew of the existence or role of the comprehensive epilepsy service.
1.1.6.2. China
China has the largest population in the world (1.3 billion). It has a relatively low IMR at 
24 per thousand live births, and relatively high life expectancy (72 years) (CIA, 2006).
Prior to the 1980s, funding for healthcare in rural areas was arranged through the 
collective, and in urban areas through medical insurance or direct provision of health 
services by employers (Walford, 2000). Since then, however, public sector healthcare 
providers have had to generate revenues to cover the difference between costs and the 
government’s allocation (Liu, 2004). In rural areas this meant that the system of referral 
(village health station, township health centre and country hospital) became fragmented, 
with different health facilities competing for revenues from patients. For many patients, 
the village health practitioner is the first and only point of contact with the medical 
system. The rural doctors have little supervision or professional training.
Despite rising medical costs, fewer people are now covered by medical insurance. In 
regions where many people live in poverty the admission rate of people without 
insurance is seven-fold lower than that of people with insurance. Many people in 
hospital in rural China are discharged against medical advice, frequently because they 
cannot afford to stay any longer (Liu, 2004).
More recently, insurance schemes have been developed to try to increase healthcare 
utilisation. The subsidised insurance is, however, intended only to help cover 
catastrophic medical expenses (Liu, 2004).
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People with epilepsy face stigmatisation, such that they become withdrawn from 
society. An epidemiological estimation in 2000 found the prevalence of epilepsy was 
seven per thousand, and the number of people with active epilepsy almost five per 
thousand. Over 40% had never received any treatment for epilepsy (Wang et al., 2003). 
Phenobarbital, phenytoin, carbamazepine and sodium valproate are all available on GP 
prescription, and investigations are available. The tasks of primary care workers include 
diagnosis, treatment, follow-up and education of patients and the community. Both 
epilepsy specialists and postgraduate education are available in China. The primary 
source of finance of epilepsy care is out-of-pocket (Dua, personal communication), 
although a National Epilepsy Programme is being set up and will cover the cost of 
AEDs (Wang et al., 2006).
1.1.6.3. Japan
Japan is a country with 125 million residents, of whom 75% live in urban areas (Seino 
and Yeh, 1997). It has one of the longest life expectancies in the world, at 81 years, and 
a low IMR (three per thousand live births) (CIA, 2006). Access to healthcare is readily 
available. The government began providing health insurance in the 1920s and it was 
extended to the whole population in the 1960s. There are two main forms of health 
insurance -  employee insurance and the national health insurance (Yeh and Seino,
1997), and it is mandatory to have a policy (Ikeda S, 2004). Neither system provides 
over-the-counter drugs, and reimbursement is provided only for those drugs listed on the 
drug price list. Although the insurance premiums are supposed to finance the health 
insurance system, there is also a system of public support (Japan Pharmaceutical 
Manufacturers Association, 2005).
In 1997, Japan had 170 physicians per 100,000 people. There are almost no GPs.
People with epilepsy are cared for by neuropsychiatrists (almost half), neurologists and 
paediatricians (almost one quarter), with a small number being cared for by 
neurosurgeons (Seino and Yeh, 1997).
In about one quarter of adults with epilepsy it is refractory to treatment, and specialists 
in epilepsy usually manage these. Those with the most severe epilepsy reside in mental
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hospitals. The National Epilepsy Centre, Shizuoka, provides comprehensive epilepsy 
care with a multidisciplinary team, and supplies training and research (Seino and Yeh,
1997).
All patients with epilepsy have an EEG at diagnosis, usually including sleep 
deprivation. At Shizuoka, outpatients who are seizure-free also have an annual EEG to 
ascertain the need for continued medication. Patients are usually seen at least four times 
a year, and many are seen more frequently. Patients with newly diagnosed epilepsy are 
usually started on monotherapy, with polytherapy reserved for treatment refractory 
patients. Surgical treatment of epilepsy was started in 1983, and by 2001 almost 500 
operations had been performed (Mihara et al., 2004).
1.1.6.4. New Zealand
New Zealand has a population of four million people, with long life expectancy (78 
years) and a fairly low IMR (almost six per thousand live births) (CIA, 2006).
The structure of the health service has been changed many times in recent years. The 
healthcare system is largely financed through taxation, whilst out-of-pocket payments 
provide much of the rest. Primary care, provided by GPs, is charged on a ‘fee-for- 
service’ basis, with subsidies for people on low incomes (European Observatory on 
Health Care Systems, 2002b). Drugs are provided free for inpatients, but in the 
community a co-payment is charged. Private insurance exists, but mainly insures people 
against the supplementary costs; most insurers do not offer comprehensive health cover. 
Hospital outpatient and inpatient services are provided free of charge. Most hospital 
specialists are paid a salary, but many also work in private practice (European 
Observatory on Health Care Systems, 2002b). Patients may choose their GP who will 
act as a gatekeeper, as patients are not able to access free specialist services without 
referral.
New Zealand has facilities for investigations, and AEDs are available (WHO, 2004).
The major role of GPs is to review the patient, maintain the treatment and educate on 
first aid and seizure prevention (Dua, personal communication). The Maori population
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apparently has an excess of hospitalisations for seizures, whilst Epilepsy New Zealand 
field officers report few Maori clients using their services of support and information 
(Hills MD et al., 2005).
1.1.6.5. Samoa
Samoa is a small group of islands in the South Pacific Ocean, with a population of 177 
thousand people. The IMR is 27 per thousand live births, and life expectancy is 70 
years (CIA, 2006).
The economy o f Samoa is dependent on development aid and overseas remittance, as 
well as on agriculture and fishing. Approximately six percent of GDP is spent on the 
health sector. The Ministry of Health provides primary, secondary and limited tertiary 
care, financed by public sources. Most tertiary care is provided in New Zealand or 
Australia. There is some private healthcare available, and some of the population uses 
traditional healers. Non-communicable diseases are the major cause of death. Many 
patients, particularly from the rural areas, present late with advanced disease (WHO 
Regional Office for the Western Pacific, 2005).
There are no epilepsy specialists in Samoa, and no facilities for investigations (Dua, 
personal communication). Phenytoin, carbamazepine and sodium valproate are 
available (WHO, 2004). The role of primary care in epilepsy is to prescribe AEDs, 
review the patients and educate them on first aid and seizure prevention (Dua, personal 
communication).
1.1.7. Conclusion
Healthcare systems around the world vary according to the way in which they are 
financed (private insurance, social insurance, tax-based or out-of pocket), and in the way 
in which they are structured. Most countries seem to have, at least in theory, a tiered 
system, with referral from primary to specialist care. Some countries provide care 
which is free at the point of use, although some rely on out-of-pocket payments for some 
expenses. In other countries compulsory health insurance ensures care. The resource- 
poor countries frequently rely on user-fees, which prohibit many people from accessing
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healthcare. Inequalities in distribution of healthcare services and in access to it persist 
in many parts of the world.
In 1999 estimates of health life expectancy were produced for the 191 WHO member 
countries. It was found that there was a striking relationship between healthy life 
expectancy at birth and average health expenditure (Mathers et al., 2001). Other 
investigations of the same countries attempted to measure the efficiency of countries in 
providing care. It is notable that all the African countries investigated here are in the 
least efficient one third of countries, along with Russia and Samoa (ranked 127 and 131 
o f 191 respectively) (Evans et al., 2006).
Thus healthcare throughout the world depends not only on the budget available, but also 
on the efficiencies o f the systems. This is a complex area. In all countries health 
services are stretched, but in the resource-poor countries the effect of this is much 
greater and healthcare is relatively poor in terms of budget and of efficiency; care 
provided for people with epilepsy reflects this.
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1.2. P ro v isio n  o f  c lin ic a l  ser v ic es  fo r  peo ple  w ith  epilepsy  in th e  Un ited  
K ingdom
The provision of medical care for people with epilepsy in the UK is reviewed here. Any 
analysis of the adequacy of services for epilepsy needs to take into account both the 
clinical needs of the patient and the patient’s preferences.
1.2.1. Brief history of the National Health Service
People who live in the UK have most of their healthcare provided by the National 
Health Service (NHS). The NHS was set up in 1948, and is the largest organisation in 
Europe. The most important part of the new service was the GP who, as provider of 
primary care, was the gatekeeper to the rest of the NHS, referring patients to secondary 
care when necessary, and prescribing drugs. From its outset the NHS aimed to provide 
care free at the point of delivery (NHS Act, 1946), on the basis of need and not on the 
ability to pay. The service was financed through central taxation, meaning that the rich 
paid more than the poor for comparable benefits (Rivett, 2005). From the start, 
however, it had financial problems, as public expectations rose, and the innovations of 
medical science increased costs. Prescription charges were introduced in 1952, together 
with a flat rate fee for dental treatment.
In the early 1990s, in an attempt to address the problems resulting from limited 
resources and increasing demands, it was decided to establish an ‘internal market’ in 
which Health Authorities would purchase care for their populations from providers. At 
the same time, many GPs elected to hold their own budgets with which to buy 
healthcare for their patients, becoming ‘Fund Holders’. Later in the same decade, but 
with a new government, a white paper entitled ‘The new NHS - Modem, Dependable’ 
was enacted, attempting to replace the internal market with integrated care. This 
introduced the National Institute for Clinical Excellence (NICE), the Commission for 
Health Improvement, and National Service Frameworks (Rivett, 2005). In 2000 the 
NHS Plan was published, a ten year plan for investment in the NHS (Binley, 2005). It 
focused attention on the patient, and, whilst it allocated investment to the NHS, it also 
planned for devolution of power from the government to the local health service
67
Section 1
(Department of Health, 1999). Various government publications since then have sought 
to clarify how the NHS plan was put into action. In 2004 the NHS Improvement Plan 
was published, setting priorities for the NHS, and in 2005 the Department of Health 
published ‘Creating a Patient-led NHS’ (Binley, 2005). The new primary care contracts 
in 2004 were designed to reward general practices for the quality of care they provided 
rather than the number of patients under their care (NHS, 2005). More recently, patients 
have been given the choice of where and when their hospital treatment takes place 
(NHS, 2006).
The NHS is constantly evolving, and is different over the four nations of the UK.
In England the Secretary of State for Health is responsible for the NHS and the 
Department of Health is responsible for the overall planning, regulation and inspection 
o f the health service. There are 28 Strategic Health Authorities, each concerned with 
the healthcare o f one region; they need to ensure that trusts achieve national objectives 
whilst keeping services in line with local needs. Primary Care Trusts (PCTs) provide 
primary care and commission hospital services; as such they are responsible for much of 
the NHS budget. Secondary care services in England are organised in almost 300 NHS 
trusts. Some NHS trusts have opted out of NHS control to become Foundation Trusts; 
these are accountable through performance contracts with PCTs and through 
independent inspections (Binley, 2005).
In Scotland, the Scottish Executive Health Department oversees the work of the 15 area 
health boards which are responsible for health service planning. There are both primary 
care and acute hospital trusts. The Scottish Intercollegiate Guidelines Network (SIGN) 
(SIGN, 2003), aiming to improve quality of care by reducing variation in practice, 
develops national clinical guidelines based on current evidence (Binley, 2005).
The NHS Wales Department sets healthcare policy in Wales. The 22 local health 
Boards buy services from healthcare professionals in primary, secondary and tertiary 
care.
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In Northern Ireland, healthcare is overseen by the Department of Health, Social Services 
and Public Safety. Specialist care is provided by 15 acute hospitals and primary care by 
local health and social care groups, centred around general practices (Binley, 2005).
People in the UK may choose to use private healthcare; this sector is much smaller than 
the NHS. Most people are registered with an NHS GP, but may use the private sector 
for specialist care. Whilst some people pay directly for private healthcare, more are 
members of health insurance schemes, sometimes funded by employers (BBC Action 
Network Team, 2005). Private healthcare is thus more often used for one-off specialist 
treatment, or specific operations, than for chronic conditions (Medic Direct, 2006).
1.2.2. Provision of care for people with epilepsy
Epilepsy is one of the most common neurological conditions yet in the UK provision of 
care for patients with epilepsy is patchy. Since 1948 there have been six government- 
sponsored reports into epilepsy services (Hanna et al., 2002). The Clinical Standards 
Advisory Group (CSAG) report, published in 2000 (CSAG, 2000), stated that still ‘there 
is a lack of focus for services for people with epilepsy and lack of co-ordination between 
primary care, secondary care, specialist centres and the voluntary sector’.
In 1997 the Scottish Intercollegiate Guidelines Network produced guidelines for the 
management of epilepsy (SIGN, 1997), and these were updated in 2003 (SIGN, 2003). 
The National Sentinel Clinical Audit of epilepsy-related death was published in 2002, 
and reported that a majority o f people had received inadequate secondary care and that 
many deaths were potentially or probably avoidable (Hanna et al., 2002). In response to 
this, the Department of Health published its Action Plan (Department of Health, 2003b) 
which focussed the attention of health departments on epilepsy. Since then, numerous 
government initiatives and reports have included epilepsy in their recommendations. 
Particularly relevant are the NICE guidelines on the diagnosis and management of the 
epilepsies in adults and children in primary and secondary care (NICE, 2004c) and the 
NICE technology appraisals on newer drugs for epilepsy (NICE, 2004a; NICE, 2004b). 
As a result of the Action Plan, the ‘Be epilepsy aware’ card was produced by the 
Department of Health (Department of Health, 2004); this includes information on the
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risks of epilepsy, and provides contact details of epilepsy organisations. The Medicines 
Partnership also produced a leaflet for people with epilepsy encouraging them to ask for 
an epilepsy review (Medicines Partnership, 2004). Other government initiatives have 
involved care for people with epilepsy amongst others (for example, the guidelines for 
the appointment of GPs with a special interest (Department of Health, 2003a) and 
Standards for Better Health (Department of Health, 2005c)). The National Service 
Framework into long-term conditions specifically mentions epilepsy (Department of 
Health, 2005b). Recent publications, including the Expert Patients Programme 
(Department of Health, 2005a), and the new white paper ‘Our health, our care, our say’ 
(Department of Health, 2006) encourage the participation of patients in their care. The 
National Primary and Care Trust Development Programme (NatPact) included a 
competency framework for epilepsy services encouraging the use of practice epilepsy 
registers, regular check ups of people with epilepsy and effective links with secondary 
care providers (NatPact, 2005). Various non-government organisations have also 
published recommendations to improve epilepsy care. For examples of these and of 
national and governmental recommendations, see appendix 1.
Modem understanding of the nature of epilepsy began in the middle of the 19th century 
(Taylor, 2000). It was then recognised that epilepsy was a symptom of a variety of brain 
disorders. Despite the fact that most of the founding fathers of British neurology had an 
interest in epilepsy, their successors became disinterested in the subject (Sander et al., 
1993). Indeed, at the time of the inception of the NHS in 1948, there were about 50 
consultant neurologists in the UK, mainly in and around London, of whom only one or 
two had a major interest in epilepsy. By the time of the CSAG report there were about 
330 consultant neurologists in the UK, relatively few of whom had a specialist interest 
in epilepsy. In 2002 the Association of British Neurologists found that there were 358 
consultant neurologists in the UK, less than eight neurologists per million population, 
whilst France had 26 per million, the Netherlands 39 and Italy 123 (Humphrey et al.,
2002). By early 2005 the number of UK consultant neurologists had risen to 
approximately 460 (British Association of Neurologists, personal communication).
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The new contract for GPs was introduced in 2004, and brought about a major change in 
funding. The contract includes quality markers, and associated financial incentives, for 
the management of ten conditions in primary care; epilepsy is one of these conditions. 
Practices wishing to gain this funding should be able to produce a register of patients 
receiving drug treatment for epilepsy. They also receive funding for the percentage of 
patients aged 16 and over who have a record of seizure frequency, for those aged 16 and 
over with a record of medication review and for those aged 16 and over who are seizure- 
free, all in the previous 15 months (NHS Confederation and British Medical 
Association, 2003). It appears that many practices are taking up this option; in England 
in 2004-5 only approximately 50 practices did not have an epilepsy register (NHS 
Health and Social Care Information Centre, 2005). Intuitively it would seem that 
improved record keeping would translate into improved quality of care, and thence to 
improved quality o f life for people with epilepsy; there are no randomised controlled 
trials available to support or refute this notion. The way in which the review is 
performed will impact on the effectiveness of the process. If the activity is seen merely 
as a ‘tick-box’ exercise, then little will change for the better for people with epilepsy. If, 
however, GPs undertake proper reviews and react to the problems they encounter, this 
may improve the lives of people with epilepsy.
The Department of Health Action plan suggested a specific framework to help develop 
more GPs and nurses with a special interest in neurology (Department of Health,
2003b). This is already happening in parts of the UK (Rogers, 2002), and there may be 
up to 100 GPs with a special interest in epilepsy now.
Most of the deficiencies perceived by GPs and patients in the CSAG studies related to 
the interface between primary and secondary/tertiary care. Suggested ways to improve 
this communication were: epilepsy co-operation cards, shared-care protocols, electronic 
patient records/healthcare records and the sharing of data sheets and information sheets 
with GPs. Pivotal to the care was seen to be the provision of epilepsy specialist nurses, 
acting as a contact point for GPs seeking advice, visiting general practices and holding 
outreach clinics, facilitating fast-track referral, acting as a resource for information 
about local services and training GPs, practice nurses and volunteers (CSAG, 2000).
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NICE guidelines also reinforce the role of epilepsy specialist nurses, stating than they 
should be an integral part of the network of care for people with epilepsy (NICE,
2004c). In 2004 over 400 nurses were members of the Epilepsy Specialist Nurses 
Association (Epilepsy Specialist Nurses Association, personal communication). Many 
of these may include epilepsy as only a minor part of their role.
1.2.2.1. Primary care
1.2.2.1.1. New diagnosis
GPs are well placed to gain an accurate account of an initial episode suggestive of 
epilepsy. The diagnosis of epilepsy is largely based on the history of the attack (SIGN, 
2003), and the GP may well be the best person to take a detailed history from the patient 
and any eye-witnesses before salient features are forgotten or (unintentionally) 
embellished. A GP with an average sized list can expect to see one or two patients with 
new-onset epilepsy each year (Hall et al., 1997). Because of the potential problems of 
diagnosis, however, it is recommended that a consultant neurologist, or other specialist 
with an interest in epilepsy should see patients with a possible diagnosis of epilepsy 
promptly; the 2003 SIGN and 2004 NICE guidelines both suggest that the diagnosis 
should be made by an epilepsy specialist, and that patients should be seen within two 
weeks (SIGN, 2003; NICE, 2004c). The SIGN guidelines also suggest that the ‘shared 
care management system’ should ‘provide appropriate information’ once a provisional 
diagnosis has been made, and the patient referred to a specialist centre (SIGN, 2003). 
The patient should be fully informed of the specialist’s findings, as should the GP (Hall 
et al., 1997).
The Epilepsy Needs Revisited document (Brown et al., 1998) suggested that GPs should 
not usually initiate treatment, and the SIGN Guidelines confirm this, stating that the 
decision to start AEDs should be made by the patient and epilepsy specialist (SIGN,
2003). The NICE Guidelines suggest that an epilepsy specialist should recommend the 
appropriate treatment, and also plan its continuation in partnership with the patient. It is 
important that treatment is initiated with the most appropriate AED at diagnosis as, once 
patients become seizure-free, they may be reluctant to change AEDs, regardless of side- 
effects, particularly if driving licences have been obtained (Goodwin et al., 2002).
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Once the diagnosis has been established, the primary care team can help the patient to 
understand the implications of epilepsy. The following checklist has been proposed for 
the first review of the patient by the primary healthcare team, after the diagnosis of 
epilepsy has been made (Hall et al., 1997):
• Discuss the diagnosis
• Review seizure frequency; consider the use of a seizure diary
• Discuss drugs -  the benefits and side-effects
• Discuss the impact on the patient’s lifestyle
• Find out what the patient knows and fill in the gaps
• Provide addresses o f patient organisations
• Discuss contraception and pregnancy with women
• Agree a timetable for follow-up.
1.2.2.1.2. Active epilepsy
About 30% of patients who develop epilepsy will continue to have seizures despite 
treatment with AEDs, and the Epilepsy Needs Revisited document suggested that most 
o f these will require further specialist follow-up (Brown et al., 1998). It is to the GP, 
however, that most patients will have ready access when problems arise. CSAG 
recommended that, for patients in whom seizure control is sub-optimal, a management 
plan should be formulated jointly by the hospital and general practice. This would help 
to alleviate the mismatch which could occur when the patient’s epilepsy is being looked 
after by secondary or tertiary care, but when the patient has access only to the GP when 
acute problems occur. During routine visits, GPs should monitor drug dosages, seizure 
frequency, adverse drug effects, adherence to AED regimen and any other problems 
(CSAG, 2000). The NICE guidelines further propose that, for each person with 
epilepsy, there should be a comprehensive care plan that is agreed between the 
individual and primary and secondary care providers, and which includes medical and 
lifestyle issues (NICE, 2004c). Patients should receive appropriate information and 
education about all aspects of epilepsy, and some can be encouraged to manage their 
epilepsy more effectively through the Expert Patients Programme (Department of 
Health, 2005a).
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1.2.2.1.3. Controlled epilepsy
It is generally accepted that those no longer experiencing seizures can be returned to 
primary care with provision for re-referral when necessary. Primary care services for 
epilepsy, however, vary from practice to practice, and many patients receive little 
epilepsy care, their care being reactive rather than proactive (Chappell and Smithson,
1998). The NICE guidelines suggest that patients should have a regular structured 
review, performed by either the GP or specialist depending on the circumstances and 
severity of epilepsy, which should occur at least once a year (NICE, 2004c). The GP 
should re-refer the patient to secondary care if  the seizures are inadequately controlled, 
or if there are specific medical or lifestyle issues, such as pregnancy or consideration of 
withdrawal of AEDs.
1.2.2.1.4. Those not under current review
There may be problems in attempting to review all patients with epilepsy, particularly 
those who have not been reviewed for some years. Patients may not wish to be 
reminded of the diagnosis, which may have been denied or concealed (Taylor, 2000), 
and there may be anxiety about the prospect of change (Elwyn et al., 2003). It has been 
suggested that the best time to offer a review is when a prescription is due (Taylor, 
2000). In keeping with the goal of patient-centred medicine, it is suggested that the first 
requirement is to define the main problems as seen by the patient; whether directly 
seizure-related, AED side-effects or psychosocial problems (Taylor, 2000). The 
correctness of the diagnosis should be challenged, the frequency and severity of seizures 
ascertained, and all aspects of AED therapy, including adherence to drug regimen, 
discussed. It has been shown that reviewing patients with epilepsy in general practice, 
reducing polypharmacy and changing treatment, can improve seizure control in over one 
quarter of patients, and reduce side-effects in almost one quarter (Taylor, 2000). In 
many cases, however, re-referral to specialist care for these alterations may be more 
appropriate.
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1.2.2.2. Specialist Care
A major recommendation of the CSAG report was that hospital epilepsy services should 
be better organised, take a local population focus and have better links to other services; 
it suggested that the core of this service would be the epilepsy centre. Emphasis should 
be on shared care and better communication between general practice and hospital 
(CSAG, 2000).
The NICE guidelines do not specifically address models of care, nor recommend what 
form of service configuration can best provide the resources required. A Cochrane 
Review found that there were no controlled trials of suitable quality to compare epilepsy 
clinics versus general neurology or medical clinics for the treatment of people with 
epilepsy (Bradley and Lindsay, 2005). Nevertheless, several studies have shown that 
neurology opinions may contribute useful advice to, or change the diagnosis in, patients 
previously under the care of non-neurologists (Hillen and Sage, 1996; Steiger et al.,
1996), and the Association of British Neurologists states that neurologists who 
specialise in epilepsy (or other conditions) are better at managing those conditions than 
neurologists without such a specialism (Humphrey et al., 2002). Whatever form the 
clinics take, there is agreement that people needing specialist care for epilepsy should be 
treated by a specialist with an interest in epilepsy.
1.2.2.2.1. New diagnosis
As long ago as 1969 the Reid report recommended that patients who develop seizures 
should be referred for specialist opinion (Reid, 1969). This recommendation has not 
altered. The function of the hospital-led service is to:
• Confirm the diagnosis
• Initiate treatment, if indicated
• Provide initial counselling and information to patients and their families
• Monitor the response to the initial treatment, and
• Refer the patient back to the GP if the condition is stable (Brown et al.,
1998).
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The NICE guidelines (NICE, 2004c) propose that the diagnosis of epilepsy should be 
established by specialist practitioners with training and expertise in epilepsy. 
(Misdiagnosis of epilepsy is common, occurring in up to one quarter of patients referred 
to a specialist clinic (Smith et al., 1999) and in at least one fifth of people from primary 
care who were assessed by a specialist (Scheepers et al., 1998); there may be physical, 
psychosocial and socioeconomic consequences of a misdiagnosis.) After a detailed 
history o f the attack has been obtained from the patient and any eye-witnesses, a full 
physical examination, including cardiac, neurological and mental state, should be 
carried out. Appropriate investigations should be available where necessary. The 
guidelines stress that information on how to recognise a seizure, and first aid for 
seizures should be provided to the individual, to the family and to carers. Some 
information should be provided while the diagnosis is awaited. Once epilepsy is 
diagnosed, seizures and syndromes should be classified using a multi-axial diagnostic 
scheme. The decision to start AED treatment should be made after full discussion of the 
risks and benefits, taking account of the person’s epilepsy syndrome, prognosis and 
lifestyle. Treatment (where appropriate) should be initiated by the specialist, who 
should also plan the continuation of treatment, and manage, or provide guidance for, 
withdrawal o f AEDs. The National Service Framework (NSF) for Long-term 
Conditions (Department of Health, 2005b) requires that people suspected of having a 
neurological condition are to have prompt access to specialist neurological expertise for 
an accurate diagnosis and treatment as close to home as possible, and also supports the 
Public Service Agreement objective III (part of HM Treasury) to ensure that by 2008 no 
one waits more than 18 weeks from GP referral to hospital treatment.
1.2.2.2.2. Active epilepsy
Those with continuing seizures should benefit from continuing secondary care, with 
additional investigations and treatments being available. Video telemetry and high 
resolution MRI may be indicated, and the patient may need to try second-line or 
experimental drugs, or be assessed for epilepsy surgery (Brown et al., 1998). All people 
with epilepsy should be able to consult a tertiary care specialist (via the secondary care 
specialist) should the circumstances require this (NICE, 2004c). Suggested criteria for 
referral to tertiary care are:
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• Epilepsy not controlled with medication within two years, or after two AEDs
• Unacceptable side-effects of AEDs
• Presence of a unilateral structural lesion
• Psychological or psychiatric comorbidity
• Diagnostic doubt (NICE, 2004c)
1.2.2.2.3. Controlled epilepsy
Although those adult patients who become seizure-free will probably not need ongoing 
secondary care, it is important that re-referral can be swiftly instigated should seizures 
recur, or circumstances changes (e.g. impending pregnancy). NICE suggests that AED 
withdrawal should be discussed with adults who have been seizure-free for at least two 
years; it is important that this decision is made by the patient and the specialist after a 
full discussion o f the risks and benefits, and that the withdrawal be under the guidance 
of the specialist (NICE, 2004c). In children a regular structured review, occurring at 
least yearly, should be provided by a specialist (NICE, 2004b).
1.2.2.3. A ccident and emergency care
A survey in Leeds in 1998 showed that less than a quarter of patients with epilepsy- 
related emergencies seen in A&E were referred for neurological follow-up, noted to be 
under regular specialist follow-up or admitted to the neurology ward (Reuber et al., 
2000). A more recent audit of 38 patients with a first seizure seen in an accident and 
emergency department found that, of 22 patients discharged, either with an appointment 
to see a neurologist or a letter to the GP advising such referral, only 10 (45%) were seen 
by a neurologist (Bhatt et al., 2005). The mean wait was 21 weeks, and range six to 44 
weeks. The NICE guidelines recommend that A&E departments should develop 
protocols to ensure that people with suspected seizures are properly assessed, and that, 
once initial screening has been performed by a suitable physician, onward referral to a 
specialist should follow whenever an epileptic seizure is suspected (NICE, 2004c).
1.2.2.4. Use o f  AEDs
Drug therapy is the most important part of the management of the epilepsies (NICE, 
2004a). In the UK AEDs are generally not prescribed unless the person has had at least
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two unprovoked seizures, unless there are other factors such as certain EEG 
abnormalities which make recurrence after a first seizure extremely likely. Therapy 
with a single AED is recommended wherever possible, but some people will need to try 
several different AEDs before the seizures are fully controlled, and a minority will need 
to be treated with two or more AEDs (NICE, 2004a). The most commonly prescribed 
AEDs in the UK are sodium valproate (often for generalised seizures) and 
carbamazepine (often for seizures with partial onset). Phenytoin and phenobarbital may 
be effective in partial onset seizures, but they are not recommended as first line 
treatment in the NICE guidelines (NICE, 2004c). A variety of other older AEDs are 
also sometimes used, often for specific indications.
Since the late 1980s, nine ‘new’ AEDs have been licensed in the UK, and two recent 
NICE technology appraisals (Newer drugs for epilepsy in adults (NICE, 2004a), and in 
children (NICE, 2004b)) have been published. In adults the use of these newer drugs is 
recommended in people who have not benefited from the older drugs, or in whom the 
latter are unsuitable for a variety of reasons such as drug interactions or in women who 
may become pregnant. The guideline for children also suggests other qualifications for 
newer AEDs, such as avoiding the introduction of sodium valproate in a young girl who 
may need to continue taking it for several years (NICE, 2004b).
The use of barbiturates (phenobarbital and primidone), phenytoin, sodium valproate and 
topiramate are considered further in this thesis. Neither carbamazepine nor lamotrigine 
is considered further as the clinical records audited did not generally provide enough 
information to assess their suitability. Most other AEDs were not taken by sufficient 
numbers of people in the audit to enable their usage to be assessed with any accuracy.
1.2.2.5. Investigations
1.2.2.5.1. EEG
In 1998 the Epilepsy Needs Revisited document suggested that every person with newly 
diagnosed epilepsy would need at least one standard EEG to assist in syndrome 
diagnosis (Brown et al., 1998). The 1997 SIGN pilot guidelines, whilst acknowledging 
the importance of syndromic classification, considered that in patients under 25 years
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old, EEG should be performed to assist in the classification of the seizures (SIGN,
1997). The age cut-off was suggested as presentation with an idiopathic generalised 
epilepsy was thought rare after 25 years old. By the time of the publication of the SIGN 
guidelines in 2003, it was stated that EEG is not routinely indicated and should not be 
used to exclude a diagnosis of epilepsy, but can be used to support the classification 
(SIGN, 2003). It should be used in young people with generalised seizures to aid 
classification and detect a photoparoxysmal response. The NICE guidelines agree that 
an EEG should only be used to support a diagnosis of epilepsy, and should not be used 
to exclude the diagnosis in cases of probable syncope or non-epileptic attack (NICE, 
2004c). Sleep or sleep-deprived EEGs, and video EEG monitoring may be required if 
diagnostic uncertainty persists.
1.2.2.5.2. Neuroimaging
In 1997 it was advised that best practice is to carry out MRI in all patients with epilepsy, 
with the exception of patients who have a definite electroclinical diagnosis of idiopathic 
generalised epilepsy, or benign epilepsy of childhood with centrotemporal spikes. It is 
particularly indicated where there is evidence of partial onset, evidence of a focal fixed 
deficit on examination, and difficulty in gaining or maintaining control of seizures 
(Wallace et al., 1997). The SIGN guidelines suggest that MRI is the current reference 
standard for epilepsy, but is not routinely required in idiopathic generalised epilepsy 
with complete response to a first line AED (SIGN, 2003). The NICE guidelines echo 
this advice, adding that MRI is also required in people who develop epilepsy under two 
years old, or in adulthood (NICE, 2004c). CT scanning is used where MRI is 
unavailable or contraindicated, and in some emergency situations (NICE, 2004c).
1.2.2.6. Surgery
Surgical treatment for epilepsy is sometimes suitable for people who have partial 
epilepsy resistant to drug treatment (having not gained seizure control with two 
appropriate AEDs in adequate dosage) (SIGN, 2003). Assessment for surgery should be 
carried out in a specialist unit, (SIGN, 2003) with experienced staff, and involves a 
multi-disciplinary approach including neurologist, neurosurgeon, psychologist, 
psychiatrist, neurophysiologist and radiologist (Walker and Fish, 2005b). In many
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cases, the aim of surgery is to remove the epileptogenic focus; to be sure of accuracy in 
doing this it is recommended that congruent results are found in the clinical history and 
in the results of a variety of investigations, such as neuropsychometry, neuroimaging 
and EEG. Sometimes more invasive investigations are performed, including intracranial 
EEG monitoring (Walker and Fish, 2005b). It is also important to establish whether 
surgery is likely to disrupt other key areas of brain function, such as speech (Harkness 
and McEvoy, 2005).
1.2.2.7. Information provision
Most epilepsy publications stress the importance of information provision for people 
with epilepsy (Brown et al., 1998; Chappell and Hall, 1997; CSAG, 2000; Hall et al., 
1997; Leeds Health Authority, 1999; Smith and Leach, 2003). Much information is 
crucial to the health and safety of the person with epilepsy, while other information is 
important in encouraging adherence to the AED regime and reducing the stigma of 
epilepsy.
1.2.2.8. Special Groups
1.2.2.8.1. Learning disability
Epilepsy and learning disabilities are both common conditions, but they both occur 
together more often than predicted by chance; this may be because the two 
neurodevelopmental disorders often have a common aetiology. The prevalence of 
epilepsy seems to increase as IQ decreases -  about 15% of those with IQ between 50 
and 69 have epilepsy, compared with 30% in those with more severe learning disability 
(EUCARE, 2003). Those with more severe learning disability are also more likely to 
have a more mixed seizure presentation (Clark et al., 2001). Epilepsy is said to be 
almost inevitable in those whose severe learning disability is caused by postnatal injury 
(Jenkins and Brown, 1992).
Both epilepsy and learning disability are indicators of early mortality and of psychiatric 
disorders (Branford et al., 1998a). The incidence of SUDEP is three-times higher in 
people with epilepsy and learning disability, compared with those with epilepsy in the 
general population (Lhatoo and Sander, 2001).
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The treatment of epilepsy in those with learning disability is complicated. Patients often 
present with multiple seizure types, and behavioural problems are more frequent 
(EUCARE, 2003). The difficulty o f diagnosing epilepsy in people with learning 
disability is recognised; difficulties arise through the presence of stereotypic and drug- 
induced movement disorders in people with learning disability (Bowley and Kerr,
2000). People with learning disability are entitled to the same degree of investigation 
and treatment as any other group (Jenkins and Brown, 1992; NatPact, 2005). The NICE 
guidelines add that the learning disability team should be involved in the care of people 
with epilepsy and learning disability (NICE, 2004c).
Epileptic syndrome diagnosis, identification of non-convulsive status, and the diagnosis 
o f Non-Epileptic Attack Disorder almost always require EEG investigation (Jenkins and 
Brown, 1992). This may be difficult, but good quality recordings can usually be 
obtained, occasionally with the use of light anaesthesia. However, caution is required in 
interpreting the EEG o f people with underlying brain damage, as it may be complicated 
by background changes. MRI may be required to make an aetiological diagnosis, to 
assess change and to aid future planning (Jenkins and Brown, 1992).
Drug treatment in people with epilepsy and learning disability is often complex.
Seizures are often difficult to treat, or even intractable, leading to the use of 
polypharmacy (EUCARE, 2003). Although monotherapy is desirable, two studies 12 
years apart in Leicestershire, with 138 subjects common to both, found both fewer 
patients on monotherapy or no AEDs and more patients with active epilepsy at the 
second time point (Branford et al., 1998b). This was contrary to expectations, and the 
authors postulated that this might be because at the earlier time epilepsy and AEDs were 
the focus of an expert team, whilst at the later date epilepsy was reviewed by GPs or by 
psychiatrists specialising in learning disability.
Drugs used in epilepsy can affect cognition because of sedative side-effects (e.g. 
phenobarbital, phenytoin, benzodiazepines), or can affect learning indirectly by causing 
side-effects such as diplopia and irritability (Besag, 2001b). Phenobarbital has been
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shown to produce serious memory impairment, and phenytoin can cause moderate to 
large effects on cognitive function (Aldenkamp, 2001). Valproate may cause mild to 
moderate impairment of psychomotor and mental speed, but carbamazepine causes 
either no or mild cognitive impairment. Few controlled studies exist to interpret the 
cognitive effects of newer AEDs, but there is clear clinical evidence for topiramate- 
induced cognitive impairment, probably even when slow titration and relatively low 
doses are used (Aldenkamp et al., 2003). Lamotrigine has a selective positive effect on 
cognitive activation, which may be partially explained by its reduction of spontaneous 
epileptiform discharges. However, lamotrigine may have some negative effects such as 
restlessness and hyperactivity. Oxcarbazepine does not affect cognitive function in 
healthy volunteers and adult patients with newly diagnosed epilepsy and no definite 
conclusions can yet be drawn on the cognitive effects of levetiracetam. Tiagabine has 
no significant effect on cognitive function, and the only problem noted with gabapentin 
is drowsiness at higher doses (Aldenkamp et al., 2003).
Polypharmacy has a more marked negative impact on cognitive function than 
monotherapy, regardless of which AEDs are used (Aldenkamp et al., 2003). An audit of 
adult inpatients with learning disability found that 16% were being treated with three or 
more AEDs, and 37% patients were identified who might benefit from a reduction in the 
number of AEDs prescribed (Tiffin and Perini, 2001). Another problem in the 
treatment of people with epilepsy and learning disability is that doctors and patients may 
see side-effects differently. Treatment of people with learning disability is often by 
‘proxy’ as the patient is not able to contribute views (Kerr, 2005). The NICE guidelines 
stress that in people with epilepsy and learning disabilities particular attention should be 
paid to the possibility of adverse cognitive and behavioural effects of AEDs (NICE, 
2004c).
As in people without learning disability, for patients with learning disability and 
epilepsy that is refractory to treatment, the question of surgery arises. This is not an 
option in some patients, as they may have diffuse epileptogenic regions (Baker, 2001). 
Surgery must be likely to lead to a decrease in seizures and to an increase in quality of 
life, and any contraindications must be considered. However, it is also necessary to
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determine whether the patient is able to understand the risks and benefits of surgery, and 
to have realistic expectations. The situation is further complicated by the fact that there 
are few neuropsychological tests available specifically for people with learning 
disability (Baker, 2001). Surgical ablation of the epilepsy focus may have positive or 
negative effects on the process of learning. Ablation generally produces positive effects, 
as it eliminates the negative consequences of the epileptic discharges that go from this 
area to other parts of the brain. However, it may lead to a functional deficit, causing 
negative postoperative results, if  the brain area previously retained some of its own 
primary function (Comaggia and Gobbi, 2001).
Overall it is important to assess the individual, and the impact of epilepsy on that 
individual, to assess treatment options and to apply a management plan, so that people 
with learning disability and epilepsy can live as inclusive a life as possible (Kerr, 
personal communication).
1.2.2.8.2. Women
In all people with epilepsy, the need for seizure control should be balanced against the 
side-effects of AEDs. Women with epilepsy have additional concerns with respect to 
interactions of AEDs with oral contraceptives and with the potential adverse effects of 
AEDs on the developing foetus, as well as any problems related to breast-feeding. 
Women with epilepsy may have additional problems, not directly related to AEDs: in 
some women seizures are affected by the menstrual cycle; fertility may be reduced in 
women with epilepsy; there may be an increased risk of foetal malformation in women 
with epilepsy compared with those without epilepsy; and a mother with epilepsy may 
have problems in caring for her baby. All women with epilepsy of childbearing age 
should be given information about epilepsy and pregnancy, and this should be repeated 
at review appointments. The advice on contraception should be given before young 
women are sexually active (NICE, 2004c; SIGN, 2003). Additionally, in young girls 
who may need to continue treatment into childbearing years, the risks and benefits of 
particular AEDs should be discussed with the child and carers when AEDs are 
prescribed (NICE, 2004c).
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Several AEDs (notably phenytoin, phenobarbital, primidone, carbamazepine, 
oxcarbazepine and topiramate) interfere with the metabolism of the oral contraceptive 
pill, requiring the use of higher oestrogen doses to avoid possible contraceptive failure 
(Bell et al., 2002). It has recently been shown that lamotrigine may cause a fall in 
norethisterone concentrations, also increasing the risk of unplanned pregnancy if usual 
oral contraceptive doses are used (Crawford, 2005). Lamotrigine levels themselves may 
be altered by hormonal contraceptive pills (Stodieck and Schwenkhagen, 2004; 
Schwenkhagen and Stodieck 2004).
About ten percent of women have catamenial seizures (where seizures increase in 
frequency around the time of menstruation) (Crawford, 2005). The prevalence of 
polycystic ovary syndrome is thought to be higher in women with epilepsy than in those 
without, and is sometimes related to use of sodium valproate. Fertility is reduced in 
women with epilepsy; the reasons are probably multifactorial (O’Brien and Gilmour- 
White, 2005).
Most women with epilepsy have uneventful pregnancies, with over half of a large cohort 
recently reported being seizure-free throughout (EURAP epilepsy pregnancy registry, 
2006). Pre-pregnancy planning is desirable for all women, but particularly so for 
women with epilepsy (Crawford, 2005); control of seizures should be optimised on the 
lowest effective dose of the most appropriate AED. Monotherapy should be used 
wherever possible, particularly as the incidence of foetal malformations increases with 
the number of AEDs taken during the first trimester of pregnancy (Nakane et al., 1980). 
Sometimes, if the woman has been seizure-free for several years, withdrawal of AEDs 
can be considered; this should be overseen by a specialist in epilepsy. Pregnancies 
exposed to sodium valproate, particularly as part of a polytherapy regime, seem to be 
especially at risk; the risk of major congenital malformation in the offspring of women 
taking valproate as part of a polytherapy combination is nine percent (Morrow et al., 
2006). Women with epilepsy need to consider the safety considerations in looking after 
their babies, particularly as sleep deprivation may have detrimental effects on seizure 
control. Practical advice such as not bathing the baby while alone may be useful, 
although evidence of the effectiveness of advice is limited (Fox and Betts, 1999). The
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decision whether or not to breast-feed has to balance the benefits to mother and child 
with the small risk o f toxicity to the infant.
1.2.2.8.3. Care for other special groups
One major aim of the NHS is equity of care. A discussion paper from the London 
School o f Economics reported that the evidence comparing NHS utilisation and 
morbidity with socio-economic groups is not clear-cut. Socially disadvantaged people, 
however, tend to present later to medical care, with more advanced disease and may be 
more likely to go to the A&E department instead of to the GP. They also tend to have 
higher drop out rates or non-compliance with management (Dixon et al., 2003). All of 
these are likely to have adverse consequences for people with epilepsy. One aim of 
good epilepsy services should be to provide equity of access and care.
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1.3. M orta lity  in peo ple  w ith  epilepsy
1.3.1. Introduction
More than two thirds of people diagnosed with epilepsy will cease to have seizures, 
either because the condition remits spontaneously, because of the use of AEDs or 
surgery, or both. There is little doubt, however, that people with epilepsy are more 
likely to die prematurely than those without it. There are several ways of quantifying 
the risk of death.
• The Standardised Mortality Ratio (SMR) uses the age-specific mortality rates of the 
population from which the study group came, and calculates the number of deaths 
expected in the study group if it experienced those age-specific mortality rates. The 
ratio of the observed number of deaths to the number expected is then calculated -  
this is the SMR.
• The case fatality is the ratio o f the number of deaths among people with the disease 
over a defined period of follow-up to the number of newly incident cases of the 
disease at the start of the follow-up period.
• The proportionate mortality ratio is the number of deaths that occur in a defined 
population due to a specific cause divided by the overall deaths.
•  Relative survivorship is the proportion of observed to expected number of survivors 
(Olafssonet al., 1998).
No one method is ideal. SMRs should not be compared across groups with different age 
structures in the study population (Forsgren et al., 2005), and PMRs are influenced not 
only by an increase of one cause of death, but also by decreases of other causes. The 
most useful and commonly used figure for epilepsy is the SMR. The risk of death is not 
uniform over the lifetime of a person with epilepsy, nor across different populations of 
people with epilepsy.
1.3.1.1. A ccuracy o f  mortality data
There are many problems in calculating mortality figures for epilepsy. Epilepsy can be 
hard to diagnose; 12 of 92 people referred to a specialist clinic with ‘refractory epilepsy’ 
did not have epilepsy (Smith et al., 1999), and 21% of patients in a study of mortality 
from a hospital in Sweden were found to have been misdiagnosed, having had acute
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symptomatic seizures, single seizures or non-epileptic attacks (Nilsson et al., 1997). Of 
223 children referred to a tertiary epilepsy centre in Denmark with difficult to treat 
paroxysmal events, 87 (39%) did not have epilepsy (Uldall et al., 2006). Classification 
of epilepsy syndromes is also problematic, particularly in resource-poor countries, but 
also in industrialised nations (Loiseau et al., 2005) and the mortality rate is different for 
different epilepsy syndromes (see later).
Case ascertainment can also be extremely difficult. Any study of epilepsy will miss 
patients who do not present their symptoms to the medical services. In a UK hospital 
study the median number of seizures before referral was four for people with tonic 
clonic seizures and 44 for those with partial seizures (Shorvon, quoted in Hart et al., 
1990). Some people may conceal their seizures to avoid stigma or other problems, 
while others may not realise that their symptoms could be epilepsy (Zielinski, 1974b). 
One commonly used method of case ascertainment for studies of death in epilepsy is the 
use of death certificates. Death certificates can be an unreliable source of information 
on cause of death (Hauser et al., 1980; Zielinski, 1974a) and, although autopsy and 
supplementary clinical data improve accuracy, certificates remain subject to bias and 
error. It has been pointed out that reliance on death certificates will underestimate the 
mortality of epilepsy (Morgan and Kerr, 2002). Although the underestimation is not 
controversial, its extent is unknown. Use of death certificates may identify many of the 
people who die from an epilepsy-related death, but it may miss many people with 
epilepsy who die of other causes. Another common method of case-ascertainment, use 
of AED prescriptions, is also liable to inaccuracies. Some people with epilepsy do not 
take AEDs, either because they choose not to do so (possibly because of side-effects), or 
because they do not adhere to the regimen. Additionally, AEDs can be used for diseases 
other than epilepsy, such as neuropathic pain, trigeminal neuralgia, bipolar affective 
disorders and migraine prophylaxis. In resource-poor countries there is a large 
treatment gap, with a majority o f people with epilepsy not taking AEDs.
Another issue in case ascertainment is the definition of the study population. Early 
studies from institutions for people with epilepsy and hospital based populations showed 
epilepsy to be a progressive, incurable disease, as milder cases were not represented.
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Population-based studies, however, may include people whose epilepsy has not been 
fully characterised.
It is difficult to disentangle the effects of epilepsy from those of the underlying 
conditions causing the epilepsy. For this reason some studies compare mortality rates in 
people with remote symptomatic epilepsy with people with the underlying condition 
(e.g. learning disability) but without seizures (Day et al., 2005; Strauss et al., 2003). 
Those with idiopathic epilepsy are usually compared with people in the general 
population, but it is difficult to account for all possible confounders. A recent editorial, 
in response to a paper considering life expectancy in people with epilepsy, asked 
whether life expectancy would be different for someone with a stroke who developed 
epilepsy and someone who did not (Tomson and Forsgren, 2005). Again, it would be 
almost impossible to eliminate confounders such as the location and severity of the 
stroke.
1.3.2. Mortality in epilepsy
Almost all studies show premature mortality in epilepsy, and the figure generally quoted 
is an SMR of two to three (Cockerell et al., 1996; Lhatoo and Sander, 2005). This 
overall figure, however, encompasses different study populations, with a variety of 
epilepsy syndromes, different ages of subjects, and different study durations, all of 
which have been shown to affect the mortality rate.
1.3.2.1. Time since diagnosis
In a study of patients with newly diagnosed epilepsy in Holland, the SMR was highest 
soon after diagnosis and decreased thereafter (being 16 in the first two years and 2.8 
later) (Shackleton et al., 1999). In the population-based UK National General Practice 
Study of Epilepsy and Epileptic Seizures (NGPSE) the overall SMR in those with 
definite epilepsy was 6.6 (95% Confidence Interval [Cl] 4.8 to 8.7) in the year after the 
index seizure (the seizure which led to identification of epilepsy), and decreased 
thereafter, remaining significantly raised until four years after the index seizure 
(Cockerell et al., 1994). Further follow-up of this cohort revealed a slight but 
significant rise in mortality after nine years after the index seizure (SMR 1.8 [95%CI 1.1
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to 2.7] at nine to 14 years) (Lhatoo et al., 2001). A similar finding was shown in a study 
of people with newly diagnosed unprovoked epileptic seizures in Sweden, where the 
SMR was increased for the first 2 years after diagnosis, but not thereafter, until nine 
years after diagnosis when it was again raised to 5.4 (95% Cl 2.7 to 11.2) (Lindsten et 
al., 2000). The early papers from Rochester (USA) found the mortality to be 
significantly raised for the first ten years after diagnosis, and again after 25 years 
(Hauser et al., 1980).
1.3.2.2. Type o f  epilepsy
This seems to be one of the most significant factors leading to the variation in SMRs 
quoted; it interacts with the time after diagnosis.
1.3.2.2.1. Idiopathic/cryptogenic epilepsy
In epidemiological studies idiopathic and cryptogenic epilepsies are frequently grouped 
together. Most studies show either no increase in SMR or a very modest, non­
significant increase (Lindsten et al., 2000; Loiseau et al., 1999). A few studies show a 
borderline raised SMR (Cockerell et al., 1994) - although this was no longer 
significantly raised in the later report from the same patient group (Lhatoo et al., 2001) - 
or increased SMRs in selected groups only (Olafsson et al., 1998). The large study from 
the US found that the SMR for idiopathic epilepsy was slightly increased for the first ten 
years after diagnosis, then was at most marginally increased until 25 years after 
diagnosis, and then was raised to 3.2 (Hauser et al., 1980). One study shows minimal 
reduction of life expectancy in this group (Gaitatzis et al., 2004b).
1.3.2.2.2. Symptomatic epilepsies
Most studies show the SMR to be increased in symptomatic epilepsies, with a range of 
SMR from 2.3 after 30 years in Iceland (Olafsson et al., 1998) to 6.5 in a short-term 
follow-up of people with a first epileptic seizure in France (Loiseau et al., 1999). 
Relative survivorship was also confirmed to be lower than for people with idiopathic 
seizures in the Iceland study (Olafsson et al., 1998).
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1.3.2.2.3. Epilepsy associated with congenital neurodeficit
This is associated with significantly raised SMRs, of between 11 (Hauser et al., 1980) 
and 50 (Cockerell et al., 1994). The longer follow-up of the latter study showed a lower 
SMR associated with these conditions, but it was still very high (Lhatoo et al., 2001).
1.3.2.3. Age
Both current age and age at diagnosis seem to affect the mortality rate in people with 
epilepsy. The NGPSE found the highest SMRs (over eight) in the 50 to 59 year age 
group, decreasing with increasing age thereafter (Lhatoo et al., 2001). The Swedish 
hospital-based study showed the highest SMR in those aged below 35 years; this also 
decreased with increase in age (Nilsson et al., 1997). The Dutch study showed an SMR 
of 48 in those aged up to four years, and this decreased fairly steadily until the age of 45 
years, when it levelled off. It was significantly increased in all those under 65 years old. 
Age at diagnosis follows a similar pattern; the Dutch study showed an SMR of 24 in 
those aged under 20 years at diagnosis, compared with an SMR of 2.5 in those older at 
diagnosis (Shackleton et al., 1999).
In children in general the excess death rate seems to be due to the underlying pathology 
and not to the seizures. Three large studies in children all show a minority of deaths to 
be possibly seizure-related (Berg et al., 2004; Camfield et al., 2002; Shinnar et al.,
2005).
1.3.3. Cause of death
The cause of death in people with epilepsy is often described as being either unrelated to 
epilepsy, related to the underlying condition causing epilepsy or related to epilepsy 
itself. It has been suggested that approximately half the deaths are epilepsy-related, and 
half not, and that only one fifth of the epilepsy-related deaths are seizure-related 
(Forsgren, quoted in Loiseau et al., 1999).
A few studies have shown rates of cause-specific mortalities (Hauser et al., 1980; 
Klenerman et al., 1993; Lhatoo et al., 2001; Lindsten et al., 2000; Rafnsson et al., 2001). 
Together they suggest that somewhere under one third of deaths are due to malignancy
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(including primary brain tumours), one tenth to one quarter are due to ischaemic heart 
disease, just under one fifth to cerebrovascular disease, and under one quarter to 
pneumonia.
1.3.3.1. Death due to the underlying disease causing epilepsy 
Death due to the underlying disease causing the epilepsy is relatively common, and 
accounted for 19% of deaths in those who died within the first two years of follow-up 
and 15% of deaths thereafter in the study from Holland. In that study the SMR was 16 
in the first two years of follow-up and 2.8 thereafter (Shackleton et al., 1999). The 
marked trend of decreased SMR over time found in studies such as the NGPSE is 
thought to be due to the early death of patients from the underlying disease (Cockerell et 
al., 1994). In the study with short term follow-up after a first seizure, 25% of those 
dying with provoked seizures did so within the first week (Loiseau et al., 1999).
In an attempt to control for deaths due to the underlying disease, studies from California 
and Sweden have looked at large populations of people with learning disability, some of 
whom also had epilepsy (Day et al., 2005; Forsgren et al., 1996; Strauss et al., 2003). 
The Swedish study, a seven-year follow-up of almost 1,500 people with learning 
disability, 296 of whom had epilepsy, found the SMR to be 2 for those without epilepsy, 
and 5 for those with epilepsy, suggesting that part of the increased mortality rate is due 
to the underlying brain disorder (Forsgren et al., 1996). The study from California, 
including only relatively high functioning subjects, and excluding those with idiopathic 
epilepsy, compared 70 thousand people without epilepsy and eight thousand with 
epilepsy. There were 1523 deaths between 1988 and 1999. The mortality ratio of 
people with epilepsy compared with those without was only 1.1 for those with no 
seizures in the previous year, 2.4 for those with seizures (but no tonic clonic seizures) in 
the previous year and 2.9 for those with generalised tonic clonic seizures (GTCS) in the 
previous year. This suggests that seizures are relevant to the deaths; the study did not 
compare death rates with those in the general population (Strauss et al., 2003).
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1.3.3.2. Death related to epilepsy
Death from status epilepticus (SE), sudden unexpected death in epilepsy (SUDEP), 
deaths due to accidents or drowning, treatment-related deaths and, sometimes, suicide 
are considered to be deaths related to epilepsy.
In some studies in institutionalised patients, the PMR due to epilepsy is up to 35% 
(Iivanainen and Lehtinen, 1979; Klenerman et al., 1993; Krohn, 1963; White et al., 
1979). It is lower in population-based studies (between two and fourteen percent) 
(Lhatoo et al., 2001; Zielinski, 1974a).
1.3.3.2.1 Status epilepticus
SE can occur de novo in people without existing epilepsy, but around half of all cases of 
SE occur in people with epilepsy. In early studies from epilepsy institutions SE 
accounted for between six and nine percent of deaths (Iivanainen and Lehtinen, 1979; 
Krohn, 1963), and more recently it was shown to account for four percent o f deaths in 
people with remote symptomatic epilepsy (Day et al., 2005).
SE can lead to profound systemic and neurological damage, and carries a significant 
short-term and long-term mortality rate (Logroscino et al., 2002; Simon et al., 1997), 
particularly in adults. The case fatality of SE is higher in those with acute symptomatic 
seizures and in the elderly, and is particularly high in myoclonic SE (Logroscino et al., 
2001). The incidence of SE may be falling (Wu et al., 2002).
In children, SE may be the first epileptic event, but in adults the data are conflicting; 
between 30 and 71% of all adults presenting in SE do not have pre-existing epilepsy 
(Shorvon, 1994). About five percent of all people with epilepsy have at least one 
episode of tonic-clonic SE, and a precipitating factor can be found in over half of these. 
Important precipitants are acute AED withdrawal (either due to poor adherence to drug 
regimen or under medical supervision), withdrawal of other drugs or alcohol, infections, 
intercurrent illness or progression of the underlying lesion (Sander and Hart, 1997). It is 
important to reduce these precipitants where possible. Adherence to drug regimen 
should be encouraged, and the risks of not doing so explained.
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1.3.3.2.2. Sudden Unexpected Death in Epilepsy (SUDEP)
SUDEP can be defined as ‘sudden, unexpected, witnessed or unwitnessed, non- 
traumatic and non-drowning death in patients with epilepsy, with or without evidence 
for a seizure and excluding documented status epilepticus, in which postmortem 
examination does not reveal a toxicological or anatomical cause for death’ (Nashef,
1997). The other commonly used definition includes death occurring suddenly and 
unexpectedly, during normal activities and benign circumstances, excluding death from 
trauma or intractable status epilepticus, in an individual diagnosed with epilepsy; no 
obvious medical cause of death should be found (Leestma et al., 1997). In 1868 Bacon 
noted the occurrence o f ‘sudden death in a fit’ (Nashef, 1997) and over 30 years later 
Spratling found that four percent of deaths in people with epilepsy were the direct result 
o f a seizure, with no other explanation found (Terrence et al., 1975). Despite this, in the 
1960s it was suggested that ‘there is no reason why ...someone with epilepsy... should 
not live as long as he would if he did not have epilepsy’ (O'Donoghue and Sander,
1997). Awareness has again increased over recent years, yet in many countries the 
medical profession has been reluctant to consider SUDEP (Lear-Kaul et al., 2005). 
Indeed, there is little comparative data on the incidence of SUDEP in different 
countries.
By definition, the causes of SUDEP are unknown. Nevertheless establishing risk factors 
can be useful; individual patients can be advised on minimising avoidable risks, and 
evaluation of risk factors can point to areas of future research to try to establish potential 
causes and mechanisms of SUDEP.
Most studies of SUDEP have been in selected populations. In the majority (about 70%) 
of people with newly incident epilepsy the seizures remit, with or without the use of 
AEDs; SUDEP is rare in these populations (Lhatoo et al., 1999). Whilst studying this 
group might provide valuable insights, searching for risk factors would require 
meticulous follow-up of large cohorts. Groups studied have therefore usually had a 
more severe form of epilepsy than most, with tertiary care clinics (Nashef et al., 1995b), 
people ever hospitalised (Nilsson et al., 1999), residential groups (Nashef et al., 1995a)
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or surgical candidates (Hennessy et al., 1999) being followed. Some studies use AED 
prescriptions to identify people with epilepsy (Derby et al., 1996; Tennis et al., 1995).
In all studies the risk of sudden death in epilepsy is found to be elevated. It is usually 
estimated as between 1:500 and 1:1000 patient-years in community-based populations 
with epilepsy, and up to 1:100 in surgical series.
Of the many risk factors suggested for SUDEP, few have been proved conclusively. 
Evidence is frequently conflicting; the size of the cohort studied, the control group used, 
the methodology of the study and the definition of SUDEP may all affect the risk factors 
identified (O'Donoghue and Sander, 1997; Tellez-Zenteno et al., 2005). More 
consistent risk factors include young adulthood, early age of onset of seizures, presence 
of generalised tonic clonic seizures, higher frequency of seizures, polytherapy and poor 
adherence to AED regimen. Others suggested have been male gender, symptomatic 
epilepsies versus idiopathic, Afro-American background, frequent changes of dose or 
type of AED, alcohol abuse, presence of comorbid learning disability and presence of 
nocturnal seizures.
1.3.3.2.2.1. SUDEP: age at death
The definitions of SUDEP require no anatomical or toxicological cause for death found 
at post-mortem examination (Leestma et al., 1997; Nashef, 1997). Many elderly people 
have evidence of cerebrovascular or cardiovascular disease and it may be difficult to 
exclude this as a cause of death; as a result the elderly are less likely to fulfil this 
negative requirement of the definition, and so be classified as SUDEP. Thus the rate of 
SUDEP estimated in the elderly may be falsely low.
Different studies have found different decades of peak incidence of SUDEP; e.g. third 
and fourth decades (Antoniuk et al., 2001), second and fifth decades (Terrence et al., 
1975). Mean ages of death range from 26 to 37 years (Langan et al., 2005; Langan et 
al., 1998; Lear-Kaul et al., 2005; Leestma et al., 1989; Leestma et al., 1997; Nashef et 
al., 1995b; Timmings, 1998). However, SUDEP may occur in children (Earnest et al., 
1992; Nashef et al., 1995a).
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1.3.3.2.2.2. SUDEP: age of onset of seizures
A retrospective study investigating deaths in a tertiary referral centre population with 
chronic refractory epilepsy found the age of onset to be slightly, but significantly, lower 
in the SUDEP group than in the group who died of causes other than SUDEP (mean age
8.2 years vs 12.7 years) (Kloster and Engelskjon, 1999). A case-control study in 
Sweden found that, in men, onset of epilepsy in childhood or early adolescence 
compared with onset after 45 years increased the relative risk of SUDEP almost 18 
times. This association was not significant in women (Nilsson et al., 1999). Other 
studies have found long duration of epilepsy in people dying with SUDEP (Earnest et 
al., 1992; Lear-Kaul et al., 2005; Leestma et al., 1989; Leestma et al., 1997; Nashef et 
al., 1995b; Timmings, 1998). Young age of onset of seizures is often correlated with 
long duration of epilepsy. A study of mortality in AED development programmes did 
not, however, find that the SUDEP rate increased with the duration of the epilepsy 
(Racoosin et al., 2001).
1.3.3.2.2.3. SUDEP: presence o f tonic-clonic seizures
SUDEP is usually unwitnessed, but when witnessed often follows a generalised tonic 
clonic seizure. Evidence for a seizure prior to death is frequently, but not always, found 
at post-mortem examination. In the study comparing patients with epilepsy who died 
with SUDEP with those dying from other causes there were signs of seizures occurring 
immediately before death in 67% of SUDEP patients compared with 35% in the non- 
SUDEP group (Kloster and Engelskjon, 1999). Of 15 witnessed cases of SUDEP in 
another study, 12 occurred in association with a generalised tonic-clonic seizure 
(Langan et al., 2000). Studies in both children (Donner et al., 2001; Nashef et al.,
1995a) and adults (Ficker et al., 1998; Hirsch and Martin, 1971; Kloster and Engelskjon, 
1999; Langan et al., 1998; Leestma et al., 1989; Terrence et al., 1975; Timmings, 1998) 
have found that most, if not all, cases of SUDEP in whom the seizure type was known, 
had a history of GTCS. Some of these seizures may have partial onset (Nashef et al.,
1998). A prospective cohort study of patients at three American epilepsy centres found 
that higher numbers of GTCS in the year before the last hospital visit was a risk factor 
for women (Walczak et al., 2001).
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1.3.3.2.2.4. SUDEP: seizure frequency
Many studies of death in epilepsy have been undertaken in different populations, and 
together they confirm SUDEP as a real phenomenon. Higher rates of SUDEP are 
reported from studies of individuals with intractable epilepsy, however, and it is 
suggested that seizure severity and frequency are risk factors (Annegers and Coan,
1999). However, some authors have suggested that seizures are often infrequent or rare 
in people dying with SUDEP (Hirsch and Martin, 1971; Leestma et al., 1989; Terrence 
et al., 1975), suggesting that seizure frequency is not a significant risk factor.
Comparing these older studies with the more recently published Swedish nested case- 
control study (Nilsson et al., 1999) shows remarkably similar findings, but different 
conclusions were drawn. The studies show that seizures occurred at least monthly in 
32% (Hirsch and Martin, 1971), 43% (Leestma et al., 1989) and 42% (Nilsson et al., 
1999). The Swedish study compared subjects who died from SUDEP with three living 
controls per subject, matched for age, sex and assessment period. They found the 
seizure frequency to be the factor most strongly associated with an increased risk of 
SUDEP, showing the importance of using living subjects from the same population 
group with epilepsy as controls in this type of study. A case-control study conducted in 
the UK found that 11 to 20 or 21 to 50 tonic-clonic seizures in the previous three 
months was a risk factor compared with those with five seizures or fewer, although 
more than 50 seizures did not appear as a significant risk factor, perhaps due to small 
numbers (Langan et al., 2005).
1.3.3.2.2.5. SUDEP: AED therapy 
Polytherapy
Several studies suggest increased risk of SUDEP with increasing number of AEDs used. 
One study used the number of simultaneous AEDs as a surrogate for persistent seizures 
(Tennis et al., 1995) whilst others found the increased risk associated with polytherapy 
was still significant after adjusting for seizure frequency (Nilsson et al., 1999; Walczak 
et al., 2001). However, neither the tertiary referral centre study comparing those dying 
with SUDEP with those dying from other causes (Kloster and Engelskjon, 1999), nor an 
Australian prospective coroners’ study also comparing SUDEP deaths with those dying
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from other causes (Opeskin and Berkovic, 2003) found any increased risk with 
polytherapy.
Specific AEDs
It has been suggested that the risk of SUDEP may be increased by certain AEDs. 
SUDEP occurred before modem AEDs were in widespread use (Timmings, 1998), but 
its frequency does not appear to have decreased with advances in therapy (Terrence et 
al., 1975). Some authors suggest that carbamazepine may be associated with SUDEP 
(Langan et al., 2005; Timmings, 1998), but this is disputed by others (Opeskin et al., 
1999; Walczak et al., 2001). Carbamazepine has been shown to affect the conduction 
system o f the heart, and to affect the autonomic nervous system (Stollberger and 
Finsterer, 2004).
Studies have been undertaken on the incidence of SUDEP in clinical trials (Leestma et 
al., 1997; Racoosin et al., 2001). These studies showed that SUDEP does not appear to 
be related to the use of specific AEDs, but that the higher rate in clinical trials o f new 
drugs is due to the high-risk patients who are entered into such trials (Lathers and 
Schraeder, 2002; Racoosin et al., 2001).
Non-adherence to drug regimen, and subtherapeutic, or supratherapeutic AED levels 
Studies have found subtherapeutic levels of AEDs in many patients dying from SUDEP 
(Earnest et al., 1992; Kloster and Engelskjon, 1999; Leestma et al., 1989; Lund and 
Gormsen, 1985; Terrence et al., 1975), sometimes associated with a history of poor 
adherence to drug regimen (Earnest et al., 1992), whilst others have found no difference 
between those dying from SUDEP and those dying from other causes (Opeskin et al., 
1999) or from living controls (Walczak et al., 2001). Toxic levels in some patients have 
also been documented (Lund and Gormsen, 1985; Terrence et al., 1975). The Swedish 
case control study found the relative risk of SUDEP was elevated in those whose 
carbamazepine levels were above the therapeutic range at last drug monitoring, with an 
even higher risk if high carbamazepine levels were present in those on polytherapy or 
with frequent dose changes. This increased risk was not found in patients on phenytoin 
(Nilsson et al., 2001).
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Change in AEDs
Anecdotal evidence suggests that SUDEP is also more likely to occur at times of AED 
change (Lip and Brodie, 1992; Shorvon, 1997) and mechanisms for this have been 
suggested (Hennessy et al., 2001). The Swedish study found that frequent changes of 
AED dosage was a risk factor (Nilsson et al., 1999), and also that patients who had had 
therapeutic drug monitoring performed during a two year observation period were less 
likely to die from SUDEP than those who had not (Nilsson et al., 2001). The UK case- 
control study found that lifetime use of four or more AEDs increased the odds of 
SUDEP compared with lifetime use of one or two, but also that having never taken 
AEDs increased the risk (Langan et al., 2005).
1.3.3.2.2.6. SUDEP: gender
Many studies have found more males than females in those dying with SUDEP, e.g. 
male:female 1.7:1 (Donner et al., 2001), 1.8:1 (Timmings, 1998), 2:1 (Langan et al.,
1998), 2.3:1 (Antoniuk et al., 2001), 2.5:1 (Lear-Kaul et al., 2005), 3.3:1 (Leestma et al., 
1989). However, other studies found no difference in the SUDEP rate between males 
and females (Bimbach et al., 1991; Kloster and Engelskjon, 1999; Racoosin et al.,
2001). The Swedish case control study found different risk factors in males and 
females, but found the annual incidence rate of SUDEP was 1.4/1000 in both men and 
women, despite the male/female ratio in the deaths being almost 3:2 (Nilsson et al.,
1999). The study population, who had been admitted to hospital with a diagnosis of 
epilepsy, included more men than women; people admitted to hospital may have 
additional diagnoses, and this may affect the sex distribution. A few studies, including 
an American study at three epilepsy centres (Walczak et al., 2001), have found the 
incidence of SUDEP to be higher in women than men. A study of the incidence of 
SUDEP in young people with epilepsy and learning difficulty investigated 14 deaths due 
to SUDEP of whom 71% were girls. However, the school had a preponderance of 
females due to a previous admissions policy, and the rate of SUDEP cases per pupil- 
year was similar for males (1:287) and females (1:298) (Nashef et al., 1995a).
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1.3.3.2.2.7. SUDEP: race
Two early studies suggested that SUDEP is more common amongst Afro-American 
populations (Leestma et al., 1989; Terrence et al., 1975) but this could be due to 
selection bias. It has not been studied recently.
1.3.3.2.2.8. SUDEP: alcohol
Alcohol abuse has been suggested as a risk factor for SUDEP (Black and Graham, 2002; 
Leestma et al., 1989). This may in some cases be due to selection bias, as those with 
problems with alcohol have different hospital admission rates. The Swedish case- 
control study found no association with alcohol abuse (Nilsson et al., 1999).
1.3.3.2.2.9. SUDEP: epilepsy syndromes
Some authors have found SUDEP to be more common amongst those with remote 
symptomatic epilepsy and neurological deficits presumed present from birth (Annegers 
and Coan, 1999; Donner et al., 2001). However, a retrospective study of patients with 
chronic refractory epilepsy at a tertiary referral centre found more patients with primary 
generalised seizures in the SUDEP group than in the group of patients with epilepsy 
who died from other causes (Kloster and Engelskjon, 1999). Similarly the Swedish case 
control study found an increased risk of SUDEP among men with idiopathic generalised 
epilepsy compared with localisation-related symptomatic epilepsy (Nilsson et al., 1999).
1.3.3.2.2.10. SUDEP: presence of nocturnal seizures
Many people dying with SUDEP are found in or near the bed (Kloster and Engelskjon,
1999). It has been suggested that nocturnal seizures may, therefore, be a risk factor for 
SUDEP. However, this has not been clearly established. People are less likely to be 
with others during the night, and so seizures are more likely to be unwitnessed. Studies 
at a school for children with epilepsy (Nashef et al., 1995a), and a recent case control 
study (Langan et al., 2005) both suggest that supervision may be an important 
preventative factor; this needs to be studied further.
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1.3.3.2.2.11. SUDEP: presence o f learning disability
An American cohort study found that, compared with those with IQ of at least 80, those 
with an IQ of less than 70 were five times as likely to die from SUDEP (Walczak et al., 
2001). A cohort study in Canada found that SUDEP incidence was higher in those with 
a history of hospitalisation for learning disability (Tennis et al., 1995). However, other 
studies have found no such association (Opeskin and Berkovic, 2003).
1.3.3.2.3. Accidents
People with epilepsy are more likely to have accidents and may die as a result of them. 
In one study over a third of subjects with seizures had had at least one injury in the 
previous 12 months (Buck et al., 1997); type, frequency and severity of seizures were 
the best predictors of all types of accidents. Another study in a tertiary referral centre 
found that over ten percent of subjects had had bums sufficient to require medical 
attention (Spitz et al., 1994). The risk was increased by the lifetime number of seizures, 
and decreased by the presence of neurological impairment. Most bums occurred during 
cooking or showering. It is likely that the same risk factors would apply to fatal 
accidents as to these non-fatal ones.
The Swedish study investigating mortality in people who had been hospitalised with 
epilepsy showed that deaths from injury and poisoning were five times higher than 
expected, and deaths from burning, drowning, and other accidents were also increased 
(Nilsson et al., 1997). A more recent study looked at the death certificates of people 
with epilepsy anywhere on the certificate (Jansson and Ahmed, 2002). Injury and 
poisoning were listed as the underlying cause of death in over five percent of subjects. 
The most frequent external causes of death were falling, drowning and accidental 
poisoning. These are usually assumed to be the result of seizures or postictal confusion, 
suggesting that improved seizure control might reduce the incidence.
Accidents are more common in people with frequent severe seizures, and falls not 
directly related to seizures are also more common in people with epilepsy, perhaps due 
to balance disturbances as a side-effect of AEDs (Jansson and Ahmed, 2002).
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People with epilepsy may drown when suffering a seizure during swimming or bathing. 
It is imperative that people with epilepsy and their families are appropriately counselled 
and the risks associated with these activities explained to them. Risk factors for 
drowning accidents in epilepsy include tonic seizures (Besag, 2001a), and risk factors 
for having a seizure while bathing or swimming include high seizure frequency and 
number of drug-related adverse events (Buck et al., 1997). Previous studies reported 
that the relative risk of drowning in children with epilepsy, compared to those without 
epilepsy, is 96 in the bath and 23 in the swimming pool (Diekema et al., 1993). The 
SMR for deaths due to drowning and suffocation in the large study in Sweden was 8.2 
(95% Cl 5.2 to 12.1) (Nilsson et al., 1997). People with epilepsy are usually advised to 
use a shower instead of a bath, to minimise the risk of drowning (Ryan and Dowling, 
1993).
1.3.3.2.4. Suicide
Suicide is considered by many people as being related to epilepsy as it seems to be more 
common in populations with epilepsy. Several attempts to ascertain the increased rate 
of suicide have been made but most have had methodological problems (see later).
Some report that rates o f suicide are increased in people with epilepsy, and that suicide 
in epilepsy may occur at the same rate as that reported among patients with manic- 
depressive illness (Blumer et al., 2002). It has been reported that various studies give 
suicide rates of about three times that of the general population, and that this rate may be 
increased even further in people with temporal lobe epilepsy (Robertson, 1997). Suicide 
appears to be a serious problem particularly among those with chronic epilepsy who 
require treatment in specialty clinics (Blumer et al., 2002). One case control study, 
conducted in Sweden in the adults who had been hospitalised with epilepsy, found a 
marked increase in relative risk for suicide associated with psychiatric co-morbidity, and 
with the use of antipsychotic drugs (Nilsson et al., 2002). Risk also seemed to increase 
with high seizure frequency and AED polytherapy, although the associations were not 
statistically significant. In contrast to this, however, others have found that suicide may 
occur in patients with longstanding complex partial seizures and dysphoric disorder 
shortly after full control of seizures is achieved (Blumer et al., 2002). In Iceland, a
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history of previous attempted suicide was shown to increase the risk of development of 
seizures, independent of major depression, suggesting that the mechanisms producing 
suicidal behaviour and depression may both be important in the development of epilepsy 
(Hesdorffer et al., 2006).
Little is known, however, of the risk of death from suicide in prevalent cases of epilepsy 
in the community. Using hospital cohorts for investigation of death may introduce a 
selection bias towards people with more severe epilepsy, and those with comorbid 
disorders which may influence mortality rates (Nilsson et al., 1997).
1.3.3.2.5. Treatment-related deaths
Fatalities caused by the treatment of epilepsy are rare (Tomson et al., 2004). The 
mortality of temporal lobectomy is less than five percent (Walker and Fish, 2005a). In a 
Swedish study of 651 surgical procedures in 596 patients, one patient died of post 
operative intracerebral haemorrhage (0.15% operations) (Nilsson et al., 2003). A UK 
study of 299 patients following surgery for temporal lobe epilepsy reported two early 
deaths related to the surgery and a third two years later (Hennessy et al., 1999). It is 
important to realise that pre-surgical investigations may also rarely lead to death 
(Walker and Fish, 2005a).
Drug-related mortality is also rare. Overdosage with phenobarbital or phenytoin can 
cause respiratory depression, and most AEDs are toxic in overdose. Stevens-Johnson 
syndrome and other idiosyncratic reactions are known to occur with several AEDs 
(Martindale, 2006).
1.3.3.3. Deaths probably unrelated to epilepsy
1.3.3.3.1. Malignancy
It is not surprising that the SMR is usually increased for central nervous system (CNS) 
tumours, as in many cases the brain tumour is the cause of the seizures. In many 
studies, however, the SMR for cancers other than primary brain tumours, is also 
increased to between 1.4 and 4.1 (Cockerell et al., 1994; Hauser et al., 1980; Nilsson et 
al., 1997; White et al., 1979). The later study from the NGPSE showed that the SMR
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for malignant neoplasms excluding primary brain tumour was increased (2.5) in the first 
seven years after diagnosis but not in the second seven years (0.8) (Lhatoo et al., 2001), 
suggesting that, in some way, the neoplasm may have contributed to the development of 
seizures. The authors suggest that these SMRs argue against the proneoplastic effect of 
AEDs. In the early study from Rochester, USA, individuals who experienced a single 
seizure only were investigated separately. In the first two years after identification 13 of 
158 patients died. In seven of these, death was caused by non-CNS neoplasms, but 
there was no indication of any metastasis to the brain, nor of any precipitating factors for 
the seizures (Hauser et al., 1980).
Early work considered the possibility of this increase in mortality rate being due to the 
carcinogenicity of AEDs (White et al., 1979). A recent review has again considered the 
relationship between AEDs and cancer (Singh et al., 2005). In animals, phenobarbital 
has been shown to promote liver tumours, although it is apparently not itself 
carcinogenic. Phenytoin has led to lymphoma in a few animal studies, and valproate 
administration has caused uterine adenocarcinomas in rats. More recently, however, an 
antitumour effect for valproate has been proposed. Human studies have reported an 
increased risk for lung cancer associated with phenobarbital, and of lymphoma and 
myeloma with phenytoin; both phenobarbital and phenytoin are considered to be 
possibly carcinogenic to humans (Singh et al., 2005).
1.3.3.3.2. Cerebrovascular disease
Death due to cerebrovascular disease seems to be common in cohorts of people with 
epilepsy, with SMRs ranging from 1.8 to 5.3 (Cockerell et al., 1994; Lhatoo et al., 2001; 
Lindsten et al., 2000; Nilsson et al., 1997; White et al., 1979). Cerebrovascular disease 
may be the underlying cause of epilepsy (Nilsson et al., 1997). The SMR for 
cerebrovascular disease in the NGPSE fell to a non-significantly raised level (1.9 [95% 
Cl 0.8 to 4.0]) by the second seven years of follow-up, and was not raised in either time 
period in those with idiopathic epilepsy, again supporting this hypothesis (Lhatoo et al., 
2001).
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1.3.3.3.3. Ischaemic heart disease
Many studies show no impact in epilepsy of death due to ischaemic heart disease, with 
SMRs around one for ischaemic heart disease (Annegers et al., 1984; Cockerell et al., 
1994; Lhatoo et al., 2001; White et al., 1979) or heart disease (Hauser et al., 1980). The 
Swedish hospital based study, however, found a significantly raised level at 2.5 (95% Cl
2.3 to 2.7). The authors suggest that, as cerebrovascular disease is overrepresented as a 
possible aetiology of epilepsy, other manifestations of vascular disease may also be 
overrepresented (Nilsson et al., 1997). An alternative explanation could be that, as 
death certificates were used to categorise the cause of death in this study, there may be a 
degree of inaccuracy in this. A study from Rochester, however, while confirming a non- 
significantly raised SMR for heart disease overall (1.16 [95% Cl 0.9 to 1.5]), reported 
significantly raised SMRs of 5.7 and 2.45 in the 25 to 44 year and 45 to 64 year age 
groups respectively, with these results echoed in those who died at least ten years after 
diagnosis (Annegers et al., 1984).
1.3.3.3.4. Pneumonia
Pneumonia is overrepresented as a cause of death in most cohorts of people with 
epilepsy (Cockerell et al., 1994; Hauser et al., 1980; Klenerman et al., 1993; Nilsson et 
al., 1997; White et al., 1979). In the NGPSE, ischaemic heart disease, cerebrovascular 
disease and pneumonia accounted for most deaths in people over 50 years old. The 
SMR for pneumonia was significantly raised in both the first and second seven years of 
follow-up, and was also significantly raised for the first seven years in those with 
idiopathic epilepsy (Lhatoo et al., 2001). In the past the effect of AEDs on pulmonary 
function was suggested (Moore MT, quoted in Cockerell et al., 1994), but never 
substantiated.
1.3.4. Conclusion
1.3.4.1. Role o f  seizures
In the Swedish study of people with learning disability, those with no seizures in the 
previous 12 months did not have a significantly raised SMR compared with those 
without epilepsy (although the SMR was two), but the SMR was 4.7 in those with 
seizures no more frequently than weekly, and 17 for those with seizures more frequently
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than weekly (Forsgren et al., 1996). A study of newly diagnosed patients in Sweden 
with 850 patient-years of follow-up found that the presence of generalised tonic-clonic 
seizures increased the risk of death in both males and females, although the increase was 
not significant in females. For those with partial seizures, the SMR was significantly 
raised in both males and females (Lindsten et al., 2000). The study from Rochester, 
USA, however, found a significantly elevated SMR for the first five years after 
achieving a five-year seizure remission, although the SMR for the 30 years following 
remission was not significantly elevated. This suggests that it is not only seizures which 
contribute to the higher mortality rate. The NGPSE found that neither seizure 
recurrence nor AED use influences mortality, although this study was population based 
and included few seizure-related deaths (Lhatoo et al., 2001).
Some studies of mortality following epilepsy surgery have shown that the rate of death 
is increased in people with seizures recurring post-operatively compared with those who 
become seizure-free (Salanova et al., 2002; Sperling et al., 1999). This would suggest 
that attainment of seizure freedom is of paramount importance in the reduction of the 
mortality rate in epilepsy. However, other studies of surgery for epilepsy have reported 
no major differences in death rates between those seizure-free and those with recurrent 
seizures after surgery (Hennessy et al., 1999; Nilsson et al., 2003; Stavem and Guldvog, 
2005). Even if  those rendered seizure-free after surgery are shown conclusively to have 
a reduced risk of death it is, o f course, possible that the factors which in others cause the 
surgery to be unsuccessful in controlling seizures may also contribute to the increased 
death rate.
Seizure frequency and severity are the strongest contenders for being risk factors in 
SUDEP, and are also implicated in deaths due to accidents and drowning. The chances 
of suicide seem to be increased in those with severe epilepsy as well as in those with 
recently controlled seizures, making the contribution of seizures to this cause of death 
difficult to assess.
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1.3.4.2. Role o f  AEDs
AEDs are often successful in reducing seizure frequency and, as such, should be 
expected to reduce the risk of death if this is genuinely related to seizure frequency. The 
adverse effects of AEDs on sudden death and possibly on the development of 
malignancy need to be considered, particularly as AEDs are taken for prolonged periods.
1.3.4.3. Future work
More work needs to be done to establish the cause or causes of SUDEP and to 
investigate all the factors which may contribute to suicide. The roles of ischaemic heart 
disease and pneumonia as causes of death in epilepsy need to be clarified, and if they are 
found to be increased then ways of reducing these need to be sought. Clearly treatment 
of the underlying condition causing epilepsy may reduce the death rate, although the 
impact of epilepsy on these deaths is likely to be small.
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2.1. T he  aim s o f  th e  C h ilter n  audit o f  prim ary  care  in epilepsy
1. To audit the documented care provided for people with epilepsy in 12 local 
general practices in the UK
2. To assess documented care provided with nationally available guidelines, where 
possible
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2.2. T he  aim s o f  the  prim ary  care  section  of  th e  National  Sen tin el  
C lin ica l  A udit o f  epilepsy -rela ted  death
1. To audit the documented primary care provided for people with epilepsy in the 
UK whose death was related to epilepsy
2. To assess documented primary care provided with nationally available 
guidelines, where possible
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2.3. T he  aim s of  th e  spec ia list  care  section  o f  the  National  Sen tin el  
C lin ica l  Audit  o f  epilepsy -rela ted  death
1. To audit the documented specialist care provided for people with epilepsy in the 
UK whose death was related to epilepsy, paying special attention to those with 
learning disability
2. To assess documented specialist care provided with nationally produced 
guidelines, where possible
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2.4. T h e  a im s  o f  t h e  i n v e s t i g a t i o n  i n t o  t h e  u s e  o f  d e a t h  c e r t i f i c a t e s  a s
CASE ASCERTAINMENT FOR EPILEPSY
1. To assess the predictive value of death certification in the case ascertainment of 
epilepsy
2. To validate the methodology of the National Sentinel Clinical Audit of epilepsy- 
related death
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2.5. T h e  a im s  o f  t h e  c a l c u l a t io n  o f  t h e  SM R f o r  s u ic id e  in  p e o p l e  w i t h  
e p i l e p s y  in  E n g l a n d  a n d  W a l e s
1. To estimate the SMR for suicide for people with epilepsy using information 
ffom two sources to identify the population of people with epilepsy
2. To validate the methodology of the National Sentinel Clinical Audit of epilepsy- 
related death by using the same ascertainment to identify those with epilepsy 
dying from suicide
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2.6. T he  aim s o f  th e  m et  a-analysis of  suicide  in peo ple  w ith  epilepsy
1. To re-analyse the data from a published meta-analysis of suicide in epilepsy, to 
overcome some of the problems with that meta-analysis
2. To quantify the number of people with epilepsy who die from suicide to 
investigate the validity of the data used in the study calculating the SMR from 
suicide in people with epilepsy in England and Wales
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Section 3
3.1. T he C h ilter n  audit
3.1.1. Audit design
The Chiltern audit was designed as a review of primary care for people with epilepsy in 
twelve general practices within one Primary Care Trust local to the National Society for 
Epilepsy. It was carried out by three experienced epilepsy specialist nurses between 
January 2001 and November 2002. One practice (75 patients with epilepsy) had an 
epilepsy specialist nurse attached.
3.1.2. Inclusion criteria
Only one practice had a disease register and so patients were identified from AED 
prescriptions. Each practice produced a list of patients prescribed AEDs; the epilepsy 
nurses conducting the audit scrutinised the clinical records and excluded those who took 
AEDs for reasons other than epilepsy. Some patients were identified who were on the 
list of people taking AEDs but had either never taken them or had stopped. These were 
included in the audit.
3.1.3. Information audited
The information required was extracted from any source available within the practice; 
this included Lloyd George records, A4 records, computerised records and letters from 
hospitals. Data were recorded on a specially prepared form before being transferred to 
computer file.
Information recorded included the date of birth and the year when the first seizure 
occurred. Any information indicating learning disability or possible problems with 
alcohol was sought, and, where present, this was noted in dichotomous form. The 
existence of a seizure description in the notes was audited, but the description itself was 
not recorded. The documentation of a seizure frequency at any time was noted and the 
most recent seizure frequency recorded, although the date of the documentation was not 
sought. Wherever possible the epilepsy was classified by the epilepsy audit nurses using 
any information available in the records. The AEDs taken at the time of the audit were 
recorded from the repeat prescription record.
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The dates of last epilepsy review by a specialist, by an epilepsy specialist and by the GP 
were recorded. The date the patient last consulted the GP for any reason was also 
recorded. The date of the first and most recent EEG, the first and most recent CT scan 
and first and most recent MRI scan were recorded. The records were searched for any 
documentation about discussion of lifestyle issues, particularly alcohol, safety and 
leisure, and the driving regulations. In women of childbearing potential, documented 
advice on contraception, preconceptual counselling and pregnancy was sought.
The duration of epilepsy (from first seizure to the date of the audit) was calculated in 
completed years. The time periods between the last GP review for epilepsy and the 
audit, and between the last review by any specialist and the audit were calculated.
3.1.4. Criteria for primary care
The audit assessed care received against the following criteria:
• People with continuing seizures should continue to have access to specialist care 
(CSAG, 2000). Patients with severe epilepsy should continue to be supervised 
by a consultant (Winterton, 1986)
• Some form of planned shared care is the preferred model of care for patients 
with epilepsy (SIGN, 1997). These guidelines do not specify the timing of the 
planned care. In view of the Quality and Outcomes Framework indicators, in 
which payments are made to GPs for the percentage of people with epilepsy 
reviewed within 15 months, this was taken as the reference point for this audit 
(NHS Confederation and British Medical Association, 2003)
• Primary care should monitor seizures and side-effects of medication, provide 
information and counselling, and should re-refer to secondary care where 
necessary (SIGN, 1997)
• AEDs should be used in monotherapy where possible (Hall et al., 1997). The 
aim should be to maintain the patient on the minimum number of drugs required 
to achieve adequate symptom control (SIGN, 1997)
• EEG should be performed in patients aged under 25 years at diagnosis. It is not 
necessary in establishing a diagnosis if a clear clinical history is available (SIGN,
116
Section 3
1997). EEG is indicated in patients with continuing seizures where there is 
diagnostic doubt (Wallace et al., 1997).
• Brain imaging is unnecessary if a firm diagnosis of an idiopathic generalised 
epilepsy syndrome has been made on the basis of the clinical history and EEG 
findings. Brain imaging should always be performed in patients aged over 25 
years. If a firm diagnosis of an idiopathic generalised epilepsy has not been 
made, both an EEG and brain imaging are necessary (SIGN, 1997). MRI is 
indicated where there is evidence of a partial onset from the clinical history or 
EEG, at any age (Wallace et al., 1997).
3.1.5. Analysis
Most analysis was done using SPSS version 11.0. Some analysis of summary data was 
performed in Clinstat, a DOS-based software programme available from St George’s 
Hospital Medical School.
For continuous data the t-test was used where the data were normally distributed, and 
the Mann-Whitney U test where they were not. For categorical data the Chi squared test 
was used. For 2 by 2 tables the difference between binomial proportions was used, and 
95% Confidence Interval (Cl) calculated. For 2 by 2 tables with small expected values, 
Fisher’s exact test was used. All comparisons were 2-sided. A p-value of < 0.05 was 
taken to indicate statistical significance.
3.1.6. Confidentiality
All electronic data were irretrievably anonymised.
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3.2. T h e  p r im a r y  c a r e  s e c t io n  o f  t h e  N a t io n a l  S e n t in e l  C l in i c a l  A u d it  o f
EPILEPSY-RELATED DEATH
3.2.1. Audit design
The intended study population was everyone who died from an epilepsy-related cause in 
the UK from 1 September 1999 until 31 August 2000.
3.2.2. Case ascertainment
The Office for National Statistics and the General Register Offices for Scotland and for 
Northern Ireland identified deaths during the study period where epilepsy was 
mentioned on the death certificate.
A panel, consisting of five physicians with interest and expertise in epilepsy, reviewed 
20% of the death certificates in which epilepsy appeared only in part II. The conclusion 
was that those deaths in which epilepsy appeared only in part II were unlikely to be 
epilepsy-related deaths. The certificates with epilepsy on part I of the certificate were 
further reviewed by two members o f the panel, and the deaths were divided into 
probably, possibly and unlikely to be related to epilepsy. The pre-mortem audits 
attempted to analyse the records of only those in whom epilepsy appeared in part I of the 
death certificate and in whom the death was considered as probably due to epilepsy.
In England and Wales, access to the clinical records was dependent on the cooperation 
of the coroner, who provided the name of the patient’s GP. The GP was then asked to 
let the audit team have access to the case records. In Scotland, the team was provided 
with details of the GP by the General Register Office, and in Northern Ireland the team 
had authority to access primary care records centrally. The research team did not 
personally have access to any patient care records, but clinical records were audited by 
field workers.
The analysis reported here includes some audit records which were received too late to 
be included in the published report.
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3.2.3. Audit tool development
Criteria for audit were developed using published guidelines, results of literature 
searches and views of the research team, and an audit tool was developed based on the 
criteria. The primary care tool was developed using seven sources of evidence 
(Bradford and Airedale Health Authority, 1998; Brown et al., 1993; Epilepsy Task 
Force, 1998; Hall et al., 1997; Leeds Health Authority, 1999; Taylor, 1996) (SIGN, 
1997).
3.2.4. Information audited
Clinical records were audited by trained research nurses. The audit required that any 
data were taken only from the primary care records themselves; audit nurses were not 
permitted to use information extracted from letters from specialist care or other 
agencies. Different audit forms were used for those who had been, and those who had 
not been referred to specialist care.
Age at death was calculated from the date of birth and date of death. Seizure frequency 
was audited only in those not referred to secondary care. Seizure description was 
audited in any patient whose first seizure occurred less than five years before death. 
AEDs taken at the time of death were recorded. Data on some aspects of information 
provision were audited.
The time of the last review prior to death was calculated, and the type of professional 
performing that review recorded.
3.2.5. Criteria for primary care
The audit assessed care received against the following criteria:
• People with continuing seizures should continue to have access to specialist care 
(CSAG, 2000). Patients with severe epilepsy should continue to be supervised 
by a consultant (Winterton, 1986)
• Some form of planned shared care is the preferred model of care for patients 
with epilepsy (SIGN, 1997). These guidelines do not specify the timing of the 
planned care. In view of the Quality and Outcomes Framework indicators, in
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which payments are made to GPs for the percentage of people with epilepsy 
reviewed within 15 months, this was taken as the reference point for this audit 
(NHS Confederation and British Medical Association, 2003)
• Primary care should monitor seizures and side-effects of medication, provide 
information and counselling, and should re-refer to secondary care where 
necessary (SIGN, 1997)
• AEDs should be used in monotherapy where possible (Hall et al., 1997). The 
aim should be to maintain the patient on the minimum number of drugs required 
to achieve adequate symptom control (SIGN, 1997)
3.2.6. Analysis
Most analysis was done using SPSS version 11.0. Some analysis of summary data was 
performed in Clinstat, a DOS-based software programme available from St George’s 
Hospital Medical School.
For continuous data the t-test was used where the data were normally distributed, and 
the Mann-Whitney U and Kruskal-Wallis tests where they were not. For categorical 
data the Chi squared test was used. For 2 by 2 tables the difference between binomial 
proportions was used, and 95% Cl calculated. All comparisons were 2-sided. A p- 
value of < 0.05 was taken to indicate statistical significance.
3.2.7. Ethics and confidentiality
All data were anonymised. Two Multi-centre Research Ethics Committees reviewed the 
proposal and each independently defined the project as audit.
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3.3. T he spec ia list  care  sectio n  of  th e  National Sentinel  C lin ica l  Audit of
EPILEPSY-RELATED DEATH
3.3.1. Audit design
The intended study population was everyone who died from an epilepsy-related cause in 
the UK from 1 September 1999 until 31 August 2000.
3.3.2. Case ascertainment
Initial case ascertainment was as described in section 3.2.1. Specialist care records were 
obtained where possible after location of the primary care records.
3.3.3. Audit tool development
The specialist care audit tool used three sources of evidence (Wallace et al., 1997; 
Winterton, 1986; SIGN, 1997), and the analysis was based on these and the CSAG 
report (CSAG, 2000) when it was published.
3.3.4. Information audited
The analysis of specialist care in this thesis concentrates on the care provided to people 
with both epilepsy and learning disability. Overall care for adults and children was 
covered in the secondary care section of the published report (Hanna et al., 2002).
The age of each patient at death and the duration of epilepsy were, wherever possible, 
calculated. When only the year of first seizure was known, it was taken as June 30th of 
that year, and when only a month was known, it was taken as the 15th of that month. 
Wherever possible, time from last outpatient appointment to death was calculated from 
the date of the appointment and the date of death. The most senior clinician and the 
most appropriate specialty were also assessed from the last three outpatient 
appointments. Where a consultant was not seen in the last three appointments, the audit 
officers documented the date when a consultant was last seen. In some cases this 
calculation was not possible as the audit officers documented the last three specialist 
appointments relating to epilepsy, and both outpatient and inpatient episodes were 
documented. Time from EEG recording and MRI or CT scanning was also calculated
121
Section 3
where these investigations had been performed. The presence or absence of a clear 
seizure description and of seizure frequency at the last consultation was noted. Seizure 
frequency at last consultation was calculated where possible. In those with two or more 
seizures per month, the audit officers assessed whether suitability for surgery had been 
considered.
The number of AEDs taken by each patient was calculated, taking into account 
information from both the primary care and secondary care audit files. The different 
items of information documented as discussed with each patient or family were 
calculated.
3.3.5. Criteria for specialist care
The audit assessed care received against the following criteria:
• People with continuing seizures should continue to have access to specialist care 
(CSAG, 2000). Patients with severe epilepsy should continue to be supervised 
by a consultant (Winterton, 1986)
• People who continue to be drug resistant should be referred for assessment for 
epilepsy surgery (SIGN, 1997). In most instances patients will be experiencing 
more than two seizures per month (Wallace et al., 1997)
• The basis of the patient record for use in the care of all patients with epilepsy 
should include a detailed history including a witness account of the frequency of 
attacks and of observations before and during the attacks (SIGN, 1997)
• EEG should be performed in patients aged under 25 years at diagnosis. It is not 
necessary in establishing a diagnosis if a clear clinical history is available (SIGN, 
1997). EEG is indicated in patients with continuing seizures where there is 
diagnostic doubt (Wallace et al., 1997)
• Brain imaging is unnecessary if a firm diagnosis of an idiopathic generalised 
epilepsy syndrome has been made on the basis of the clinical history and EEG 
findings. Brain imaging should always be performed in patients aged over 25 
years. If a firm diagnosis of an idiopathic generalised epilepsy has not been 
made, both an EEG and brain imaging are necessary (SIGN, 1997). MRI is
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indicated where there is evidence of a partial onset from the clinical history or 
EEG, at any age (Wallace et al., 1997)
• The aim should be to maintain the patient on the minimum number of drugs 
required to achieve adequate symptom control (SIGN, 1997)
• The care and management of people with epilepsy is not complete without 
provision of clear and accurate advice and information (SIGN, 1997). Ensure 
that patients have clear information about the drugs they are taking, including 
information about possible side-effects and drug interactions. The importance of 
compliance should be stressed (Wallace et al., 1997)
3.3.6. Analysis
Most analysis was done using SPSS version 11.0. Some analysis of summary data was 
performed in Clinstat, a DOS-based software programme available from St George’s 
Hospital Medical School.
For continuous data the t-test was used where the data were normally distributed, and 
the Mann-Whitney U test where they were not. For categorical data the Chi squared test 
was used. For 2 by 2 tables the difference between binomial proportions was used, and 
95% Cl calculated. For 2 by 2 tables with small expected values, Fisher’s exact test was 
used. All comparisons were 2-sided. A p-value of < 0.05 was taken to indicate 
statistical significance.
3.3.6.1. Analysis o f  investigations according to available guidelines 
To analyse use of EEG when appropriate, information was grouped, according to 1997 
SIGN guidelines, into those who had EEG, those who had no EEG but in whom this 
was acceptable (e.g. first seizure at age over 25 years, and clear history available), those 
who had no EEG in whom this was not acceptable (e.g. aged under 25 at diagnosis), and 
those in whom need for EEG is unclear (e.g. aged over 25 at diagnosis in whom seizure 
history is unclear). The information regarding neuroimaging was grouped according to 
whether imaging status was satisfactory (either imaging had been performed, or it was 
not necessary due to a clear diagnosis of idiopathic generalised epilepsy, or imaging was 
not possible due to lack of co-operation), those in whom the need for imaging was
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unclear due to the lack of a clear description of a seizure in the case records, those in 
whom it was unclear for other reasons, and those who should have had imaging (those 
with ongoing seizures in whom the probable diagnosis was not idiopathic generalised 
epilepsy, and those with a change in seizure type or pattern) but had not.
3.3.6.2. Analysis o f  care in those with learning disability
For those with learning disability, the specialty of clinician seen was considered. A 
consultant specialist in learning disability categorised the clinicians caring for the adults 
into ‘good’, ‘satisfactory’, ‘not satisfactory’ and ‘unclear’. The clinicians caring for 
children with learning disability were categorised by a consultant paediatric neurologist 
into the same categories.
For the time between the last outpatient appointment and death, and suitability for 
surgery, the results are presented separately for those with and without learning 
disability. For the other criteria, results are compared between those with and those 
without learning disability, among those seen by the various categories of clinicians, and 
between those ever seen by a consultant and those not.
The people taking AEDs thought to have negative impact on cognition in people with 
learning disability (phenobarbital [and primidone], phenytoin, sodium valproate and 
topiramate) and those taking newer AEDs (lamotrigine, topiramate, tiagabine, 
gabapentin and vigabatrin) were identified.
3.3.6.3. Quality o f  care
In the National Sentinel Clinical Audit the completed audit tools were also assessed 
independently by at least two panel members. Summaries of the primary, specialist and 
pathology audit tools were prepared for each case by the author. The full panel met and 
discussed each case in detail, taking into account all information available from the 
primary care and pathology audit tools, and each others’ expert opinions and guidelines 
where available. Each case was classified as having received adequate care, or care 
which failed to meet guidelines. Cases were screened for large errors, which were 
defined as major deviations from standard care. Where no information was available,
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the information was insufficient, or where there was any doubt, the cases were classified 
as unclear. Each case was further classified as death unavoidable, potentially avoidable, 
probably avoidable or unclear. This information is presented comparing those with and 
without learning disability and, in those with learning disability, according to the 
categories listed above.
3.3.7. Ethics and confidentiality
All data were anonymised. Two Multi-centre Research Ethics Committees reviewed the 
proposal and each independently defined the project as audit.
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3.4. Investigation  into  th e  use o f  death  c er tific a tes  as case ascertain m ent
FOR EPILEPSY
3.4.1. Initial study design
The National General Practice Study of Epilepsy and Epileptic Seizures was initiated in 
1984. It aimed to identify 1200 people in whom a new diagnosis of epileptic seizures 
was suspected, and to monitor their progress. GPs, who volunteered for the study after 
it had been publicised in medical journals, were asked to notify the study o f any patient 
in whom epileptic seizures were suspected, excluding babies with neonatal seizures. 
Initial registration o f patients took place between June 1984 and October 1987, and 175 
GPs registered 1195 patients. The form for the initial notification contained details of 
the medical history, family history, likely aetiology of the seizure and the circumstances 
and description of the seizure, and included a checklist. Six months after registration 
GPs were asked to complete follow-up forms with details of seizure recurrence, AED 
treatment and any other developments. The hospital consultants of any patients who 
had been referred were also asked to complete a form with details of diagnosis and any 
investigations. At this stage, patients were classified by an expert panel using all 
available information; 792 patients were classified as having either definite epilepsy 
(564) or possible epilepsy (228). A further 220 were classified as having had febrile 
convulsions and 79 as having non-epileptic events (such as syncope, non-epileptic 
attack disorder or breath holding attacks). In total 104 patients were excluded, and not 
followed further, due to either a previous diagnosis of epilepsy or the diagnosis being 
neonatal seizures (Hart et al., 1989; Sander et al., 1990).
From then on GPs were asked to complete follow-up forms on a yearly basis until the 
death of the patient or until early 2000. The follow-up form contained a summary of the 
information held by the study and asked for any neurological, medical or psychological 
developments, for details of seizure recurrence including dates, timing and any change 
in character o f the seizures and for current AED treatment. If the patient had died, the 
GP was asked for any details about the death. The cohort was flagged by the National 
Health Service Central Register (NHSCR), and all deaths were notified to the study. 
Death certificates and any post-mortem reports were then obtained by the study.
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3.4.2. The current study
Eight criteria were hypothesised which might influence whether or not epilepsy was 
included on the death certificate. These were:
• Classification at six months after study entry into ‘definite’ or ‘possible’ epilepsy
• Convulsive seizures
• Seizures during follow-up
• Average number of seizures/year in the five years before death, or average 
number of seizures/year during lifetime after seizure onset if seizure onset was 
less than five years before death
• Age at death
• Physician who certified death
• Cause of death
• Number of AEDs prescribed at the time of the last follow-up
The follow-up forms were examined to establish whether or not subjects had ever had 
convulsive seizures, and whether they had further seizures during the study. The 
average number of seizures per year during the last five years before death (or during 
lifetime, after onset, in those dying less than five years after onset) was calculated. In 
those with seizures occurring more frequently than daily the average number of seizures 
per year was taken as 365. Age at death was calculated from the date of birth and date 
of death. Patients were then divided into four groups according to age at death. The 
number of AEDs prescribed was taken from the most recent follow-up form.
Death certificates were examined manually to see whether epilepsy (or seizures or status 
epilepticus) was mentioned in either part of the death certificate. The name of the 
person who completed the death certificate (the certifying physician) was compared with 
the name of the physician who completed the most recent follow-up form (current 
physician), and with the name of the physician who initially registered the patient with 
the study (referring physician). The presumed cause of death was established from the 
death certificate and available clinical information, and classified into three groups: 
malignancy, vascular (including cerebrovascular and cardiovascular deaths), and other.
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3.4.3. Analysis
Each of the eight categories was divided into subgroups and the number of death 
certificates indicating epilepsy was calculated as a percentage of the deaths.
The categories were then individually entered into a univariate logistic regression 
model, and the results expressed as odds ratios (and 95% Cl) for epilepsy mentioned on 
the death certificate. Statistical analysis was performed using SPSS for Windows, 
release 11 (SPSS, Inc., Chicago, IL).
3.4.4. Ethics and confidentiality
All data were anonymised. NGPSE was approved by the Joint Ethics Committee of the 
Institute of Neurology and the National Hospital for Neurology and Neurosurgery.
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3.5. S u ic id e  in p e o p le  w i th  e p ile p sy  in E n g la n d  a n d  W a le s
3.5.1. Study design
The National Sentinel Clinical Audit of epilepsy-related death (Hanna NJ et al., 2002) 
used national registries to search for people with epilepsy who died from an epilepsy- 
related cause in the UK between 1st September 1999 and 31st August 2000. Specifically, 
the Office for National Statistics and the General Register Offices for Scotland and for 
Northern Ireland identified deaths during the study period where epilepsy was 
mentioned on the death certificate. The methodology of this audit has been detailed 
earlier (3.2. and 3.3.).
3.5.2. Analysis
The death certificates in England and Wales in which epilepsy was recorded (N = 2060) 
were reviewed. Deaths by suicide were sought using words such as “suicide”, “self 
harm”, and key words used to specify the ICD-9 subcategories for suicide and self- 
inflicted injury (ICD-9, E950-959). Deaths by hanging were also specifically sought.
The population of people with epilepsy in England and Wales was estimated by 
applying the 1998 prevalence rates of treated epilepsy in England and Wales per age 
group and sex (Purcell et al., 2002) to the resident general population (Office for 
National Statistics., 2001). The expected number of deaths in people with epilepsy was 
then calculated by applying the relevant year 2000 death rates for the population of 
England and Wales per age group (0-4, 5-14, 15-24, subsequent decades up to 84, and 
85+) and sex (Office for National Statistics., 2001) to the population of people with 
epilepsy. The population of England and Wales in mid-2000 was 52.9 million (Office 
for National Statistics, 2001).
The total number of expected deaths and observed deaths in males and females in the 
population with epilepsy were then calculated using the age-specific rates. The SMR 
was calculated as the ratio of the observed to the expected number of deaths, and 
confidence intervals calculated using the Poisson distribution. An assumption was 
made that all deaths identified occurred amongst people with treated epilepsy.
All analysis was performed in Microsoft Excel.
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3.6. A MET A-ANALYSIS OF SUICIDE IN PEOPLE WITH EPILEPSY
3.6.1. Overview
A published meta-analysis of suicide in epilepsy included 29 studies from various 
countries (Pompili et al., 2005). Seven of these, however, should have been excluded 
(see 3.6.3. below): some articles were later publications on the same set of patients as 
reported previously and included in the analysis, and in others the data are not available 
to calculate the person-years at risk. The authors concluded that ‘our meta-analysis 
shows that suicide in patients with epilepsy is more frequent than in the general 
population’, yet they did not produce an SMR despite pooling the data. A re-analysis of 
the eligible studies was performed to avoid these problems.
3.6.2. Included studies
Twenty two articles provided the information needed to perform the meta-analysis:
• Bladin, 1992
• Camfield et al., 2002
• Currie et al., 1971
• Dalby, 1969
• Guldvog et al., 1994a
• Guldvog et al., 1994b
• Hauser et al., 1980
• Hennessy et al., 1999
• Klenerman et al., 1993
• Lhatoo et al., 2001
• Lindsay et al., 1979
• Lip and Brodie, 1992
• Loiseau et al., 1999
• Nilsson et al., 1997
• Rafnsson et al., 2001
• Salanova et al., 2002
• Shackleton et al., 1999
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• Sillanpaa, 1983
• Stepien et al., 1969
• Taylor and Falconer, 1968
• White et al., 1979
• Zielinski, 1974a
3.6.3. Excluded studies
Seven of the articles in the previous publication were not used in the current analysis of 
suicide. For four, it was not possible to determine the number of patient-years of 
follow-up:
• Blumer et al., 2002
• Iivanainen and Lehtinen, 1979
• Krohn, 1963
• Mendez and Doss, 1992
Two contained data that was repeated in a later follow-up of the same series:
• Cockerell et al., 1994
• Sillanpaa, 1973
One study was a case control study which was a follow on from a previous cohort study:
• Nilsson et al., 2002
3.6.4. Analysis
3.6.4.1. Unweighted SMR
The articles were each reviewed by two independent researchers, and deaths stated as 
suicide were ascertained. The number of patient-years follow-up in each paper was 
calculated from the number of patients in the study and the mean follow-up duration. If 
no mean was given, the median was used instead, or the mean was taken as the average 
of the maximum and minimum. If the paper gave the number of patient-years at risk, 
this was used in preference to a calculated rate
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Expected deaths were calculated by applying the rates for each cause of death using 
WHO datasets for the country taken, where possible for the year at the midpoint of the 
study. Where this was not possible, data for the earliest year available were used. In the 
case of early studies from England and Wales, ONS data were used (Office for National 
Statistics, 2003). For two studies the authors provided expected number of deaths, and 
these were used instead of WHO data. Gender was rarely given in the papers, and so 
was not considered in calculating the expected values. The SMR was calculated as the 
ratio of the observed deaths to those expected, and the 95% Cl for the SMR calculated 
using the Poisson distribution.
3.6.4.2. Weighted SMR
The data were also analysed using RevMan software (Cochrane Collaboration, v42. 
2005); this software applies weighting to the SMR but does not allow for population 
sizes of greater than 999,999. The software also requires the numerator (the number of 
deaths from suicide) and the denominator data (the number of people in the population) 
and so the figures provided by two of the papers for the expected numbers of suicides 
could not be used. The analysis was therefore performed in RevMan using the number 
of population suicides and the total denominator population, both divided by 1,000 to 
allow for appropriate weighting. This allowed all 22 studies to be included. As the 
population numbers needed to be integers, these data were rounded. The unweighted 
analysis was also repeated using the population suicides and total population from WHO 
data sets.
3.6.4.3. Unweighted SMR by year o f  publication
The data were further analysed according to whether they were published in the last ten 
years or earlier. Eight studies were published after 1996 (Camfield et al., 2002; 
Hennessy et al., 1999; Lhatoo et al., 2001; Loiseau et al., 1999; Nilsson et al., 1997; 
Rafnsson et al., 2001; Salanova et al., 2002; Shackleton et al., 1999). Unweighted 
SMRs were calculated for each group.
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4.1. T he  C hiltern  audit
4.1.1. Demographic details
The notes of 608 patients (335 [55%] male) were audited. The mean age of patients was 
47 years (median 46 years), range one to 97 years. Nineteen patients (3%) had 
documented problems with alcohol. Sixty three patients (10%) had documented 
learning disability.
4.1.2. Access to care
The documented evidence for epilepsy review is illustrated below. Those who do not 
appear to have had an epilepsy review within 15 months of the audit (highlighted in 
figure 1) are described in more detail, and illustrated in appendix 2.
Figure 1 Access to care within 15 months in the Chiltern audit
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4.1.2.1. GP review
One hundred and thirty five patients (22%) had seen the GP for epilepsy review within 
six months of the audit, 205 (34%) within a year, and 233 (38%) within 15 months.
One hundred and thirty four (22%) had no documented epilepsy review with the GP.
Of those who had never had epilepsy review with the GP, 44% had no seizure frequency 
documented or else the seizure frequency was unclear. Thirty seven percent were 
seizure-free and three percent had seizures at least weekly. Twenty percent were on no 
AEDs, 56% on monotherapy and 20% on polytherapy.
4.1.2.2. No epilepsy review documented
Thirty seven people (6%) appear to have seen neither a specialist nor a GP for epilepsy. 
In two of these, the situation is unclear: one was under a specialist neurological hospital 
for another illness; in the other, the diagnosis was in doubt (the patient collapsed many 
years previously and took no AEDs).
The situation of the other 35 people is illustrated in appendix 2 (figure A l). Four people 
probably had fewer than five seizures; two were taking AEDs, and in one AEDs are 
unknown. In 18 no seizure frequency has been documented, or was very unclear; five of 
these may have been seizure-free. Fourteen of these 18 were taking AEDs, including 
four on polytherapy. Fifty one percent had seen their GP for another reason within the 
13 weeks before the audit, and a further 23% within a year. Fourteen percent appear 
never to have consulted the GP.
4.1.2.3. Last GP epilepsy review more than 15 months before the audit
Of all patients, 241 (40%) had last had a GP review for epilepsy more than 15 months 
before the audit. Of these 41% were seizure-free, and three percent had seizures weekly 
or daily. In 46% seizure frequency was unclear or not documented. Over half (55%) 
were on monotherapy, 22% on no AEDs, and 23% on polytherapy (up to 4 AEDs).
One hundred and ninety five (81%) of these people had seen a specialist. Forty three 
(18%) had seen a specialist within 6 months of the audit, 53 (22%) within a year and 60
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(25%) within 15 months. The mean time since these 195 people had seen a specialist 
was over 6 years, and the median over 3 years. Maximum time since last specialist 
review was 41 years.
4.1.2.4. Last epilepsy review more than 15 months before the audit
One hundred and thirty five patients (22%) were last reviewed for epilepsy by anyone 
more than 15 months before the audit (figure A2). Of these, 60 (44%) were known to 
be seizure-free (19 on no AEDs, 37 on monotherapy and four on polytherapy), and a 
further 25 (19%) may have been seizure-free (six on no AEDs, 14 on monotherapy, four 
on two AEDs and one on three AEDs). In 29 there was no record of seizure frequency 
in the case notes; nine were on no AEDs, 16 were on monotherapy and four were on two 
AEDs.
Of those whose last epilepsy review by a GP was more than 15 months before the audit, 
46 (19%) do not appear to have been reviewed by any specialist (figure A3). The 
majority of these (24, 52%) were either seizure-free, or had experienced fewer than five 
documented seizures. However, seven of these (29%) were on AED polytherapy.
4.1.2.5. No epilepsy review by GP
Of those who had no GP review, 97 (72%) were seen at some stage by a specialist. The 
date of one specialist appointment is not known. Of the other 96, 22 (23%) were seen 
within six months of the audit, 30 (31%) within 12 months, and 33 (34%) within 15 
months. Sixty three (66%) were seen over 15 months before the audit (figure A4). Of 
the 63 seen by the specialist over 15 months before the audit, 32 were seizure-free (eight 
on no AEDs, 20 on monotherapy and four on two AEDs). Five had fewer than five 
seizures documented; three were on no AEDs. All of those with seizures occurring at 
least yearly were on AEDs, with the majority (three of five, 60%) on polytherapy, one of 
whom, with weekly seizures, was on three AEDs.
Of the 375 who had never seen a GP or who had seen a GP for epilepsy review more 
than 15 months before the audit, 307 (82%) had seen a GP for another reason in the 
previous 15 months.
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4.1.2.6. No epilepsy review within 15 months o f  audit
In the whole group of case records audited, 279 (46%) patients had not had an epilepsy 
review by either a GP or specialist within 15 months of death. Of those, 72 (26%) were 
taking no AEDs, but 46 (16%) were on AED polytherapy.
The two whose diagnosis or review is in doubt are excluded from the following 
analyses.
4.1.2.6.1. Time of last review and use of AEDs
Those without review took significantly fewer AEDs (mean 0.9 AEDs, SD 0.7) than 
those with review (mean 1.4 AEDs, SD 0.77; Mann Whitney U = 29940, p < 0.0001). 
AEDs taken are shown in table 1.
Table 1 Chiltern audit: number of AEDs taken, where known, in those who 
had/had not been reviewed within 15 months of the audit
No AEDs Monotherapy Polytherapy Total
N % N % N %
No review 72 26 157 57 46 17 275
Review 12 4 200 62 110 34 322
Total 84 14 357 60 156 26 597
4.1.2.6.2. Time of last review and age
Those who had no epilepsy review for at least 15 months before the audit were 
significantly older than those who had a review in that time; the mean age of those with 
no review was 52.0 years, SD 20.8 and in those with review was 42.9 years, SD 22.9 
(difference = 9.0 years [95% Cl 5.5 to 12.6 years], t = 5.0, p< 0.0001).
4.1.2.6.3. Time of last review and learning disability
A significantly higher percentage of those who were reviewed had learning disability 
(48/327 [15%] of those reviewed compared with 15/279 [5%] of those not reviewed; 
difference 9%, [95% Cl 5 to 14%], p = 0.0002).
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4.1.2.6.4. Time of last review and alcohol problems.
There was no difference in time of last review between those with and without 
documented alcohol related problems (13 of 327 [4%] with review had alcohol 
problems compared with 6/279 [2%], not reviewed; difference 2%, [95% Cl -1 to 5%],
p = 0.2).
4.1.2.6.5. Time of last review and episodes of status epilepticus
A higher proportion of those who had been reviewed had had at least one episode of 
status (those reviewed 31/327 [9%], those not reviewed 9/279 [3%]; difference = 6%, 
95% Cl 3 to 10%, p = 0.002).
4.1.2.6.6. Time of last review and seizure status
Those with no review were more likely to be seizure-free, or to have had fewer than five 
seizures than those with review (those not reviewed 138/150 [92%], those reviewed 
99/185 [54%]; difference = 38%, 95% Cl 30 to 47%, p < 0.0001) in whom seizure 
frequency is known.
The seizure status is shown in table 2.
Table 2 Chiltern audit: seizure status, where known, in those who had/had not 
been reviewed within 15 months of the audit
Seizure < 5 Yearly or Weekly to Daily Total
free seizures less monthly
N % N % N % N % N %
No review 121 81 17 11 6 4 6 4 0 0 150
Review 84 45 15 8 21 11 59 32 6 3 185
Total 205 61 32 10 27 8 65 19 6 2 335
Chi squared (4df) = 61.36, p <0.0001 
Chi squared trend (ldf) = 59.71, p < 0.0001
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The trend shows that those who had epilepsy review within 15 months of the audit had 
more frequent seizures than those with no review. In interpreting these figures it should 
be noted that in 43% of those with review, and 46% of those with no review, the seizure 
frequency was either not documented or was unclear.
4.1.2.7. No review by a specialist
In all, 122 (20%) patients appear never to have been seen by a specialist. In 30% of 
these there is no seizure frequency documented and in a further nine percent it was 
unclear. Almost one third were seizure-free and nine percent had fewer than five 
lifetime seizures. Only two percent appeared to have a clear history of ongoing seizures.
4.1.2.8. Review by epilepsy specialist nurse
In the practice with an attached epilepsy specialist nurse, all patients (N = 75) had 
documented review for epilepsy.
Fourteen of these patients (19%) had not had epilepsy review for at least 15 months 
before the audit. Seven were seizure-free (two on no AEDs, three on monotherapy and 
two on polytherapy). Three had seizures weekly to yearly (two on monotherapy, one on 
polytherapy). One had fewer than five seizures (monotherapy) and in three, seizure 
frequency was not documented (one on no AEDs, two on monotherapy).
4.1.3. Documented history of seizures available
4.1.3.1. Seizure frequency documented
Seizure frequency was documented in 335 (55%), of whom 205 (61%) were seizure-free 
when this was last recorded. Twenty eight (8%) were experiencing seizures at least 
weekly. Seizure frequency was documented in 76% of the records in the practice with 
an epilepsy specialist nurse, compared with 52% in the others (difference 24% [95% Cl 
13 to 34%], p = 0.0001).
4.1.3.2. Seizure description documented
A seizure description was available in 280 (46%) records. It was available in the 
records of 42 (47%) of the 90 diagnosed in the five years before the audit. A description
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was documented in 71% of records in the practice with an epilepsy specialist nurse 
compared with 43% in the others (difference 28% [95% Cl 17 to 39%], p <0.0001).
4.1.3.3. Classification o f  seizures possible
The audit nurses were able to classify the epilepsy in 438 (72%) patients. Classification 
was possible in 87% of the records in the practice with an epilepsy specialist nurse, 
compared with 70% in the others (difference 17% [95% Cl 8 to 25%], p = 0.003).
4.1.4 Investigations of epilepsy
4.1.4.1. EEG
Of 348 (57%) patients whose seizures started before 25 years old, 262 (75%) had had an 
EEG. In seven cases this appears to have predated the first seizure, usually because of 
other pathology such as skull fracture or cerebral palsy. 52% had had an EEG within 3 
years of the first seizure. Altogether 414 (68%) had an EEG and 194 (32%) did not.
The situation of those with no EEG is illustrated in figure 2.
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Figure 2 Chiltern audit: clinical status of those with no EEG
(Those (ftiglilfehtedl required EEG according to guidelines and in those 
the situation is particularly unclear).
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4.1.4.2. Neuroimaging
Of the 608 Chiltern patients 263 (43%) appear to have had no imaging at all. The audit 
nurses were able to classify the seizures of 168 (64%) of these: 113 had generalised 
onset and 55 partial onset. Of those with no seizure classification, 61/95 had also had 
no EEG recording. Thirty seven (39%) were seizure-free and a further six (6%) may 
have been seizure-free. Ten (11%) had had fewer than five seizures in total. However, 
one had yearly seizures, three had monthly seizures, one had weekly seizures and in two, 
seizures were described as ‘ongoing’. In 35 people, there was no seizure frequency 
documented, or it was unclear. This is illustrated in figure 3.
Figure 3 Chiltern audit: clinical status of those with no neuroimaging
(Those [highlightedl had indications for neuroimaging, according to guidelines and those 
lerosshatehed 1 may have required neuroimaging)
No neuroimaging 
N = 263
Generalised onset 
N =  113
Seizure free 
N = 37
< 5 seizures 
N =  10
Partial onset
:' ;'>T=55 ' ^
Seizures occunring 
weekly to yearly 
N = 5
Insufficient 
information to classify 
N  = 95
No seizure frequency 
documented 
N=41, 
including 6 possibly 
seizure free
‘Ongoing’ 
N  = 2
There were 103 people who did not have imaging in whom it may have been indicated; 
57 (55%) had had an epilepsy review within 15 months of the audit with either a 
specialist or the GP.
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4.1.5. Use of AEDs
In nine patients (1%) it was not possible to establish the number of AEDs taken.
4.1.5.1. Number o f  AEDs taken 
This is shown in table 3.
Table 3 Chiltern audit: AEDs taken
No of AEDs No of 
patients
(%)
0 85 14
1 357 60
2 121 20
3 29 5
4 7 1
Total 599
4.1.5.2. Use o f  particular AEDs
4.1.5.2.1. Barbiturates (phenobarbital or primidone)
Of 514 patients currently taking AEDs, 54 (11%) were taking phenobarbital and 14 
(3%) were taking primidone; two patients were taking both. Thus 66 (13%) patients 
were taking barbiturates.
A slightly higher percentage of females (35/225, 16%) than males (31/289, 11%) were 
taking barbiturates (difference 5% [95% Cl -1 to 11%], p = 0.1). Fewer people with 
learning disability (4/58, 7%) were taking barbiturates than those without learning 
disability (62/456, 14%; difference 7% [95% Cl -1 to 14%], p = 0.15), but the 
difference was not significant. In those in whom it was possible to assess seizure 
frequency, there was no difference in the proportion who were seizure-free (135 of 239, 
56%, not taking barbiturates were seizure-free, compared with 25 of 38, 66% taking 
barbiturates; difference 9% [95% Cl -7  to 26%], p = 0.28). However, those taking
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barbiturates were significantly less likely to have had an epilepsy review in the previous 
15 months by either the GP or a specialist than those not taking barbiturates (24/66, 36% 
of those on barbiturates had been reviewed compared with 288/448, 64% of those not 
taking barbiturates, (difference = 28% [95% Cl 15 to 40%], p < 0.0001).
Of those taking barbiturates, 48/66 (73%) had ever seen their GP for epilepsy (mean 
time since last review 4.5 years, median 1.8 years). Of those not taking barbiturates, 
364/448 (81%) had ever seen their GP for epilepsy (mean time since last review 2.1 
years, median 1 year; difference between groups, Mann Whitney U = 7141, p = 0.04).
Of those taking barbiturates, 38/66 (58%) had seen a specialist for epilepsy (mean time 
since last review 14.0 years, median 10.5 years). Of those not taking barbiturates, 
376/448 (84%) had seen a specialist for epilepsy (mean time since last review 3.5 years, 
median 1.0 years; difference between groups, Mann Whitney U = 3543, p< 0.0001).
Those taking barbiturates were significantly older than those not taking them (those 
taking barbiturates mean age 63 years, SD 16, median 65 years, those on no barbiturates 
mean age 46 years, SD 22, median 44 years; difference between the groups, Mann 
Whitney U = 7886, p < 0.0001). Those taking barbiturates had had epilepsy for mean 
and median 41 years compared with those not taking them, whose duration was mean 19 
years, median 16 years (Mann-Whitney U = 3616, P < 0.0001).
4.1.5.2.2. Phenytoin
One hundred and seventy four of 514 (34%) patients were taking phenytoin. Ten of 58 
(17%) with learning disability took phenytoin, compared with 164 of 456 (36%) of 
those without learning disability (difference 19%, 95% Cl 8 to 29%, p = 0.0045). There 
was no difference in use of phenytoin between those reported as having a history of 
problems with alcohol (four of 16, 25%) compared with those without (170 of 498,
34%; difference 9% [95% Cl -12 to 31%], p = 0.447).
In those in whom it was possible to estimate seizure frequency, 49 of 94 (52%) of those 
taking phenytoin were seizure-free compared with 111 of 183, (61%) not taking 
phenytoin, (difference = 9% [95% Cl —4 to 21%], p = 0.17). However, almost half of
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both groups had missing or unclear information on seizure frequency. Side-effects had 
been reported in 24% of the phenytoin group and in 23% of those not on phenytoin.
Ninety of 174 (52%) on phenytoin had been reviewed in the 15 months before the audit, 
compared with 222 of 340 (65%) not on phenytoin (difference = 14% [95% Cl 5 to 
23%], p = 0.0029). Those on phenytoin had been reviewed by a specialist less recently 
than those not on phenytoin (mean 6.1 years, median 2.6 years in those on phenytoin 
compared with mean 3.8 years, median 0.9 years in those not on phenytoin; Mann 
Whitney U = 13560, p < 0.0001). There was no significant difference in the time from 
the last GP review of epilepsy (mean 2.7 years, median 1.4 years, for those taking 
phenytoin compared with mean 2.3, median 1.0 years, for those not; Mann Whitney U = 
17658, p = 0.27). Those taking phenytoin were significantly older (mean 59.8 years) 
than those not on phenytoin (mean 42.5 years; t = 9.04, p < 0.0001). Those taking 
phenytoin had had epilepsy for a mean of 26.8 years, median 26 years, compared with 
mean 20.0 years, median 16 years, for those not taking phenytoin (Mann-Whitney U = 
18974, p <  0.0001).
4.1.5.2.3. Sodium valproate
Of 58 people with learning disability, 20 (34%) took valproate compared with 113 of 
456 (25%) without learning disability (difference 10% [95% Cl -3  to 23%], p = 0.11).
Slightly more females (61 of 225, 27%) than males (72 of 289, 25%) who took AEDs 
were taking valproate, although the difference is not statistically significant (difference 
2% [95% Cl -5 to 10%], p = 0.57). Twenty-three of the women taking valproate were 
in the age group 14 to 45 years; two had had a hysterectomy, and in two, information is 
missing in the audit record. Of the 19 females of childbearing potential, eight were on 
monotherapy, ten on two AEDs and one (with frequent seizures who had had a recent 
epilepsy review) on four AEDs. Eight of 19 women of childbearing potential taking 
valproate had received advice about contraception, six had received preconceptual 
advice, and eight had had advice about pregnancy. In the six females aged 18-30 years 
who had not had a hysterectomy, three had received contraceptive advice, two 
preconceptual advice and three advice about pregnancy.
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4.1.5.2.4. Topiramate
Only 14 (3%) of the 514 patients taking AEDs were on topiramate. Four of 58 (7%) 
with learning disability took topiramate compared with ten of 456 (2%) without learning 
disability (Fisher’s exact p = 0.12).
Those on topiramate tended to be younger (mean 32 years, median 33 years) than those 
not on topiramate (mean 49 years, median 48 years; Mann Whitney U = 1887.5, p = 
0.003).
4.1.6. Information provision
There were 98 females between 14 and 54 years old who were potentially child-bearing; 
others had had a hysterectomy, or been sterilised. Approximately one third of these had 
received any information pertaining to contraception or childbearing. It was noticeable 
that, with few exceptions, no advice was given to those of childbearing age with 
learning disabilities. This is illustrated in table 4.
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Table 4 Chiltern audit: documented information provision to women with 
epilepsy
All women Those without
learning
disability
Those with
learning
disability
Women between 14 and 45 years
Advice on 35/98 32/85 3/13
contraception
Preconceptual advice 28/98 28/85 0/13
Pregnancy advice 27/98 26/85 1/13
Women between 16 and 20 years
Advice on contraception 0/8 0/6 0/2
Preconceptual advice 0/8 0/6 0/2
Pregnancy advice 1/8 0/6 1/2
Women between 21 and 30 years
Advice on 12/30 12/25 0/5
contraception
Preconceptual advice 13/30 13/25 0/5
Pregnancy advice 11/30 11/25 0/5
Women between 31 and 40 years
Advice on 14/32 12/28 2/4
contraception
Preconceptual advice 10/32 11/28 0/4
Pregnancy advice 10/32 10/28 0/4
Information about driving had been documented in only 243 of 547 (44%) patients aged 
16 years and over (47% in those without learning disability and 15% in those with 
learning disability).
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Twenty six percent of patients had received lifestyle advice, and seven percent had been 
told about receiving free prescriptions, (93% of these were in the practice with an 
epilepsy specialist nurse attached).
4.1.7. Summary
• Almost half (46%) of patients had had no epilepsy review in the 15 months prior 
to the audit
o Those not reviewed took fewer AEDs and were likely to have fewer 
seizures, where recorded
• Seizure frequency and description were available in around half of records
• Documented information provision was available in a minority of records
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4.2. T h e  p r im a r y  c a r e  s e c t io n  o f  t h e  N a t io n a l  S e n t i n e l  C l in i c a l  A u d it  o f
EPILEPSY-RELATED DEATH
In the UK during the study period 2412 deaths were recorded in which epilepsy 
appeared on the certificate. Of these, 298 deaths were audited in the primary care 
section of the National Sentinel Clinical Audit; 48 of these people do not appear ever to 
have been referred to specialist care.
4.2.1. Demographic details
4.2.1.1 Those not referred to specialist care
The notes of 48 patients (27 [56%] male) were audited. The mean age at death was 55 
years (median 55 years), range 23 to 89 years. Seventeen (35%) had documented 
problems with alcohol. Six patients (13%) had documented learning disability.
4.2.1.2. Those referred to specialist care
The notes of 250 patients (155 [62%] male) were audited. The mean age at death was 
40 years (median 40 years), range two to 86 years. Forty seven (19%) had documented 
problems with alcohol. Sixty patients (24%) had documented learning disability.
Those dying without being referred were significantly older than those referred (Mann 
Whitney U = 2874.5, p < 0.0001).
4.2.2. Access to care
4.2.2.1. People not referred to specialist care
In those whose first seizure was within five years of death, the audit nurses were asked 
to record any reason why the patient was not referred to a specialist. O f the 14 patients 
in this category (age range 23-89 years, mean 56 years), in six (43%) no reason was 
given; four of these were known to have problems with alcohol. Two patients (14%) 
died immediately after the first seizure, two were in care homes and one was already 
under the care of psychiatrists. One had multiple other health problems, and the other 
two never consulted the GP, but attended A&E only.
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The audit did not request information on the reason for the lack of referral in those 
diagnosed over five years before death (N = 34). In many cases, searching the audit 
record revealed no obvious reason why specialist care was not involved.
Eleven (32%) such patients were under 50 years old at the time of death. Four 
(36%) of these had learning disability; none had a clear seizure frequency 
documented. Five (45%) had documented problems with alcohol -  two of these 
(40%) had seizures at least weekly. Of the other two, one was seizure-free.
Nine (26%) such patients were between 50 and 59 years old at death. Two had 
documented problems with alcohol, but no documented seizure frequency. The 
other seven had each had epilepsy for at least 19 years; the four with documented 
seizure frequency all had rare seizures.
Of eight (24%) such patients aged between 60 and 69 years, none had seizure 
frequency documented clearly. Four (50%) had documented problems with 
alcohol, one of whom had problems with adherence with medication which had 
been discussed. In the other four, all with duration of epilepsy of at least seven 
years, there was no obvious reason for the lack of referral.
Six (18%) such patients were over 70 years old at death. None had documented 
problems with alcohol or learning disability. Only one, with epilepsy duration in 
excess of 30 years, had seizure frequency documented (less than yearly). The 
others had a minimum duration of 30 years, apart from one who also had 
dementia.
4.2.2.2. Review in all people audited
In the whole primary care section of the Sentinel Audit, the last review was carried out 
by a specialist in 139 people (47%), by the GP in 95 (32%), and by a specialist nurse in 
two; in 59 (20%) people no review was recorded. In three audit records the information 
was not available.
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• Last review by specialist: the median time to last review was 24 weeks (mean 64 
weeks), and it was carried out within 15 months in 110 (79%)
• Last reviewed by the GP: the median time to last review was 21 weeks (mean 65 
weeks) and it was carried out within 15 months in 71 (75%)
• Last review by the epilepsy specialist nurse: last review was six days and eight 
weeks before death.
Altogether, review was last undertaken more than 15 months before death (by any 
relevant professional) in 53 (18%) and in under 15 months in 183 (62%).
Of those whose epilepsy had never been reviewed (59 people) 17 (29%) had seen the 
GP within 28 days of death for another reason. Five of these consultations may have 
been epilepsy-related. Of those last reviewed more than 15 months before death, (53 
people), ten (19%) had seen the GP within 28 days of death, with two being apparently 
epilepsy-related.
4.2.2.2.1. Use of AEDs according to time of last review 
This is shown in table 5.
Table 5 Sentinel Audit (primary care): number of AEDs taken by patients 
according to time of last review
(AED information missing in 3 patients, review information missing in 3 patients)
N No AEDs Monotherapy Polytherapy Mean Range
N % N % N %
No review 57 22 39 27 47 8 14 0.8 0-3
Review more 53 6 11 35 66 12 23 1.2 0-3
than 15 months
Review 15 182 5 3 93 51 84 46 1.6 0-5
months or less
Total 292 33 155 104
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The number of AEDs taken in the three groups was significantly different (Kruskal 
Wallis Chi square = 47.9, p < 0.0001). Those with no review took significantly fewer 
AEDs than those reviewed more than 15 months previously (Mann-Whitney U =
1074.5, p = 0.004), who in turn took significantly fewer AEDs than those seen within 15 
months of death (Mann-Whitney U = 3396.5, p< 0.0001).
4.2.2.2.2. Time of last review and duration of epilepsy
Comparing those with review within 15 months of death and those without review in 
that time, there was little difference in the duration of epilepsy (in those with no review 
within 15 months of death mean duration was 19.1 years, median 14.3 years and in 
those with review within 15 months of death, mean duration of epilepsy was 20.4 years, 
median 19.2 years [Mann Whitney U = 8342, p = 0.30]).
4.2.2.2.3. Time of last review and age at death
The age at death was significantly different between the two groups (those with no 
review within 15 months mean age was 49.1 years, median 47 years, and those with 
review within 15 months death mean age was 39.4 years, median 39 years (Mann 
Whitney U = 6823.5, p< 0.0001).
4.2.2.2.4. Time of last review and learning disability
Those with documented learning disability were more likely to have been reviewed 
within 15 months of death (50/66, 76% reviewed) than those without documented 
learning disability (133/229, 58% reviewed; difference 18% [95% Cl 6 to 30%], p = 
0.009).
4.2.2.2.5. Time of last review and alcohol problems
Those with documented problems with alcohol were significantly less likely to have 
been reviewed (26/64, 41% reviewed) than those without such problems documented 
(157/231, 68% reviewed; difference 27% [95% Cl 14 to 41%], p = 0.0001).
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4.2.3. Documented history of seizures available
4.2.3.1. Seizure frequency documented
Seizure frequency was documented in 16 (33%) of people not referred to specialist care. 
One had a single seizure, one was seizure-free, three had seizures less than yearly, four 
had seizures between weekly and yearly, two had seizures more frequently than once per 
week, and in five the seizure frequency was unclear. Seizure frequency was not audited 
in people referred to specialist care
4.2.3.2. Seizure description documented
This was only audited in people whose first seizure was less than five years before 
death. In people not referred to specialist care, there was a seizure description in 7/14 
(50%). The descriptions were usually vague (such as ‘thrashing about in bed’ or ‘was 
rigid’).
In people referred to specialist care, a seizure description was available in 25 of 40 
(63%). In 15 (60%) the seizure was described fairly clearly, in eight (32%) it was stated 
in terms such as ‘fit’, ‘myoclonic jerk’, ‘grand mal epilepsy’, ‘tonic clonic seizures’, and 
in two the description was vague.
4.2.3.3. Cause o f  epilepsy documented
In people not referred to specialist care there was a presumed cause of epilepsy 
documented in the notes of ten (21%) people. In six epilepsy was probably due to 
alcohol in excess or withdrawal, two patients had dementia, in one the cause was a 
cerebrovascular accident and in one followed a serious head injury. This was not 
audited in people referred to specialist care
4.2.4. Management plan in the records
This was only audited in those not referred to specialist care. There was a GP 
management plan in the notes of five (10%).
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4.2.5. AED treatment
4.2.5.1 Number o f  AEDs taken at the time o f  death
4.2.5.1.1. People not referred to specialist care
Fifteen patients were apparently taking no AEDs. One may have been on valproate and 
one may have been seizure-free for many years. One visited A&E frequently, but did 
not apparently see the GP. One elderly patient had multiple other health problems. 
Seven had problems related to alcohol. Three died within a few days of the first seizure. 
There was no further information on the other.
Of the 33 patients taking AEDs at the time of death, 28 (85%) were on monotherapy and 
five (15%) on two AEDs. In 11 patients the GP had checked AED levels in the five 
years prior to death. In five patients, this was to check phenytoin levels and in three 
other cases, the levels of different AEDs were checked to monitor adherence to the 
regimen. In the final three cases, it is not clear why levels were estimated.
4.2.5.1.2. People referred to specialist care
This is shown in table 6. AED information was not available in three people.
Table 6 Sentinel Audit (primary care) AEDs in people referred to specialist care
No of AEDs No of patients (%)
0 20 8
1 128 52
2 66 27
3 28 11
4 3 1
5 2 1
Total 247
154
Section 4
4.2.5.2. Use o f  particular AEDs (in all people taking AEDs)
4.2.5.2.1. Phenobarbital or primidone
Of the 260 people in the Sentinel Audit who were taking AEDs, 20 were taking 
phenobarbital and four primidone; no-one was taking both, thus 24 (9%) were taking 
either. Five of 64 (8%) with learning disability were taking barbiturates compared with 
19 of 196 (10%) without learning disability (difference = 2%, 95% Cl -6  to 10%, p = 
0.65). Only one with documented problems with alcohol was taking phenobarbital.
Twelve of 24 (50%) taking barbiturates had been reviewed in the 15 months before 
death, compared with 165 of 235 (70%) not taking them (difference 20% [95% Cl -1 to 
41%], p = 0.04). The last epilepsy review had been with a specialist in ten of the 24 on 
barbiturates (42%), and the GP in six (25%); in eight (33%) no review had been 
recorded.
Those taking barbiturates were older (mean 50 years, median 49.5 years) than those not 
on these AEDs (mean and median 41 years; Mann Whitney U = 1890, p = 0.008).
4.2.5.2.2. Phenytoin
Eighty two (32%) were taking phenytoin. Sixteen (25%) of those with learning 
disability were using phenytoin, compared with 66 (34%) of those without learning 
disability (difference = 9% [95% Cl -4  to 21%], p = 0.19). One third of those with 
documented alcohol problems were taking phenytoin compared with 31% of those 
without such problems (difference = 2% [95% Cl -13 to 17%], p = 0.77).
Those taking phenytoin were less likely to have been reviewed in the 15 months before 
death, but the difference is not significant (those taking phenytoin 51 of 81, 63%, 
reviewed compared with 126 of 178, 71%, not taking phenytoin; difference 8%, 95% Cl 
-5  to 20%, p = 0.21). The last epilepsy review in those taking phenytoin had been by a 
specialist in almost one half and with the GP in one third; in almost one fifth no review 
had been recorded.
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Those taking phenytoin were significantly older (mean 50 years, median 52 years) than 
those not taking it (mean 38 years, median 37 years; Mann-Whitney U = 4249, p < 
0.0001). Those taking phenytoin had a slightly longer duration of epilepsy than those 
not (mean 24 years, median 22 years, compared with mean 19 years, median 18 years) 
but the difference is not significant (Mann Whitney U = 5345, p = 0.07).
4.2.5.2.3. Sodium valproate
Over 40% of patients (107) took sodium valproate. Males and females were equally 
likely to be taking valproate (each 41%). Thirty two (30%) were females between 14 
and 54 years; in none of these was any provision of information on issues pertaining to 
contraception or child-bearing documented. Half of all people with learning disability 
on AEDs were taking valproate, compared with 38% of those without learning 
disability, but the difference (12% [95% Cl -2  to 26%]) is not significant.
In those on valproate, over half last had an epilepsy review with a specialist, 38% with 
the GP, two with the specialist nurse, and in nine no review was recorded.
4.2.5.2.4. Topiramate
Only eleven (4%) of patients took topiramate, including five (8%) of those with learning 
disability. Those taking topiramate were significantly younger (mean age 22 years, 
median 26 years) than the others (mean age 43 years, median 42 years; Mann Whitney U 
= 486, p <  0.0001).
4.2.6. Information provision
4.2.6.1. People not referred to specialist care
Only two people were documented to have received information about epilepsy, one of 
which was in relation to alcohol withdrawal and the other related to AED use. One was 
alerted to the hazards of seizures, but in no case was the risk of epilepsy causing death 
apparently discussed.
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4.2.6.2. People referred to specialist care
Ninety-two patients (37%) had any information provision documented. Ten percent had 
been given information on lifestyle issues, 13% on issues pertaining to AED treatment, 
7% about epilepsy itself and 7% of those aged 16 and over on driving. There were 71 
women between 14 and 54 years old, of whom only two (3%), aged 26 and 36 years, 
had received any information pertaining to contraception or childbearing.
4.2.7. Summary
• Epilepsy review occurred within 15 months of the audit in 62%
o Those with no review within 15 months of the audit took fewer AEDs 
than those reviewed within 15 months 
o Those with no review within 15 months were older than those reviewed 
within 15 months
• Documented information provision was available in a minority of records
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4.3. T h e  s p e c ia l is t  c a r e  s e c t io n  o f  t h e  N a t io n a l  S e n t i n e l  C l in ic a l  A u d it
OF EPILEPSY-RELATED DEATH
Extra tables in appendix 3 give further details of results in this section.
4.3.1. Demographic details and classification of death
One hundred and ninety nine cases were assessed initially. Of those, nineteen cases 
were excluded as having non-epilepsy related deaths. Four had acute symptomatic 
seizures, four had probable cardiac deaths, in two there was no evidence of epilepsy, one 
died of the disease causing epilepsy, eight died of unrelated causes.
The remaining 180 cases were included in the analysis (111 [62%] male). Age at death 
was between two and 82 years (mean 36.7 years, median 36 years). The specialist care 
section considered both adults and children and people with and without learning 
disability (see tables 7 and 8).
Table 7 Sentinel Audit (specialist care): characteristics
N %
Adults no learning difficulties 108 60
Adults with learning difficulties 50 28
Children no learning difficulties 7 4
Children with learning difficulties 15 8
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Table 8 Sentinel Audit (specialist care): demographics
N
Learning
disability
65
No learning
disability
115
Male 37 (57%) 74 (64%) Difference 7% (95% Cl
-7 to 22%) p = 0.33
Mean (SD) age at death (years) 31.6(16) 40.5(16) t =3.6, p<  0.0001
Mean (SD) age at 1st seizure 9.6(11) 23.0(18) Mann Whitney U =
(years) 1586, p<  0.0001
Of 180 cases, 66 (37%) were classified as having adequate care, 98 (54%) as having 
received care which failed to meet guidelines, four (2%) cases had had one or more 
large error in their care, and in 12 (7%) the care was unclear. In 66 (37%) cases the 
death was classified as unavoidable, 59 (33%) as potentially avoidable, 16 (9%) as 
probably avoidable and 39 (22%) as unclear.
For those with learning disability, the suitability of specialist seen was categorised as: 
Good 10(15%)
Satisfactory 38 (58%)
Not satisfactory 10(15%)
Unclear 7(11%).
159
Section 4
4.3.2. Access to care
This is illustrated in figure 4, and detailed below.
Figure 4 Sentinel Audit (specialist care); access to specialist care
Adult no learning Adult with Child no learning Child with
disability learning disability learning
N =  108 disability N = 7 disability
N = 50 N =  15
Seen in OP Seen in OP Seen in OP Seen in OP
N  =  95 N =  43 N = 6 N =  14
56 seen in year 21 seen in year All seen in year All seen in year
before death before death before death before death
No documentation 
from OP 
N =  13
2 admitted as IP last 3 
occasions
1 died in first admission 
for seizure
3 had frequent 
emergency admissions 
3 did not attend 
appointments
1 awaiting OP 
appointment following 
admission 
1 audit file missing 
information
No documentation 
from OP 
N  = 7
2 admitted as IP last 3 
occasions 
2 in long term care 
2 no follow-up after 
emergency admissions 
1 audit file missing 
information
No documentation No documentation
from OP from OP
N = 1 N  = 1
Died in second seizure Missing information in
audit file
OP = outpatient appointment
4.3.2.1. Access to care (those with no learning disability)
Of the 115 people with no learning disability 101 (88%) had documented epilepsy 
review in outpatients. In fourteen cases it was not possible to calculate the time from 
the last outpatient visit to death. (In two cases, the last three secondary care episodes 
were all for inpatient admissions, within six months of death, so the date of the last 
outpatient appointment is not known. A child died in the second seizure, weeks after 
the first seizure. One patient was admitted to hospital at the time of the first seizure and 
died there six months later. Four had had frequent emergency admissions for seizures, 
three of whom had absconded. A further one who had been seen by neurologists in the 
past had had two emergency admissions one year and four years before death, with no 
further outpatient follow-up. Three had failed to attend outpatients on at least two
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occasions. One was discharged after a first seizure with a request to be seen by a 
neurologist; this appointment had not been made several months later. One audit record 
lacked information.)
Of the 95 adults in whom we were able to calculate the time period from the last 
appointment until death, 56 had been seen in under a year, including 39 in under six 
months. Of the 39 who were last seen more than a year before death, in the majority 
(22) we were unable to account for the loss to follow-up -  they appeared to have 
become ‘lost’. Of the other 17, five had failed to attend one or more appointment, and 
four had been discharged. In one case the consultant had tried assiduously to follow-up 
the patient, even suggesting domiciliary visits. In one case, only one outpatient 
appointment was made, and in five cases it is unclear whether the patient may in fact 
have been seen at another hospital in which the notes were not audited. In one case, a 
Specialist Registrar had questioned the diagnosis of epilepsy and discharged the patient 
with advice to stop AEDs.
The six children with outpatient appointments had all been seen within seven months of 
death.
4.3.2.2. Access to care (those with learning disability)
Of the 65 people with learning disability, 57 had documented outpatient appointments. 
Those who did not are as follows: one young child, with long-standing epilepsy, died 
following an admission for status epilepticus, but the audit tool is incomplete regarding 
outpatient appointments. Two of the seven adults with no outpatient appointments were 
long-term inpatients, and two had had three inpatient appointments within the nine 
months before death, so we were unable to ascertain whether they had had outpatient 
appointments. Two had had at least one admission for seizures with no follow-up 
arrangements, although one of these may have been seen at another hospital, and the last 
had significant missing information in the audit tool.
The 14 children with learning disability with documented outpatient appointments had 
all been seen in the year before death, 13 of these within 6 months of death. Twenty one
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(49%) of the 43 adults with documented outpatient appointments had been seen in the 
year before death. The other 22 had been seen between one and 15 years before death 
(median 4 years). Of these, in nine cases we were unable to account for the lack of 
follow-up; they appear to have become ‘lost’ despite at least four having ongoing 
seizures when last seen. Three cases appear to have been discharged (one with 
infrequent seizures, another had no seizure frequency documented when discharged and 
the other with two to three seizures in the previous six weeks). Two had failed to attend 
appointments, one with a single seizure had only one appointment, and four cases may 
have been seen at other hospitals. In three cases it seems probable that the patients may 
have become Tost’ in the handover from paediatric to adult care.
4.3.2.3. Access to care (those failing to attend appointments)
Of 24 patients (23 adults) in whom there is evidence of having failed to attend 
outpatient appointments, five appeared to have problems with alcohol. Of the 24, 18 
missed one of their last three appointments, five missed two appointments, and one 
missed all three. In 15 cases (ten of those missing one appointment, four of those 
missing two, and the one who missed all three) there is evidence that a further 
appointment was sent. Only four of the non-attending adults and one child had learning 
disability, but only one adult and the child were sent further appointments.
4.3.3. Surgery
Twenty seven adults (ten with learning disability) and seven children (six with learning 
disability) were documented to be experiencing at least two seizures per month when 
last reviewed. Of these, eight adults (two with learning disability) and no children were 
considered for epilepsy surgery. (In four adults [two with learning disability and two 
without] specialist opinion was that surgery was not suitable. One declined surgery, one 
was waiting for referral, one died in the post-operative period and in one no information 
is available.) In the 19 adults and seven children not considered for surgery, seven 
adults and three children had probably general onset of seizures and so would probably 
not be suitable for surgery. Eight adults and two children probably had epilepsy of focal 
onset which might have benefited from surgery.
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4.3.4. Comparing care provided to those with learning disability and those without
4.3.4.1. Overall standard o f  care
In those with no learning disability care was adequate in 48 of the 110 (44%) in whom 
this was assessable (ignoring those whose care was classified as unclear). Care was 
adequate in 18 of 58 (31%) with learning disability (difference 13% [95% Cl -3  to
28%], p = 0.11).
4.3.4.2. Death avoidable or not
In those with no learning disability death was unavoidable in 42 of 89 (47%) in those in 
whom it was assessable, whilst in those with learning disability, death was unavoidable 
in 24 of 52 (46%) assessable cases (difference 1% [95% Cl -16  to 18%], p = 0.91).
4.3.4.3. Documented evidence o f  having seen a consultant
Of 115 people without learning disability, 81 (70%) had seen a consultant in at least one 
of the last three outpatient appointments. A further 14 had documented evidence of 
having seen a consultant at some other time, so 95 (83%) had seen a consultant at some 
time. Of the 20 who had no documented evidence of having seen a consultant, five 
were frequent attendees at the A&E department, and three died after one or two 
seizures.
Of those with learning disability, 40 (62%) saw a consultant in the last three outpatient 
appointments, and a further eleven saw a consultant at some other time. Thus 78% had 
seen a consultant at some time. There is no significant difference in the numbers known 
to have seen a consultant (difference 4% [95% Cl -8  to 16%], p = 0.49).
4.3.4.4. Documented history o f  seizures available
The audit files on one person with learning disability lacked significant amounts of 
information, and so were excluded from this analysis.
4.3.4.4.1. Seizure frequency noted at last consultation
This was present in the clinical notes of 75% people with no learning disability and 77% 
people with learning disability (difference 2% [95% Cl -11 to 15%], p = 0.79).
163
Section 4
4.3.4.4.2. Clear description of seizures recorded
This was present in the clinical records of 86% people without learning disability and in 
81% of those with learning disability (difference 6% [95% Cl -7  to 16%], p = 0.39).
4. 3. 4. 5. Investigations o f epilepsy
4.3.4.5.1. EEG
Two cases with learning disability were excluded from this analysis due to inadequate 
information in the audit file.
Overall, the proportion of those whose EEG status was satisfactory (those with EEG and 
those who needed no EEG) was 93/106 (88%) in those without learning disability and 
49/62 (79%) in those with learning disability (difference 9% [95% Cl -3  to 21%], p =
0.13). Of the 13 people with learning disability who had no EEG but, according to 
SIGN guidelines should have done, eight had severe learning disability, two sets of audit 
files were missing information, and the other three people had no obvious reason for the 
lack of EEG.
4.3.4.5.2. Neuroimaging
Ignoring those in which the need was unclear for reasons other than lack of seizure 
description, neuroimaging status was satisfactory in 97 of 115 (84%) of those with no 
learning disability and 39 of 58 (67%) of those with learning disability (difference 7% 
[95% Cl 3 to 31%], p = 0.01).
4. 3. 4. 6. Use o f  A EDs
In two cases it was not possible to calculate the number or type of AEDs taken; one set 
of audit files was missing significant amounts of information, and the other patient 
appears to have been lost to follow-up.
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4.3.4.6.1. Number of AEDs taken at the time of death
This is shown in table 9.
Table 9 Sentinel Audit (specialist care): number of AEDs taken by those with 
and without learning disability
No learning Learning Total
disability disability
N % N % N %
No AEDs 10 9 5 8 15 8
Monotherapy 56 49 19 30 75 42
Polytherapy 49 43 39 62 88 49
Total 115 63 178
There is a difference between the two groups in the use of no AEDs, monotherapy or 
polytherapy (Chi squared = 6.41, df = 2, p = 0.04). Further analysis shows that there 
was no significant difference in the number taking no AEDs (difference 1% [95% Cl -8  
to 9%], p = 0.86), but that significantly more people with learning disability were on 
polytherapy (difference in those taking AEDs 21% [95% Cl 5 to 36%], p = 0.01).
4.3.4.6.2. New AEDs taken (those taking AEDs)
There was no difference in the proportions of patients taking new AEDs in those 
without learning disability (37 of 105, 35%) and those with learning disability (27 of 58, 
47%; difference 11% [95% Cl -4  to 27%], p = 0.16).
4.3.4.6.3. Use of AEDs thought to affect cognition
Five (5%) patients without learning disability took phenobarbital or primidone 
compared with four (7%) with learning disability, (difference 2% [95% Cl -6  to 10%], p 
= 0.57). Thirty (29%) of those without learning disability took phenytoin compared 
with 15 (26%) of those with learning disability (difference 3% [95% Cl -11 to 17%], p 
= 0.71). Five (5%) of those without learning disability took topiramate compared with 6 
(10%) of those with learning disability (Fisher’s exact test, p = 0.30). However, more
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with learning disability (31, 53%) took sodium valproate than those without learning 
disability (36, 34%; difference 20% [95% Cl 3 to 35%], p = 0.02).
4.3.4.7. Information provision 
This is shown in table 10.
Table 10 Sentinel Audit (specialist care): information provision in those with and 
without learning disability
Type of information No learning disability Learning disability Fisher’s
(N=l 15) (N=65) exact test, p
N % N %
Type of epilepsy or 30 26 17 26 1
syndrome
Hazards of seizures 10 9 1 2 0.09
Leisure factors 19 17 12 18 0.89
Social factors 28 24 20 31 0.45
Possibility of fatal 3 3 0 0 0.52
seizures
Patient support group 8 7 6 9 0.78
information
AED information N=105 N=58
Importance of AEDs 17 16 3 5 0.06
Side-effects of AEDs 36 34 17 29 0.93
4.3.5. Comparing care provided in those with learning disability according to the 
suitability of specialist seen
4.3.5.1. Overall standard o f  care
The standard of care was, to some extent, dependent on the suitability of specialist seen. 
This analysis was, therefore, not performed.
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4. 3. 5. 2. Death avoidable or not
There is no difference in the number of unavoidable deaths between those seen in a 
satisfactory or good specialty (21 of 40, 53%) and those seen in a specialty classified as 
not satisfactory (two of nine, 22%; Fisher’s exact test, p = 0.20).
4. 3.5. 3. Documented evidence o f  having seen a consultant
There is no significant difference between the proportions known to have seen a 
consultant between those whose specialty was satisfactory or good, (39 of 48, 81% saw 
a consultant at some time) and in those in whom the specialty was not satisfactory (ten 
of ten saw a consultant; Fisher’s exact test, p = 0.32).
4. 3. 5. 4. Documented history o f  seizures available
4.3.5.4.1. Seizure frequency noted at last consultation.
(Information was missing in one audit record).
There is no difference in the proportion with seizure frequency noted at the last 
consultation between those seen in a specialty classified as satisfactory or good (39 of 
48, 81%), and in those seen in a specialty classified as not satisfactory (6 of 10, 60%; 
Fisher’s exact test, p = 0.29).
4.3.5.4.2. Clear description of seizures recorded.
(Information was missing in one audit record).
There is no difference in the proportion with a clear description of seizures recorded 
between those seen in a satisfactory or good specialty (41 of 48, 85%), and in those seen 
in a specialty which was not satisfactory (7 of 10, 70%; Fisher’s exact test, p = 0.46).
4. 3. 5. 5. Investigations o f  epilepsy
4.3.5.5.I. EEG
(Excluding those with inadequate information in the audit records and the one for whom 
need for EEG is unclear).
There is no difference in the proportion whose EEG status was satisfactory between 
those seen in a satisfactory or good specialty (39 of 47, 83%), and in those seen in a 
specialty which was not satisfactory (7 of 10, 70%; Fisher’s exact test, p = 0.59).
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4.3.5.5.2. Neuroimaging
There is no difference in the proportion whose neuroimaging status was satisfactory 
between those seen in a satisfactory or good specialty (30 of 43, 70%), and in those seen 
in a specialty which was not satisfactory (six of ten; Fisher’s exact test, p = 0.81).
43.5.6. Use o f  AEDs
4.3.5.6.1. Number of AEDs taken at the time of death
There was no significant difference in whether or not polytherapy was used between 
those who received care from a specialty which was not satisfactory (5 of 10, 50%) 
compared with those who received care from a specialty which was satisfactory or good 
(31 of 47 on polytherapy, 66%; Fisher’s exact test, p = 0.55).
4.3.5.6.2. New AEDs taken (those taking AEDs)
There is no significant difference in whether or not new AEDs were used between those 
who received care from a specialty which was not satisfactory (5 of 9, 56%) and those 
who received care from a specialty which was satisfactory or good (19 of 43, 44%; 
difference 11% [95% Cl -24 to 47%], p = 0.53).
4.3.5.6.3. Use of AEDs thought to affect cognition
The analysis was not performed for barbiturates or topiramate due to the small numbers 
of people with learning disability taking them. Three of nine (33%) people seen in a 
specialty considered not satisfactory were taking phenytoin, compared with 12 of 43 
(28%) seen in a specialty classified as satisfactory or good (difference 5% [95% Cl -28 
to 39%], p = 0.74). Three of nine seen in a specialty considered not satisfactory were 
taking sodium valproate compared with 26 of 43 (60%) seen in a specialty classified as 
satisfactory or good (difference 27%, 95% Cl -7  to 61%, p = 0.14).
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4.3.5.7. Information provision
This is shown in table 11.
Table 11 Sentinel Audit (specialist care): information provision in those with 
learning disability according to specialty seen
Type of information Specialty not Specialty Fisher’s
satisfactory satisfactory or exact test, p
(N=10) good (N=48)
N % N %
Type of epilepsy or 2 20 15 31 0.77
syndrome
Hazards of seizures 1 10 0 0 0.34
Leisure factors 2 20 10 21 1
Social factors 4 40 16 33 0.95
Possibility of fatal seizures 0 0
Patient support group 0 0 6 13 0.61
information
AED information N=9 N=43
Importance of AEDs 0 0 3 7 1
Side-effects of AEDs 3 33 14 33 1
4.3.6. Comparing care provided to those with learning disability according to 
whether or not a consultant was seen
In six audit files it was not possible to establish whether or not the patient had ever seen 
a consultant.
4.3.6.1. Overall standard o f  care
The standard of care was, to some extent, dependent on whether a consultant had been 
seen. This analysis was, therefore, not performed.
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4.3.6.2. Death avoidable or not
There is no difference in the proportion with unavoidable death in those who did (19 of 
43, 44%) or did not see a consultant (two of six; Fisher’s exact p = 0.96)
4.3.6.3. Documented evidence o f  having seen a consultant 
Not applicable
4.3.6.4. Documented history o f  seizures available
4.3.6.4.1. Seizure frequency noted at last consultation
There was no difference between those who had seen a consultant (38 of 51, 75%) and 
those who had never seen a consultant (7 of 8, 88%; Fisher’s exact test, p = 0.77).
4.3.6.4.2. Clear description of seizures recorded
There was a witness account of the seizures in 45 of 51 (88%) case records of people 
seen by a consultant compared with three of eight (38%) not seen by a consultant 
(Fisher’s exact test, p = 0.008).
4.3.6.5. Investigations o f epilepsy
4.3.6.5.1. EEG
There was no difference between those who had seen a consultant (39/49, 80% with 
satisfactory status) and those who had never seen a consultant (all 7 had satisfactory 
EEG status; Fisher’s exact test, p = 0.46).
4.3.6.5.2. Neuroimaging
There was no difference between those who had seen a consultant (32 of 46, 70%) and 
those who had never seen a consultant (satisfactory in four of seven (57%) eligible for 
analysis; Fisher’s exact test, p = 0.80).
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4.3.6.6. Use o f  AEDs
4.3.6.6.1. Number of AEDs taken at the time of death
There was no significant difference in whether or not polytherapy was used between 
those who had never seen a consultant (six of eight on polytherapy, 75%), and those 
who had seen a consultant (31 of 50 on polytherapy, 62%; Fisher’s exact test, p = 0.78).
4.3.6.6.2. New AEDs taken (those taking AEDs)
Five of eight (63%) who had never seen a consultant had used new AEDs, compared 
with 20 of 46 (43%) who had seen a consultant (Fisher’s exact test, p = 0.54).
4.3.6.6.3. Use of AEDs thought to affect cognition
This analysis was not performed for barbiturates or topiramate due to the small numbers 
of people with learning disability taking them. Three of eight (38%) of those who never 
saw a consultant were taking phenytoin compared with 12 of 46 (26%) who saw a 
consultant (Fisher’s exact test, p = 0.78). Five of eight (63%) of those who never saw a 
consultant were taking sodium valproate compared with 24 of 46 (52%) who never saw 
a consultant (Fisher’s exact test, p = 0.88).
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4.3.6.7. Information provision
This is shown in table 12.
Table 12 Sentinel Audit (specialist care): information provision in those with 
learning disability according to whether or not a consultant was seen
Type of Consultant never Consultant seen Fisher’s
information seen (N=8) (N=51) exact test, p
N % N %
Type of epilepsy or 0 0 17 33 0.11
syndrome
Hazards of 0 0 1 2 1
seizures
Leisure factors 1 13 11 22 0.96
Social factors 2 25 17 33 0.98
Possibility of fatal 0 0
seizures
Patient support 0 0 6 12 0.80
group information
AED information N=8 N=46
Importance of AEDs 1 13 2 4 0.78
Side-effects of 0 0 17 37 0.07
AEDs
4.3.7. Summary
• Care was considered adequate in 44% of those without learning disability and 
31% of those with learning disability
• Death was unavoidable in just under half of assessable cases both with and 
without learning disability
• Seizure frequency and description were available in over three quarters of people 
both with and without learning disability
• Information provision was documented in a minority of case records
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4.4. I nvestigation  into  the  use o f  death  certifica tes  as case
ASCERTAINMENT FOR EPILEPSY
There were 246 deaths during the follow-up period. After excluding three because of 
incomplete information, 181 (74%) deaths occurred in those with definite epilepsy and 
62 (26%) in those with possible epilepsy. Epilepsy was mentioned on the death 
certificates of 16 (7%) altogether; ten (6%) with definite epilepsy and six (10%) with 
possible epilepsy. Causes of death could be grouped into vascular disease (mostly 
cerebrovascular disease and ischaemic heart disease) (44%), CNS malignancy (9%), 
other malignancy (21%), dementia and old age (6%), respiratory disease (5%), 
congenital disease (3%) and others (including alcohol related, accidents and injuries, 
other CNS disease, infections) (12%).
In 211 people it was possible to compute the average number of seizures per year either 
in the five years prior to death or during lifetime prior to death where that was less than 
five years. Most patients (106, 50%) had no seizures and the mean number of 
seizures/year was 15 (where seizures occurring more frequently than daily were counted 
as 365 seizures/year).
Mean age at death was 70 years and median 75 years (range 3 to 98 years).
Factors that appeared to influence mention of epilepsy on the death certificate were 
seizure frequency, AED treatment, cause of death, and certifying physician (see table 
13). Epilepsy was on the death certificate of 23% (3/13) of those on AEDs for ongoing 
seizures and was on the certificate of 21% (4/19) of those on AEDs who were certified 
by a coroner.
Subjects with death certificates, those with epilepsy on the death certificates and the 
results of exploratory logistic regression analysis are shown in Table 13.
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Review of clinical and death certificate information suggested that epilepsy should have 
been on the certificates of 105 (43%) subjects.
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Table 13 Exploratory logistic regression of mention of Epilepsy on Death Certificate
Number with Number with Odds Ratio
death epilepsy on death (95% Cl)
certificates certificate (%)
Classification
Possible epilepsy 62 6(10) 1
Definite epilepsy 181 10 (6) 0.5 (0.2 to 1.6)
Convulsive seizures
Yes 175 14 (8) 1
No 59 2 (3) 0.4 (0.1 to 1.8)
Not known 9
Age at death (years)
< 65 71 6 (8) 1
6 5 -7 4 48 1 (2) 0.2 (0.0 to 2.0)
7 5 -8 4 76 4 (5) 0.6 (0.2 to 2.2)
85+ 48 5 (10) 1.3 (0.4 to 4.4)
Seizures during follow-up
Yes 129 12 (9) 1
No 82 2 (2) 0.2 (0.1 to 1.1)
Not known 32
Certifying physician
Other physician 144 6 (4) 1
Current physician 18 1 (6) 1.4 (0.2 to 12)
Referring physician 47 4 (9) 2.1 (0.6 to 7.9)
Coroner 34 5(15) 4.0 (1.1 to 14)
Average seizures/year
None 106 4 (4) 1
1 - 12 87 7 (8) 2.2 (0.6 to 7.9)
More than 12 18 3(17) 5.1 (1.04 to 25)
Not known 32
Cause of death
Malignancy 73 1 (1) 1
Vascular 106 7 (7) 5.1 (0.6 to 42)
Other 64 8(13) 10.3(1.3 to 85)
AEDs at last follow-up
None 97 1 CD 1
Monotherapy 122 13(11) 11.4(1.5 to 89)
Polytherapy 17 2(12) 12.8(1.1 to 150)
Not known 7
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4.5. Suicide  in people  w ith  epilepsy  in E ngland and W ales
Eleven people with epilepsy were identified (age range 28-62 years, mean 40 years) who 
died probably as a result of suicide. Six deaths were attributed directly to drug overdose 
and in another five deaths drug poisoning was a contributory factor. Three of the deaths 
were due to overdose with AEDs, but the verdict was given as suicide in two cases and 
misadventure in the third. No deaths were recorded in people with epilepsy from 
hanging. All deaths were investigated and certified by a Coroner, but in only the two 
cases previously mentioned was the verdict given as suicide. The overall SMR for 
suicide was significantly reduced at 0.36 (95% Cl 0.18 to 0.65), and the SMR was lower 
in males, despite the fact that more deaths from probable suicide occurred in males (see 
table). The age at death was similar in males (mean 42 years) and females (mean 37 
years) (Mann Whitney U = 9000, p = 0.412).
Table 14 Deaths from suicide with Standardized Mortality Ratios (SMRs)
Observed number Expected SMR (95% Cl)
Sep -  Dec 
1999
Jan -  Apr 
2000
May -  
Aug 2000
Total
Males 3 1 3 7 23.39 0.30 
(0.12 to 0.62)
Females 3 1 0 4 6.98 0.57 
(0.16 to 1.47)
Total 6 2 3 11 30.37 0.36 
(0.18 to 0.65)
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4.6. A MET A-ANALYSIS OF SUICIDE IN PEOPLE WITH EPILEPSY
4.6.1. Unweighted SMR
The results of the unweighted analysis of SMR are shown in table 15 and illustrated in 
figure 5. There were 133 suicides reported in the 22 articles, compared with 29.8 
expected from national figures, providing an SMR of 4.5 (95% Cl 3.7 to 5.3).
4.6.2. Weighted SMR
Further analysis, using national data available for all studies (including Rafnsson and 
Nilsson) gives an SMR of 5.3 (95% Cl 4.5 to 6.3). Using the national data in RevMan 
software (after rounding the population data) gives an SMR of 5.5 (95% Cl 3.8 to 8.0), 
suggesting that, in this analysis, the weighting of studies according to size of sample 
does not seriously alter the outcome.
4.6.3. Unweighted SMR by year of publication
Analysis of the early studies, with 62 observed suicides and 8.22 expected provides an 
unweighted SMR of 7.5 (95% Cl 5.8 to 9.7). Analysis of the more recently published 
studies with 71 observed suicides compared with 21.6 expected provides an unweighted 
SMR of 3.3 (95% Cl 2.6 to 4.2). The ratio of the SMRs is 2.3 (95% Cl 1.6 to 3.3).
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Table 15 Meta-analysis: observed and expected suicides in 22 populations of people with epilepsy
(TLE -  temporal lobe e p i l e p s y ) ________________________ ______________________________________________
Study Country Description No of 
patients
Patient-years 
at risk
Deaths from 
suicide
Expected
deaths
SMR 95% Cl
Taylor England TLE surgery patients 100 566.7 5 0.0358 140 45.4 - 326
Dalby Denmark Absence epilepsy 346 3149 2 0.341 5.86 0.71 to 21.2
Stepien Poland TLE surgery patients 64 313.5 2 0.0389 51.4 6.11 to 182
Currie England TLE patients 666 4662 3 0.521 5.76 1.19 to 16.8
Zielinski Poland All people with epilepsy 6710 6710 16 0.832 19.2 11.0 to 31.2
White England Epilepsy institution 1980 32873 21 3.87 5.43 3.36 to 8.30
Lindsay England Children with TLE 100 1300 1 0.0908 11.0 0.275 to 61.4
Hauser USA All people with epilepsy 618 8233 3 0.997 3.01 0.620 to 8.79
Sillanpaa Finland Follow-up of children 233 4930 1 0.611 1.64 0.041 to 9.12
Bladin Australia TLE surgery patients 110 440 1 0.0486 20.6 0.515 to 115
Lip Scotland Clinic patients 1000 2462 3 0.252 11.9 2.46 to 34.8
Klenerman England Epilepsy institution 3392 0 0.371 0 0.0 to 9.96
Guldvog (adults) Norway Adults post surgery 124 868 2 0.158 12.6 1.53 to 45.6
Guldvog (children) Norway Children post surgery 64 1009 2 0.0602 33.2 4.02 tol20.0
Nilsson Sweden Hospitalised 9061 53520 53 15.2 3.49 2.61 to 4.56
Loiseau France First seizure 804 804 1 0.182 5.49 0.137 to 30.6
Hennessy England TLE surgery 299 2729 1 0.242 4.14 0.105 to 23.1
Shackleton Holland Epilepsy institute 1355 38665 7 4.03 1.73 0.697 to 3.57
Lhatoo UK Population incidence 792 11400 1 0.888 1.13 0.029 to 6.28
Rafhsson Iceland Population incidence 224 6598 4 0.8 5 1.36 to 12.8
Camfield Canada Children new diagnosis 686 8918 2 0.048 41.5 5.02 to 150
Salanova USA TLE surgery 215 1514 2 0.180 11.1 1.34 to 40.1
Total 133 29.80 4.46 3.74 to 5.29
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Se c t io n  5 : D is c u s s io n
Section 5
5.1. T he audits
5.1.1. Limitations of the audits
5.1.1.1. Chiltern audit
The Chiltern audit was conducted over a period of almost two years, and inevitably 
over that time-scale procedures and personnel within the practice change.
Nonetheless, the audit provides some indication of the documented care for people 
with epilepsy in a localised area, and whether it met defined standards.
The area in which the audit took place was not chosen at random, and may not be 
representative of the care for people with epilepsy as a whole in the UK. The area is 
relatively affluent, and is close to London, with access to major hospitals.
Case ascertainment was largely through the use of AED prescriptions and should have 
missed people with epilepsy who were not taking AEDs. The records of some who 
had taken AEDs in the past were audited.
The audit records covered a large area of clinical activity, but did not involve detailed 
descriptions. Thus some finer points may have been missed.
5.1.1.2. Sentinel Audit
In the National Sentinel Clinical Audit, 812 of 2412 deaths identified by the use of 
‘epilepsy’ on the death certificate during the study period were considered as probably 
due to epilepsy and therefore of primary interest to the audit. It was only possible, 
however, to audit the secondary care of 180, and the primary care of 298, of these.
This was largely due to the methodology of the audit. As a result of conducting a 
Sentinel Audit and not a Confidential Inquiry, the study team was not empowered to 
require the release of medical records and so was dependent on the cooperation of 
clinicians. An unknown number of the over 600 deaths whose secondary care was not 
audited will not have received any secondary care; nevertheless, it is probable that we 
gained access to the clinical records of less than 50% of people who died an epilepsy- 
related death during the study period.
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It is thus fair to question whether or not the results are valid, or suitable for 
extrapolation to the people who died an epilepsy-related death but whose clinical 
records have not been audited. The main criticism would be that the results are 
biased. This is a possibility, but it would seem intuitive that if any systematic bias 
occurred it would tend to exclude from the audit those whose care is deemed to be 
worse. This cannot, however, be assumed.
In the primary care section of the audit, in an attempt to reduce bias caused by using 
information from specialist care sources in the audit, the officers were instructed not 
to use any information from letters when gathering information (see section 3.2.4.). It 
is likely that this reduced the amount of information available to the audit, as 
information available otherwise is rarely duplicated in primary care records.
Some clinical information was not required in the primary care audit records, as it was 
felt that this information is more relevant to specialist care. Information regarding 
seizure frequency was only requested in those not referred to specialist care, and 
seizure descriptions were only audited in those with onset of seizures within five years 
of death. It would be relevant to know whether these details are available in all 
clinical records, whether written by the GP or the specialist, so that another 
professional unfamiliar with the patient would be able to provide adequate care.
In several cases in the specialist care section of the Sentinel Audit it was not possible 
to determine whether or not the patient had been seen in the outpatient department; 
this was in part due to a short-coming in the audit process which required the date of 
the last three specialist appointments. Four patients (two with learning disability) had 
had three inpatient episodes in the nine months prior to death and these were 
documented in the audit record. Three such admissions in a short space of time might 
lead one to question whether outpatient appointments should have been made in a 
shorter time-frame. There may be short-comings in follow-up from emergency 
admissions and A&E visits due to seizures, although those who abscond are difficult 
to review.
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In an audit it is often not possible to determine whether care provided was appropriate 
or met standards, as many aspects of care for people with epilepsy are dependent on 
precise clinical details and the acumen and expertise of the clinician. It was not 
possible, for example, to establish the misdiagnosis rate in either primary or specialist 
care. Misdiagnosis has important consequences, caused by both the problems 
associated with a diagnosis of epilepsy and the prolonged use of AEDs, and by 
missing alternative diagnoses (Scheepers et al., 1998).
5.1.2. Strengths of the audits
5.1.2.1. Chiltern audit
The Chiltern audit was conducted by experienced epilepsy nurses, with good 
knowledge of the care for people with epilepsy. Only three nurses took part in the 
data gathering, limiting subjective differences in opinion.
Despite the use of AED prescriptions for case ascertainment in the Chiltern audit, the 
records of 85 people taking no AEDs were audited. Most people with active epilepsy 
take AEDs.
5.1.2.2. Sentinel A udit
The main strength of the Sentinel Audit is that it was conducted across all four 
countries of the United Kingdom and therefore covers a spread of providers o f care for 
people with epilepsy. The audit was designed by a multi-disciplinary team and led by 
a patient group, thus causing the focus to be on issues relevant to people with epilepsy 
and their relatives.
5.1.3. Primary care audits
5.1.3.1. Age o f  sample
The mean age of patients in the Chiltern audit was 47 years, while in the Sentinel 
Audit the mean age of those not referred to specialist care was 55 years and o f those 
referred to specialist care was 40 years. The difference in age between the two parts 
of the Sentinel Audit may be due to differences in referral pattern, with those who are 
older less likely to be referred. The fact that those dying having had specialist care
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were younger than those still alive at audit might suggest premature death in those 
with an epilepsy-related death.
5.1.3.2. Referral o f  patients
In the Sentinel Audit, it is disquieting that 48 patients were never referred to specialist 
care for review of their seizures. In some cases the patient was severely ill, and the 
seizures may well have been the least of the problems experienced. In others, the 
patient does not appear to have presented to the GP, instead presenting one or more 
times at the A&E department; it is unknown whether such patients were advised to 
attend the GP, or whether further arrangements for follow-up were made by the 
hospital. Of the eleven people aged under 50 years and diagnosed more than five 
years before death, but without referral, nine had either documented learning disability 
or documented problems with alcohol; these diagnoses were much less frequently 
documented in those in the older age groups who were not referred, and the 
implication that either of these problems makes referral unnecessary is worrying. 
Overall, however, there was a slightly higher proportion of people with learning 
disability in the group that was referred than in the group which was not referred. It 
may be that the patients refused referral or did not attend, or were already under the 
care of specialist services (although this is unlikely, as they were not known to be 
receiving specialist care).
In the Chiltern audit twenty percent had apparently never consulted a specialist; 
almost one third of these were seizure-free, but in many there was no seizure 
frequency recorded. The figure is similar to that of 19% who had never consulted a 
specialist found in a questionnaire study to patients in General Practice eleven years 
ago (Hart and Shorvon, 1995). A recently reported study found that of 55 people with 
active epilepsy who had not previously been under hospital review, 31% achieved at 
least one year seizure freedom following consultation with a specialist (Leach et al., 
2005). This suggests that all people with epilepsy should be reviewed by the GP to 
establish current seizure status. Those who are not seizure-free could profitably be 
offered review with a specialist.
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5.1.3.3. Epilepsy review
The analysis of the time to last review was based on a 15 month review period, as this 
is the time period of interest in the new GP contract. This contract was not, however, 
in place at the time of either audit, so this may be seen as somewhat arbitrary. 
Nevertheless, prior to the new contract, many GPs suggested that optimal frequency of 
review for people with epilepsy would be more often than yearly (Ridsdale et al.,
1996). The NICE guidelines, also published since the audits were conducted, 
recommend that both adults and children with epilepsy should have a regular 
structured review with a maximum interval between reviews of one year (NICE, 
2004c). The Chiltern general practices are located close to specialist epilepsy 
services. Despite this, almost half had had epilepsy review by neither GP nor 
specialist within 15 months of the audit, including a substantial minority taking AED 
polytherapy. Of these, most had consulted a GP for another reason in the previous 15 
months. In the Sentinel Audit, just under 40% had not had any epilepsy review in the 
15 months before the audit; almost one quarter had consulted the GP for another 
reason within 28 days of death. This compares unfavourably with the questionnaire 
study of people with epilepsy in which only nine percent had had no epilepsy 
consultation in the previous year (Hart and Shorvon, 1995). Although all the patients 
in that study were taking AEDs for epilepsy, in the two audits reported here the 
majority of people were on AEDs and should have been reviewed. It seems that, in 
many cases, patients are not being given care that is relatively easily available; the 
proximity of the National Society for Epilepsy to the Chiltern practices does not 
appear to encourage referral, neither do GPs in either audit appear to make the most of 
opportunistic chances to review epilepsy or assess its impact on patients’ lives. The 
former missed opportunity may be influenced by budgetary constraints, while the 
latter may have more to do with pressure of time.
Compared with those more recently reviewed, those not reviewed within 15 months in 
the Chiltern audit seem to have less severe epilepsy, as witnessed by the chances of 
being seizure-free and of taking fewer AEDs. Nonetheless some of those not 
reviewed were taking AED polytherapy, and a small number were experiencing 
seizures at least monthly. In the Sentinel Audit, those with no review within 15 
months of death also took significantly fewer AEDs than those who had had epilepsy
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review, but again a sizeable minority with either no review at all, or with no review 
within 15 months of death, were taking AED polytherapy.
5.1.3.4. Seizure information
The Sentinel Audit (those not referred) found seizure frequency had been documented 
in only one third, and a seizure description in 50% (of those recently diagnosed). The 
Sentinel Audit (those referred) did not investigate seizure frequency and only 
considered the seizure description in those recently diagnosed. The rate of over 60% 
compares favourably with that in the Chiltern audit (under half of those recently 
diagnosed). It is interesting that the notes appear more full in those for whom the GP 
does not accept the full responsibility, although the numbers are small, and in a 
substantial minority there is no description.
5.1.3.5. Use o f  AEDs
The two audits did not use the same protocol. Specifically, they are not a case-control 
study. However, some useful preliminary data can be obtained by comparing AEDs 
taken between the studies. The fact that the patients in the Sentinel Audit who were 
not referred took fewer AEDs than the others could be due to a variety of reasons, 
such as that they may have had less severe epilepsy, or that concurrent illnesses made 
them too ill for either referral or consideration of AEDs. The reasons for the slightly 
greater number of AEDs taken by those who died having been referred are open to 
speculation; no firm conclusions can be drawn. Possible reasons could be either that 
those who died had more severe epilepsy or, perhaps less likely, that the AEDs 
contributed to the death. This has been suggested for carbamazepine (Timmings, 
1998), but not for other AEDs.
5.1.3.5.1. Specific AEDs
Barbiturates (phenobarbital and primidone)
Phenobarbital has been used for seizure control for many years, and is still considered 
an effective drug for partial onset and generalised tonic-clonic seizures. It is 
recommended by the WHO as a first line AED in developing countries, and was 
recently used to good effect in a community-based intervention trial in rural China 
(Wang et al., 2006). It is rarely used as such in developed countries, however, due to
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its side-effects of sedation, other behavioural problems and effects on cognition 
(Kwan and Brodie, 2004). It is also involved in several drug interactions, largely due 
to the induction of hepatic enzymes. Primidone is metabolised to phenobarbital and 
phenylethylmalonamide, and its anti-seizure effects are thought to be largely due to its 
conversion to phenobarbital. It is rarely recommended.
The results of these audits suggest that some of these patients may have been taking 
phenobarbital ‘by default’; those on barbiturates were significantly less likely to have 
been reviewed in the 15 months prior to the audit, and were significantly older. It may 
be, however, that those taking phenobarbital were reluctant to change AEDs because 
of fear of having further seizures.
Phenytoin
Phenytoin is described as effective treatment for partial onset and tonic-clonic seizures 
and, although not a first line drug, is still relatively widely used. It may be given once 
daily. It has, however, a narrow therapeutic index and non-linear relationship between 
the dose and plasma concentration. Hence toxicity can be a problem. A variety of 
side-effects including hirsutism and gingival hyperplasia are associated with 
phenytoin (Joint Formulary Committee, 2005) and it is also a hepatic enzyme inducer.
As with phenobarbital, those in these audits taking phenytoin were older than those 
not. Although those taking phenytoin had a slightly longer duration of epilepsy than 
those without, the difference is not clinically important, as the same AEDs were 
available at the time most patients were diagnosed. The smaller percentage of people 
reviewed in the groups taking phenytoin may suggest that either clinicians or patients 
did not wish to review the treatment.
Sodium valproate
Sodium valproate is a broad spectrum AED whose main restriction of use is in women 
of child-bearing potential, or girls who may become so whilst taking the drug (see 
section 1.2.2.8.2.). It may also have minor adverse effects in people with learning 
disability.
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Many patients in these audits took sodium valproate. It is somewhat disconcerting 
that as many women as men were taking this, and particularly that, in the Sentinel 
Audit, those most likely to be of childbearing potential had no record of information 
on child-bearing issues; the audit record did not specify issues of child-bearing in the 
information section, so there is a possibility that this was recorded in the clinical 
record but missed in the audit. The Chiltern audit found some information provided 
to relevant women, but even so, this is recorded in minority.
Topiramate
Topiramate is recommended by NICE as treatment for generalised tonic-clonic 
seizures and focal seizures in people who have not benefited from the older AEDs, or 
for whom they are unsuitable (NICE, 2004c; NICE, 2004a). Its side-effects include 
somnolence and difficulties with memory and concentration. In these audits only a 
small number of patients took topiramate, including some with learning disabilities.
5.1.3.6. Investigations
According to the guidelines current at the time of the Chiltern audit, in almost one 
sixth of people there was no documented evidence to suggest that EEG was not 
necessary, but no EEG was documented. A similar proportion in whom neuroimaging 
may have been indicated appeared to have had none. Whilst investigations of epilepsy 
are largely in the remit of specialists, it could be argued that the GP could be more 
proactive in the care of the patient, and perhaps have considered referral for further 
investigation, particularly as only a minority were known to be seizure-free.
5.1.3.7. Information provision
As noted earlier, documented information provision was generally poor, particularly 
with regard to issues pertaining to contraception or childbearing. It is noticeable that 
information provided to people with learning disability seems to be particularly poor.
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5.1.4. Specialist care
5.1.4.1. Demographics
Those with learning disability died younger than those without, perhaps because of 
having more severe epilepsy or due to the compounded risks with comorbidity. This 
cannot be reliably assessed in a clinical records audit.
5.1.4.2. Epilepsy review
Of 158 patients in whom it was possible to calculate the time period from the last 
outpatient appointment to death, over one half (97) had been seen in the year before 
death.
All but two of the children who died had been seen by a specialist within a year of 
death; one of the other two died in the second seizure, and the other may have been 
seen. Fewer adults had been seen, including 37% who may have had ongoing seizures 
(Hanna et al., 2002). The National Sentinel Audit was concerned that one fifth of 
adults appeared to have been Tost to follow-up’, with a further three people probably 
lost in the handover from paediatric to adult care (Hanna et al., 2002). Concern was 
raised by the audit team at the handling of some patients who repeatedly did not attend 
outpatient appointments; frequently there was no documentation to suggest that effort 
had been made to establish a reason for non-attendance or to send a further 
appointment. A study in Northern Ireland of non-attenders at a gastroenterology clinic 
found that 30% had forgotten to attend or to cancel the appointment, and the authors 
suggest that no strategy is likely to improve on this (Murdock et al., 2002). However, 
a small study from New Zealand found that a group who were telephoned 24 hours 
prior to the appointment had a non-attendance rate of five percent compared with 27% 
in a control group (Reti, 2003). The Irish study found that, of follow-up patients, 27% 
had failed to attend at least once previously (Murdock et al., 2002).
An audit of clinical records may not pick up all the options considered by the 
clinicians. Nevertheless, it is disappointing that surgery was apparently only 
considered in eight of twenty four patients in whom it may have been indicated.
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5.1.4.3. Care in different groups
In virtually all areas of care considered, there was no difference found between those 
with learning disability and those without, between those whose care had been in a 
specialty considered satisfactory or not, and between those who had ever seen a 
consultant or not. Had the care in all settings been excellent, this would suggest that 
there is no discrimination shown to those with learning disability. Poor record 
keeping, although better than that found in the primary care audits, hampered the 
audit. Although three analyses appear to show statistically significant results (fewer 
people with learning disability than without had a satisfactory neuroimaging status, 
more of those with learning disability than without were on polytherapy, and, in those 
with learning disability, more people seen by a consultant had a clear description of 
the seizures in the clinical records), these results could well have appeared as 
significant by chance, as so many analyses were performed. Using Bonferoni’s 
correction the p-values found become non-significant.
There was no difference in the overall standard of care, as assessed by the specialist 
panel, received by those with and without learning disability, but this is no cause for 
complacency, as the care was only considered adequate in less than half of either 
group. Death was unavoidable in less than half of assessable cases in each group.
The fact that in one fifth of deaths this was not assessable suggests that deaths could 
be potentially or probably avoidable in even more (or fewer) cases overall. 
Approximately 80% of patients have documented evidence of having seen a 
consultant at some time. The implication that one fifth of the patients in this audit, 
who later died an epilepsy death, may never have seen a consultant is disquieting.
Only fifteen percent of those with learning disability were seen in a specialty classified 
as ‘good’ (see Methods 3.3.6.2.). However, over half were seen in a specialty 
designated as satisfactory.
5.1.4.4. Documented history o f  seizures
Seizure frequency was noted at the last consultation in around three quarters of 
people, but in many of these cases, was very unclear (Hanna et al., 2002). The 
specialist treating the patient may have a good memory for all the salient facts, but
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notes are also used to allow another physician caring for the patient to know what has 
been done (Brook et al., 1996). As seizure freedom is the aim of treatment in 
epilepsy, it is imperative that seizure status is clearly documented in the clinical 
records. Similarly, as treatment is often determined by the epilepsy syndrome, this 
should be clearly stated in the records, along with a seizure description.
5.1.4.5. Investigations
Around four fifths of patients in whom an EEG was indicated had had one. Many of 
those with learning disability who did not have an EEG had severe learning disability, 
which may have made the decision to arrange an EEG more difficult; however, in this 
group diagnosis is often complex, and an EEG may have helped to clarify the 
diagnosis (Jenkins and Brown, 1992). Similarly, those with learning disability were 
less likely to have had neuroimaging. This apparently statistically significant 
difference will no longer be so after correcting for multiple analyses, but the fact 
remains that in only two thirds of people with learning disability was the 
neuroimaging status satisfactory.
5.1.4.6. AEDs
The finding that slightly more people with learning disability were using AED 
polytherapy is not surprising (EUCARE, 2003). It is disappointing, however, that 
there was no difference in the proportions of people with and without learning 
disability who were taking drugs which may adversely affect cognition as it could be 
argued that extra care should be taken in those with learning disability.
5.1.4.7. Information provision
Information provision is perhaps difficult to ascertain accurately from a clinical 
records audit. However, the case records may be used for medicolegal purposes, and 
it behoves the clinician to make adequate records about information provision. The 
Sentinel Audit did not specifically audit information concerning fertility issues in 
specialist care, but overall, documented information provision was small; the highest 
documented information was on side-effects of AEDs, which was documented in the 
records of just under one third of those on AEDs. Even if patients recall more than is 
documented, this clearly leaves much room for improvement.
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5.2. C ause o f  death  in peo ple  w ith  epilepsy
5.2.1. Use of death certificates as case ascertainment
Epilepsy was mentioned on the death certificates of a minority of patients even when 
there was a history of relatively recent seizures, which could be taken as a surrogate 
for seizure severity. Those with more than 12 seizures per year were more likely to 
have epilepsy on the certificate than those with no seizures, but epilepsy was only 
recorded in three of 18 with such frequent seizures. Those on AEDs were more likely 
to have epilepsy recorded than those not on AEDs, but again in a small minority 
(15/139). There was no increased rate of reporting epilepsy by physicians who had 
completed the most recent follow-up form and should therefore be aware of the 
diagnosis of epilepsy; indeed the coroner was the most likely to report epilepsy. 
Neither the presence of convulsive seizures, nor younger age at death appeared to 
influence mention of epilepsy on the certificate. Cause of death influenced the 
mention of epilepsy, as those dying from malignancy were less likely to have epilepsy 
on the death certificate than those certified as dying from causes other than 
malignancy or vascular disease.
Many studies have been based on information found on death certificates (Antoniuk et 
al., 2001; Senanayake and Peiris, 1995), but it has long been known that they are an 
inaccurate record of cause of death (Coyle et al., 1994; Medical Services Study Group, 
1978). Death certificates have been found to be a poor source of estimating mortality 
in diabetes (Morgan et al., 2000), asthma (Hunt et al., 1993; Reid et al., 1998; Wright 
et al., 1994), and cancer (Rigdon, 1981). In investigations into deaths related to 
epilepsy, it has been found that, in many cases, epilepsy has not been mentioned on 
the death certificate. For example, in a paediatric study of deaths in children, where 
cases were identified by both direct and indirect means, in only 55% of deaths 
attributable to epilepsy was the diagnosis of epilepsy on the death certificate (Harvey 
et al., 1993). Similarly, a study of older patients with known seizures included 11 
patients who died suddenly and unexpectedly of unknown cause, and were found dead 
under circumstances compatible with death occurring during a seizure. In only one 
case was epilepsy mentioned on the death certificate (Luhdorf et al., 1987). It has 
been suggested that in over 90% of people with epilepsy, it is not mentioned on the
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certificate (Morgan and Kerr, 2002). Even in those cases where epilepsy is 
mentioned, many patients certified as dying from status epilepticus were more likely 
to have died from SUDEP (Langan et al., 2002).
There are several reasons why epilepsy may not be recorded on death certificates. 
Death certification is not primarily intended for epidemiological research, but in the 
UK was instigated in 1837 as an important legal and social requirement. The Home 
Office, the government department responsible for internal affairs in England and 
Wales, initiated a review into death certification in 2001, in response to the conviction 
of a GP for the murder of 15 patients. This review lists nine items as being the most 
essential elements of death certification. As well as confirming that death has 
occurred, establishing the identity of the deceased person and ensuring that unnatural 
deaths are properly investigated, this list includes the provision of an indication of the 
likely cause of death, and provision of statistical information about the cause and 
circumstances of the death (The Home Office, 2001).
In 1978, it was suggested that in a fifth of deaths there was a major discrepancy 
between the cause of death certified and that determined by the consultant and the 
case notes (Medical Services Study Group, 1978). The highest proportion of major 
discrepancies occurred among deaths certified by the coroner, but it was noted that 
most other death certificates are completed by the most junior member of the hospital 
team. However, it has been argued that the errors were not as serious as appeared 
(Adelstein, 1978). Furthermore, in a more recent study senior hospital doctors were 
found to make more errors than their juniors (James and Bull, 1995). The Home 
Office review suggested that the quality of death certification by doctors was uneven 
due to lack of training and to the low priority given to this duty (The Home Office, 
2001). The error rate in deaths certified by coroners may be exacerbated by the fact 
that the primary purpose of post-mortem examinations performed is legal, and any 
history available to the pathologist is more likely to come from the police than from 
clinicians (Devis and Rooney, 1999).
Under the current system of death certification in the UK it is likely that, in many 
cases, the diagnosis of epilepsy is correctly absent from the certificate. This is
193
Section 5
because the information required is that of conditions leading to death, and of other 
conditions contributing to death. Our results are in keeping with this, as those dying 
with malignancy were significantly less likely to have epilepsy on the certificate than 
those with other pathologies, excluding vascular. However, SMRs for malignancy are 
increased in many studies of mortality in epilepsy (Lhatoo et al., 2001; Nilsson et al.,
1997). Although the malignancy could be the cause of the seizures this is not 
necessarily always the case, particularly as SMRs for non-CNS tumours are often 
raised in people with epilepsy. The Home Office review suggested that, as well as 
recording the fact and circumstances of the death, and thus assisting the prevention 
and investigation of crime, the collection of mortality data was of considerable 
epidemiological importance (The Home Office, 2001). The review suggested that any 
study of death certification should take account of its current uses and also consider 
how these might change in the future. The Baker Report, also set up in response to 
the above conviction, suggested that in a revised certification system, brief 
information about the circumstances of death and the patient’s clinical history should 
be recorded (Baker, 2001). However, the Report of the Fundamental Review of death 
certification and coroner services did not appear to include this recommendation 
(Home Office, 2003). The Shipman Inquiry (The Shipman Inquiry Third Report, 
2003) suggested a dual system of forms, the second of which provides space for a 
‘brief chronological account of the deceased’s medical history before death... ’. The 
government is reviewing the coroners’ service, based on the above reports (without 
following all the recommendations), and this will probably change the way in which 
deaths are certificated. The certificate would still record the medical cause of death, 
however, and so may not record clinical details which are not pertinent to the death 
(Department for Constitutional Affairs, 2006). Unless this sort of information is 
provided for registration purposes, death certificates used in isolation will continue to 
be a poor source of information about mortality in epilepsy or other chronic diseases.
The current situation complicates efforts to conduct research into the epidemiology 
and causes of SUDEP, as this can only be diagnosed with any degree of certainty after 
a postmortem examination has not revealed a toxicological or anatomical cause for 
death. Unless the coroner or clinician requesting the post-mortem is both aware that 
the subject had epilepsy and aware of the existence of SUDEP, this diagnosis might
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not be reached. Furthermore, it suggests that the case ascertainment of the Sentinel 
Audit may have missed some epilepsy-related deaths, although it is not possible to 
quantify the proportion missed.
This study seems to indicate that in the UK a minority of people with epilepsy would 
be picked up by a study of death certificates alone. Although a high seizure 
frequency, the use of AEDs and the absence of malignancy appear to influence the 
likelihood of epilepsy being on the death certificate, it is still recorded in only a small 
minority of patients.
The present system of death certificates in the UK is not an effective way to look at 
mortality in epilepsy, and only large general population-based studies, with ‘flagging’ 
of records by the NHSCR can hope to investigate the causes of death in people with 
epilepsy.
5.2.2. Suicide in people with epilepsy in England and Wales
The SMR of 0.36 appears to indicate a protective effect of epilepsy on death by 
suicide. No previous study has reported an SMR for suicide in epilepsy o f less than 
one, and there is no evidence that epilepsy protects people from suicide, as the low 
SMR implies. If epilepsy were not recorded in all death certificates of people with 
epilepsy who died during the study period, then the number of deaths from suicide in 
people with epilepsy would be underestimated.
It is interesting that none of the deaths in people with epilepsy in this study was due to 
hanging, despite the fact that over 40% of deaths from suicide in England and Wales 
in 2000 were due to hanging (Office for National Statistics, 2003). Suicide by 
hanging is more common in males in the general population, and this may be reflected 
in the lower SMRs for suicide in males in this cohort. The case control study in 
Sweden, using different case ascertainment, also found the method of suicide was 
more often intoxication and less often hanging and shooting compared with the 
general population of Sweden (Nilsson et al., 2002).
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In that study the SMR for suicide was 3.5 (95% Cl 2.6 to 4.6) (Nilsson et al., 1997). 
This study, however, was amongst adults (>15 years) and was not a population-based 
study. People who attend hospitals have higher morbidity and mortality than those in 
community cohorts.
Calculations in the current study are based on the assumption that the information is 
accurate and representative of the general and epilepsy populations. In England and 
Wales a coroner investigates deaths that may have been suicide and it is therefore 
unlikely that any such deaths have been missed. Deaths where coroners recorded open 
verdicts were specifically sought but no further deaths that could be suicide were 
identified. Sometimes the attribution of cause of death is difficult, and there is a risk 
that deaths due to suicidal intent are not considered or not registered as such. This 
situation may not necessarily introduce bias, as information on the cause of death was 
obtained in the same way for the epilepsy and the general population cohorts. The low 
SMR found suggests that, although deaths from suicide may not have been missed, 
some of the deaths from suicide have been attributed to people in the general 
population (without epilepsy). This is consistent with the conclusion (see 5.2.1.) that 
death certificates are unreliable as a source of case ascertainment for studies of death 
in people with epilepsy.
It is important that the risk factors, prognosis and causes of death in epilepsy are 
understood fully, to reduce any avoidable morbidity and mortality from epilepsy. In 
the interim, adequate seizure control and taking of precautions should be established 
for all patients in order to avoid more deaths.
5.2.3. Meta-analysis of suicide in people with epilepsy
The SMR for suicide in people with epilepsy is estimated as 4.5, clearly higher than 
that suggested by the previous study (section 5.2.2.). Anecdotal evidence suggests 
that the rate of suicide in people with epilepsy may be falling, and the ratio of the 
SMR of the earlier published studies to the later ones suggests that this may indeed be 
the case. This work needs to be validated, taking into account the timing of the deaths 
and using weighting of the SMRs.
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There are several limitations for the study. A new literature search was not done, and 
studies may have been missed; a further follow-up of the Sillanpaa papers has been 
published. It was not always possible to obtain national data for the midpoint time of 
the study to calculate expected deaths. Where possible these were taken from the 
papers themselves. No account was taken of the age at death of the patients, although 
the overall age of the cohort was considered when choosing the age group used from 
national datasets. The readily available software to produce weighted SMRs did not 
allow for numbers as large as the total country populations, and so the weighted SMR 
is only an approximation.
There are many problems inherent in performing a meta-analysis. The first is in 
performing the literature search to extract all appropriate studies, including studies in 
other languages and those unpublished. On this occasion a new literature search was 
not done, and a search done by others, several years ago, was relied on. This does not 
appear to have included unpublished or other language literature.
Other authors have attempted to produce an overall figure for suicide in epilepsy. One 
published in 1997 produced a figure for the percentage of deaths in epilepsy due to 
suicide, but averaged the rates (Robertson, 1997). This provided a figure of 13.2% of 
all deaths in people with epilepsy compared with 1.4% in the general population. 
Finding the ratio of the total number of deaths by suicide to the total number of deaths 
in epilepsy provides a more accurate figure of 4.1%. The inappropriate calculation 
was repeated including more studies in 2003 (Jones et al., 2003), this time suggesting 
that suicides constitute 11.5% of epilepsy deaths, whereas the more accurate ratio of 
all deaths by suicide to all deaths in epilepsy is 3.8%. The ratio of total deaths by 
suicide to total deaths still does not take fully into account the size of the study 
populations, and weighting should ideally be applied.
A review of the mortality risk in epilepsy found that the overall mortality rate was 
influenced by the source population and, to a smaller degree, by whether an incident 
or a prevalent population was considered (Shackleton et al., 2002). This was not 
considered in the current study. SMRs have also been shown to be influenced by the 
type of epilepsy and the population studied. An unweighted meta-analysis published
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in 1997 found the overall SMR to be 5.1 (95% Cl 3.9 to 6.6), but that it was 8.0 in 
people with temporal lobe epilepsy, 87.5 in surgically treated patients, 4.9 in 
institutionalised patients but only 4.1 in outpatients (Harris and Barraclough, 1997).
5.2.4. Cause of death in people with epilepsy
These results together show that death certificates are not a reliable method of case 
ascertainment for studying death in people with epilepsy as a whole, or for 
investigating deaths in people with epilepsy from suicide. They do not, however, 
show that death certificates are not useful for investigating deaths due to epilepsy. It 
seems probable that deaths related to epilepsy are more likely to be identified in this 
way than deaths unrelated to epilepsy; the present studies cannot quantify this.
5.3. Use of  clinical  guidelines
Guidelines can be defined as ‘systematically developed statements to assist 
practitioner decisions about appropriate healthcare for specific clinical circumstances’ 
(Field, quoted in Grimshaw and Russell, 1993). As described in the section on 
provision of clinical services for people with epilepsy in the UK in this thesis, there is 
no shortage of guidelines and government recommendations on the care of people 
with epilepsy. The main purpose of clinical guidelines is to improve the quality of 
care for patients (Feder et al., 1999), but in practice they may do little to change 
behaviour (Woolf et al., 1999). They may, however, draw attention to previously 
unrecognised health problems. Guidelines which are firmly evidence-based can 
clarify which interventions work, and which do not; however scientific evidence is 
often lacking (Woolf et al., 1999). Guidelines are considered valid if ‘when followed, 
they lead to the health gains and costs predicted for them’ (Institute of Medicine, 
quoted in Eccles et al., 1996). They should also be reproducible and reliable 
(Littlejohns and Cluzeau, 2000).
Guideline recommendations may be wrong or, even if good for patients in general, 
may be inappropriate for individuals or ignore their preferences (Woolf et al., 1999). 
They may also need to be adapted for use within the local healthcare setting (Feder et 
al., 1999). It has been shown that clinical guidelines can improve the quality of care
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(Grimshaw and Russell, 1993), but they may not always do so; in part this may be 
because they are not put into practice (Woolf et al., 1999).
A systematic review in the early 1990s looked at 59 evaluations of the effect of 
guidelines. All but four studies detected significant improvements in the care process 
following the use of the relevant guidelines. The review found that guidelines were 
more likely to be followed when the physicians had been involved in their 
development than when they were developed by others (Grimshaw and Russell, 1993). 
Eleven of the studies involved the outcome of care, and all but two of these found 
significant improvements in outcome.
The attitudes towards the use of guidelines has been investigated in a questionnaire 
study of randomly selected GPs in the west of England. GPs were asked to complete 
the sentence ‘The one thing most likely to make me turn to a guideline is ... and the 
key factors identified were brevity, simplicity, ease of retrievability, reputable source 
and quality, and the complexity of the presenting problem. Almost all GPs said that 
they adapted guidelines to the needs of particular patients (Watkins et al., 1999).
Dissemination of guidelines may be a significant factor in their use. In the 
Netherlands, a systematic implementation programme follows guideline development. 
In France guidelines are disseminated through GP networks, and their effectiveness 
evaluated through local audit. In the USA guidelines are commonly used for both 
quality improvement and cost control (Woolf et al., 1999). Reviews have shown that 
relatively passive methods of dissemination (for example, with publication in 
professional journals or by mail) infrequently leads to changes in practice. Methods 
suggested to improve on this include seminars and workshops, audit and feedback, 
and reminders (Feder et al., 1999).
Following the publication of the 1997 SIGN guidelines for the diagnosis and treatment 
of adults with epilepsy, a study (The TIGER trial, [Tayside Implementation of 
Guidelines in Epilepsy Randomized trial]) aimed to determine the effectiveness of 
dissemination strategies (Davis et al., 2004). All general practices (except those in the 
pilot study) in the local area were invited to take part in the study, and GPs responding
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were grouped by practice location. Sixty eight practices in 53 locations were 
randomised. The practices in the control group (24 practices in 18 locations) were 
sent a copy of the guideline by post. The intermediate intervention group (22 
practices in 18 locations) received the guideline, an invitation to interactive 
workshops, and two structured protocol documents to use with the guideline. The 
intensive intervention group, as well as being offered the same interventions as the 
intermediate group, were also offered the services of a specialist epilepsy nurse, to 
promote the use of the guideline, to help establish epilepsy review programmes and to 
provide epilepsy information for both GPs and patients. Adult patients receiving 
AEDs on the list of participating GPs were sent questionnaires including questions 
measuring eight dimensions of health-related quality of life (the SF-36 general health- 
related quality of life instrument [the SF-36 scale]) before and after the interventions. 
The numbers of prearranged review consultations for epilepsy and the numbers of 
consultations in which epilepsy counselling was given were also determined in the 
practices. Analysis was conducted by intention to treat. Fifty six percent of eligible 
patients returned the first questionnaire, and 72% of those returned the second.
Of 238 primary care staff invited to a workshop, less than ten percent attended 
(including no practice managers), and only two practices routinely used the protocols 
provided. Only six of 22 practices in the intensive intervention group took up the 
offer of help from the epilepsy specialist nurse. There were no significant differences 
among the patients of the three groups in SF-36 scale either before or after the 
intervention. The number of planned reviews per patient did not change after the 
intervention, while the number of sessions at which counselling was given increased 
marginally. There was no difference in these data in the three arms of the study. After 
the intervention the mean number of reviews per patient per year was 0.14 (compared 
with the recommendation of at least one). The authors speculate that the problem may 
be related to a lack of perceived need for change in practice rather than lack of time or 
resources. They also suggest that many primary care practitioners do not see epilepsy 
care as their responsibility, but rather that of secondary care (Davis et al., 2004).
A more recent study from Norway investigated adherence to guidelines on the 
management of women with epilepsy by neurologists, and also sent a questionnaire to
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assess the knowledge of these issues to some of the patients (Kampman et al., 2005). 
The study consisted of two periods: in the first two years guidelines were not actively 
disseminated, but were available in publications. In the second period a condensed 
local recommendation was developed and this was presented at an interactive meeting, 
made available on the internet and in print; patient education handouts were also 
placed in waiting rooms. The case notes of patients seen by the neurologists were 
investigated for documentation that issues relevant to women with epilepsy had been 
discussed, during both time periods. Sixty percent of women had been seen during 
both periods. Fertility-related issues had been discussed at least once in one third of 
cases (but a higher proportion during the earlier period of passive dissemination).
Five oral contraceptive failures were documented in 62 women taking carbamazepine. 
Pregnancy-related issues had been discussed with 65% of (28) women prior to 
conception. Questionnaires sent to women who had consulted a neurologist in the 
first time period were returned by 71%. Seventy one percent of women needing 
contraception and taking enzyme-inducing AEDs were aware of potential conflicts 
with the oral contraceptive pill; under half remembered hearing this from the 
neurologist. Over 60% of women had heard from their neurologist that they should 
contact the neurologist when planning pregnancy, and 56% of women knew from the 
neurologist that folate was recommended in women of child-bearing potential. It 
seemed that patients completing the questionnaire remembered hearing more 
information from the neurologists than was documented in the medical records, 
although approximately one quarter of relevant women did not remember having 
received the information at all (Kampman et al., 2005).
5.4. Use OF AUDIT
One problem inherent in a clinical records audit is that it is reliant on data recorded in 
the clinical records. The Chiltem and Sentinel audits have confirmed that record 
keeping is poor, particularly in primary care. Whilst clinical record keeping is of 
importance to clinical audit, it is also of vital use in patient management and care. It 
is possible that some care was better than found in the audit, but good care should not 
reduce the need for good clinical records. It has, however, been suggested that ‘the 
weakness of such a system of audit... is that excellent humane medical care can be 
given by a doctor who writes appalling records’ and that ‘complaints may be made by
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patients that “he never even looked at me, he was too busy writing”’ (Hopkins, 1990). 
Nevertheless, it has been hypothesised that the process of making and documenting a 
complete assessment, and of developing and documenting a clear plan would be 
associated with improved clinical outcomes and patient satisfaction (Solomon et al., 
2000).
Quality of care is generally considered in three dimensions: structure, process and 
outcome (Hopkins, 1990). Whilst the structure (the availability of buildings, 
equipment and suitably trained staff, for example) is relatively easy to audit, it is 
unlikely to be a good guide to the quality of care; ‘bad care can occur in well equipped 
hospitals’ (Hopkins, 1990). The process (the activities of medical care) is the subject 
of these audits. Auditing the outcome seems at first sight to be a more useful measure 
of quality of care -  the end result is what is probably most important to patients and 
their relatives. However, outcomes as an endpoint are only useful if  they relate to the 
quality of care -  many people get better despite their treatment. For some chronic 
conditions like epilepsy the time interval between the care provided and the outcome 
can be long, and poor care does not always relate to bad outcome (Kampman et al., 
2005). Mortality rates in the UK have improved vastly over the past 100 years, and 
the initial improvements were due in large part to improvements in housing and 
hygiene, and to improved understanding of infectious diseases. Avoidable mortality 
should be a more useful parameter to measure, and this was attempted in the Sentinel 
Audit. The expert panel identified that specialist care had been inadequate in over 
half of adults. However, as found by others, difficulties arise in identifying deaths 
which were avoidable and those which are dependent on other factors such severity of 
the illness, comorbidities and age. The panel felt that death was probably avoidable in 
nine percent, although potentially avoidable in 30%. In almost one quarter they were 
unable to make a judgment (Hanna et al., 2002). Many forms of epilepsy-related 
death, particularly SUDEP, but to a lesser extent death from status epilepticus and 
from accidents, occur unexpectedly, and so it is even more difficult to distinguish 
those which are due to deficiencies in care. The Sentinel Audit considered such areas 
as inadequate control of seizures (known to be a risk factor for SUDEP), insufficient 
follow-up or premature discharge from secondary care, inadequate investigations to 
make a safe diagnosis, and inappropriate or inadequate AEDs used.
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The Sentinel Audit considered the main outcome of interest as death, particularly 
epilepsy-related death. Improved seizure control could also be regarded as a positive 
outcome; in the audits presented here documentation of seizure control was taken as 
evidence of quality of care. There was insufficient data in the clinical records to 
investigate seizure control as such. Achieving monotherapy with AEDs whilst 
controlling seizures may also be a positive outcome as side-effects are likely to be 
reduced. Again, this was regarded as evidence of quality of care in these audits. 
Information provision may also aid the patient in coping with a long-term condition. 
Patients may regard improvements in quality of life as being of equal importance as 
reduction of premature mortality.
5.5. Audits of  epilepsy  services
Many guidelines suggest that audit should be an integral part of epilepsy care (CSAG, 
2000; SIGN, 2003) and over the years many audits have been carried out. An audit in 
the 1970s of care in 17 general practices for adults with epilepsy found that 95% of 
patients had been referred to hospital at some stage, although a small minority had 
been referred to a hospital without a neurologist. At that time most patients were on 
phenobarbital or phenytoin, but the authors found that half of those with generalised 
convulsive seizures were probably undertreated. A further finding was that follow-up 
seemed disorganised; two of three patients with daily generalised seizures had last 
seen the GP several months previously. Of the 11% of subjects currently supervised 
in hospitals, half were having generalised seizures less frequently than yearly, while 
three subjects had been discharged from hospital follow-up whilst experiencing 
weekly seizures. Two thirds of the subjects were ineligible to drive under the 
regulations current at that time, but almost one fifth of these were driving. A small 
minority were driving against advice, but larger numbers had either been told they 
could drive or felt that they had received such consent (Hopkins and Scambler, 1977).
Another study, published only two years later, of care of people with epilepsy in one 
general practice found a slightly different picture (Zander et al., 1979). Twenty one of 
29 patients who had either had seizures or had taken AEDs in the previous two years 
were reviewed; 13 (62%) had had no seizures within two years and only four had had
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a seizure within one year. A further four subjects were not reviewed, as they were 
under regular hospital follow-up; three of these had seizures which were very difficult 
to control. Six subjects (29%) had possible side-effects of AEDs.
An audit of the care for adults with active epilepsy (taking AEDs or having had a 
seizure within two years) in six general practices in the south-east of England in the 
1990s used three sources of information; a questionnaire sent to GPs, a medical 
records audit and a questionnaire sent to patients (Ridsdale et al., 1996). Ninety 
percent of 283 patients selected to receive questionnaires returned them completed; 
32% of these reported having seizures in the previous six months. GPs estimated that 
the patients would have seen a specialist within 24 months (the records audit 
estimated median 39 months) and would have consulted a GP in 12 months (the 
records audit estimated 14 months). Most GPs felt that ideal epilepsy monitoring by 
GPs would take place at least six monthly. GPs estimated that 73% of patients would 
have received advice on driving; the medical records audit found documented 
evidence in 46%, and 59% of patients reported having received such advice. GPs 
estimated that 30% patients would have received advice on side-effects of AEDs; 
medical records found documented evidence in only nine percent, while 51% of 
patients recalled receiving such advice.
A general practice records audit of care for people with epilepsy also published in the 
1990s sought more documented information on the process of care (Jacoby et al., 
1996). Whilst more than four fifths recorded the date of the first seizure, less than 
half had recorded the seizure frequency in the previous year. The seizure type was 
documented in two thirds, and there was a witness description of the seizure in half. 
Three quarters had had an EEG, and one third CT scanning. Of those on AEDs, 31% 
were on polytherapy, and in one quarter AED side-effects had been discussed. Less 
than a quarter of women had documented information provision on interactions 
between AEDs and the oral contraceptive pill. A similar finding to the two audits of 
primary care described in this thesis was that, although over half had not had any 
epilepsy review in the year before the audit, only eight percent had not seen the GP at 
all during that time.
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A recently published audit of epilepsy care in general practice from the north of 
England, conducted at a similar time to the Chiltem audit (December 2001 to March 
2003 compared with January 2001 to November 2002) showed similar conclusions 
(Minshall and Smith, 2006). The authors found that it was not possible to collect 
reliable information on seizure frequency, side-effects of AEDs or lifestyle issues. 
Only 41% of people with epilepsy had been seen for epilepsy by the GP in the 
previous year (compared with 38% in 15 months in the Chiltem audit) and 49% had 
seen no doctor for an epilepsy review in one year (compared with 46% in 15 months 
in the Chilten Audit). These results suggest that our findings are not anomalous.
One specialised epilepsy clinic, whose origin predated the recommendations of the 
Winterton report, audited the first one thousand patients referred to it (Tobias et al., 
1994). Patients were referred for rationalisation of their AED therapy or for 
clarification of the diagnosis in up to one third of patients each. One fifth had 
recurrent seizures despite treatment, and 15% were referred from the A&E 
department. Over 90% had EEG recording, of which over 80% were reported as 
abnormal. One third had CT scanning, of which one third demonstrated 
abnormalities. On referral, 38% of patients were taking monotherapy and 27% 
polytherapy; 35% were taking no AEDs. By the time of the audit, over half the 
patients were taking monotherapy and one quarter were taking polytherapy; one 
quarter were not treated. In those patients whose pre-referral and pre-audit seizure 
data were both available, seizure frequency had improved in three quarters, and half 
were seizure-free. Interestingly, one third of patients were lost to follow-up, of whom 
40% had a history of alcohol abuse. This audit demonstrates some of the problems 
observed in attempting to audit outcome in specialist care clinics; the outcome figures 
are likely to be less favourable due to the number of patients with intractable epilepsy 
referred, together with those with alcohol-related epilepsy, and epilepsy associated 
with other morbidities, such as learning disabilities and neurodevelopmental disorders.
Another audit of a specialist clinic also published in the 1990s illustrates the same 
problem (Martin and Millac, 1994). The records were audited of 55 patients with 
refractory epilepsy seen at a specialist clinic, who had data available for two three 
month periods nine months apart. In 40% of patients seizure frequency actually
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increased substantially, while in only 11% was there a substantial reduction in 
seizures. Use of AED monotherapy was similarly disappointing, with fewer people 
taking monotherapy in the second time period.
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Conclusions
This work describes six different studies with a common purpose of investigating 
standards of care for people with epilepsy in the UK and the ways in which this may 
affect the mortality rate in people with epilepsy.
The thesis confirms previous suggestions that care for many people with epilepsy is 
substandard. It has not, however, been able to confirm or refute the implication that 
substandard care may contribute to premature mortality in epilepsy. The Sentinel 
Audit found that of those seen in hospitals, care was substandard and death probably 
avoidable in many. In most cases, however, the audit did not have access to reliable 
data on the details of the death, and it is not possible to be sure that the deaths were 
related to epilepsy. Even if the cause of death is known for certain, it is rare that this 
can be blamed directly on medical services or lack of them. Unlike diabetes or 
asthma, for example, where death may be a direct result of poor control, death in 
epilepsy is not an inevitable consequence of poor seizure control. Other important 
outcomes for patients, such as improved seizure frequency and reduced side-effects of 
AEDs may be more directly related to quality of care.
The use of audit to quantify the process of care is problematic while record keeping 
remains poor. The new GP contract may well be instrumental in improving record 
keeping, as GPs are paid according to set standards. Data from the first completed 
year of the Quality and Outcomes Framework shows that almost all practices have set 
up a register of people with epilepsy (NHS Health and Social Care Information 
Centre, 2005). Over 90% of adult patients registered by general practices have a 
record of seizure frequency and of epilepsy medication review in the previous 15 
months and over 60% are said to be seizure-free. It will be of great interest to see 
whether this results in any changes in care. Will people with frequent seizures or 
disabling AED side-effects be referred to a GP with a special interest in epilepsy or to 
specialist care? Will people who have been seizure-free for many years be asked to 
consider AED reduction? Will women of child-bearing potential with epilepsy be 
encouraged to take AEDs suitable for their situation? Will all people with epilepsy be 
provided with the information they need?
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The Sentinel Audit alerted many people to the risks inherent in epilepsy, and 
particularly to the existence of SUDEP, and led to many government and non­
governmental initiatives. It is hoped that the combined effect of these will lead to 
improvements in care of people with epilepsy.
Randomised clinical trials of care for people with epilepsy are not an option. It would 
not be ethical to randomise any patient to substandard care and, even if a group were 
randomised to ‘usual care’ it is likely that the existence of the trial would alter the 
management of any patient in the trial. Audit assesses the situation as it is, and takes 
into account the realities of real life. If record keeping is generally improved, then this 
is likely to be the best way of monitoring patient care.
This thesis has shown that case ascertainment is problematic. Death certificates may 
identify a proportion of people whose death was related to epilepsy, but only if they 
are completed by someone who knows that the person had epilepsy and who is aware 
of the risks of SUDEP and of suicide in people with epilepsy. The Sentinel Audit may 
have increased the awareness of SUDEP by pathologists. It seems likely that the only 
reliable way to ensure complete case ascertainment of epilepsy-related death will be to 
use large-scale prospective studies of people with epilepsy, with timely reporting of 
death to the study, so that contemporaneous enquiries can be made about the manner 
and cause of death. Whether this would be feasible is open to doubt.
Epilepsy care in some countries is generally considered to be superior to that in the 
UK. Comparing death rates from epilepsy (even if they were reliably available) 
between countries with different models of care would suffer from many confounding 
issues. It is possible, however, that simultaneous audits of care of people dying from 
epilepsy-related causes in different (but geographically, culturally and economically 
similar) countries may be useful. In this thesis it was not possible to find a direct link 
between standards of care, and death. Were more reliable data available on cause of 
death and standards of care, however, correlations could be sought between quality of 
care and mortality rates from epilepsy in different regions of the world.
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It is important that the risk factors for both SUDEP and suicide in epilepsy are firmly 
established so that efforts can be made to reduce those that are avoidable. Further 
research is needed to determine the cause(s) of SUDEP.
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S u g g e s t io n s  f o r  f u t u r e  w o r k
1. A further audit of the Chiltem practices following the Quality and Outcomes 
Framework to see whether the presumed improvement in record keeping is 
matched by appropriate care for people with epilepsy.
2. Further audit of epilepsy-related death following the publication of the 
previous audit. This would ideally be a Confidential Inquiry, which would 
ease access to the records but also, and more importantly, would eliminate 
some bias in case ascertainment.
3. A concurrent audit of epilepsy-related death in another European country to 
see if any link can be found between epilepsy-related death and service 
provision.
4. Further research into the cause of SUDEP. Large epidemiological studies 
could improve our knowledge of the risk factors for SUDEP, and identify 
predictors for death. Identifying the cause or causes of SUDEP would clearly 
provide the most satisfactory information, and then risk factors could be 
identified much more clearly and eliminated or reduced where possible.
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A p p e n d ic e s
Appendix 1
Appendix  1. E xamples o f  recom m endations and guidelines fo r  care
PUBLISHED RECENTLY IN THE UK
Non-government publications
■ 1998. The Joint Epilepsy Council, ‘Service Development Kit’ (Epilepsy Task
Force., 1998)
o Provided specifications for epilepsy services 
o Provided examples of good practice from all over the country 
o Recommended that there should be equity of access to epilepsy 
services in response to needs assessment
■ 1999. British Epilepsy Association ‘Epilepsy Care: Making it Happen’ (British
Epilepsy Association, 1998)
o Recommended a service vision of high quality services which are 
accessible, appropriate and well informed 
o Recommended a service which offers early diagnosis, treatment and 
ongoing support
o Recommended that services should be cost and clinically effective 
o Recommended that primary care-based patient management should be 
closely integrated with epilepsy specialists in secondary care, 
o Recommended the appointment of clinical nurse specialists, 
o Recommended increased liaison between primary, secondary and 
tertiary care
o Provided minimum standards for all levels of care, as well as for health 
authorities
■ 2002. Joint Epilepsy Council ‘National Statement of Good Practice for the
treatment and care of people who have epilepsy’ (Frost S et al., 2003) aimed 
to:
o Improve the clinical management of epilepsy
o Improve the quality of life for those with epilepsy, whether seizure-free 
or not
o Increase the number of people who successfully withdraw from therapy 
o Describe how general practice should contribute to quality epilepsy 
care, as part of integrated care
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■ Primary Care Guidelines for the management of females with epilepsy 
(Epilepsy Guidelines Group, 2004).
o This gives guidance to help the non-specialist address the specific 
needs of women with epilepsy
Government and national publications
■ 2000. Clinical Standards Advisory Group report ‘Services for Patients with 
Epilepsy’ (CSAG, 2000)
o Based on an assessment of service provision and on the views of over 
2000 patients and clinicians 
o Found clear advances in the previous decade in the provision of 
specialist services for epilepsy, but these were usually on an ad hoc 
basis
o Found an enthusiasm to develop high quality local services 
o Made various recommendations to provide services equitably across 
the country.
■ 2002. National Sentinel Clinical Audit into epilepsy-related death (Hanna NJ 
et al., 2002) (commissioned by NICE and managed by the charity ‘Epilepsy 
Bereaved’) found that:
o 54% of adults and 77% of children had inadequate secondary care 
o 39% deaths in adults and 59% in children were potentially or probably 
avoidable
o Primary care showed lack of access to specialists and little evidence of 
structured management plans
■ 2003. Improving Services for people with Epilepsy. Department of Health 
Action Plan in response to the National Clinical Audit of Epilepsy-related 
death (Department of Health, 2003b)
o Asked NHS and primary care trusts and strategic Health Authorities to 
review local epilepsy services and address any shortfall as part of their 
local delivery plans 
o Included some funding to enable the National Society for Epilepsy to 
develop further the information outreach services
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o Included funding to be spent in developing neurological services 
through the work of the Modernisation Agency 
o Suggested more general practitioners and nurses with a special interest 
(GpwSI) in neurology
■ 2003 Guidelines for the appointment of General Practitioners with special
interest in epilepsy were published (Department of Health, 2003a).
■ 2003 (Scotland). Scottish Intercollegiate Guidelines Network ‘Diagnosis and
Management of Epilepsy in adults’ (SIGN, 2003). This:
o Provided guidance about diagnosis, treatment and management of 
epilepsy
o Made recommendations relating to models of care 
o Made recommendations relating to audit of epilepsy care and provision 
of information
■ 2004. NICE guidelines ‘The diagnosis and management of the epilepsies in
adults and children in primary and secondary care’ (NICE, 2004c)
■ 2004. NICE technology appraisals ‘Newer drugs for epilepsy in adults’ and
‘Newer drugs for epilepsy in children’ (NICE, 2004a; NICE, 2004b).
■ The National Primary and Care Trust Development Programme suggested 
competencies for primary care (NatPact, 2005). Included in these is quality in 
clinical care, including epilepsy. PCTs should:
o Work with the voluntary sector 
o Have an epilepsy register
o Undertake regular check ups to assess progress and adherence to drug 
regimes
o Have developed effective links with secondary care providers 
o Commission services to provide timely access to consultants
■ The National Service Framework (NSF) into long-term conditions was 
published in March 2005, with implementation over a ten-year period. NSFs 
aim to:
o Provide blueprints for care 
o Raise standards 
o Reduce variations in services
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o Address particular issues including the provision of a ‘seamless 
service’ with continuity of care, including guidance on the transition 
from paediatric to aduit services.
The NSF into long-term conditions (Department of Health, 2005b) does not 
address individual neurological conditions in detail, but Quality Requirements 
relevant for people with epilepsy included:
o Integrated assessment to prevent unnecessary reassessment and 
repetition of basic information 
o Developing a personalised care plan, including reviewing information 
provision
o Each person having a named point of contact for advice and 
information
o Provision of prompt access to ongoing neurological advice and 
treatment
o Access to appropriate vocational assessment and vocational 
rehabilitation 
o The offer of appropriate respite care
■ As part of ‘Standards for Better Health’, health care organisations will need to 
ensure that care given conforms to nationally agreed best practice; NICE 
technology appraisals form part of the core standards to which health care 
organisations must conform, and NICE guidance and NSFs are part of the 
developmental standards, to which progress is expected to be made 
(Department of Health, 2005c). The Healthcare Commission, covering work 
formerly done by the Commission for Health Improvement, will undertake an 
annual review of the provision of health care by each NHS body in England, 
and will aim to determine that all trusts are meeting core standards and 
achieving developmental standards.
■ ‘Our health, our care, our say’ is a recent white paper concerned with 
reforming health and social care (Department of Health, 2006). It aims to give 
people access to the GP of their choice at a suitable time. It also aims to tackle 
inequalities in access to community services and to support people with long­
term needs.
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A p p e n d ix  2. A d d i t i o n a l  f i g u r e s  f r o m  s e c t i o n  4.1
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Figure A 1 . P eop le  with ep ilepsy  with no ep ilepsy  review by GP or specialist
I." '□ No AEDs
Monotherapy
Polytherapy
Seizure-free
N = 10
1
1 AEDs not known
No review by GP or 
specialist 
N = 35
1 subject seizure frequency not 
documented by researcher (0 AEDs)
1 on prophylaxis post head injury (1 AED)
Fewer than 5 seizures
documented N = 4
r
Seizures occurring 
weekly to yearly N = 1
No seizure frequency 
documented N = 18 
including 5 possibly seizure-free
2 AEDs not known
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Figure A2: people with epilepsy without recent review by GP or specialist
No AEDs
Monotherapy
Polytherapy
Last review by specialist and GP 
> 15 months.
N = 135
1 on prophylaxis post head injury (1 aed)
6  ‘on goin g’ se izu res (2 each on 0,1 & 3 AEDs)
1 ‘free if com pliant’ (1 aed )
1 ‘well-controlled nocturnal ep ilep sy ’ (1 aed) 
1 ‘frequent falls - possibly se izu res’ (1 aed)
1 ‘still h as auras’ (1 aed )
Seizure-free *
N = 60
4
Fewer than 5 seizures 
documented N = 4
Seizures occurring 
weekly to yearly N = 6
No seizure frequency 
documented N = 54 including 
25 possibly seizure-free
©
* In 2 cases, ‘epilepsy specialist’ was epilepsy specialist nurse
Figure A3: people with epilepsy with no review by specialist and no recent review by GP
1.....1 No AEDs
Monotherapy
Polytherapy
Seizure-free 
N = 20
No review by specialist 
Last review by GP > 15 months 
N = 46
Fewer than 5 seizures 
documented N = 4
No seizure frequency 
documented N = 22 
(including 13 possibly 
seizure-free)
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Figure A4: people with epilepsy with no review by GP and no recent review by specialist
1 1 No AEDs
Monotherapy
Polytherapy
Last review by specialist > 15 
months. No review by GP 
N = 63
1 with seizures ‘ongoing’ 
on polytherapy
Seizure-free *
N == 32
4
Fewer than 5 seizures
documented N = 5
(T
. 3
Seizures occurring 
weekly to yearly N = 5
No seizure frequency 
documented N = 20 
including 8 possibly 
seizure-free
* In one case ‘epilepsy specialist’ was an epilepsy specialist nurse
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Appendix  3. Additional tables from  section  4.3: the  specialist  care
SECTION OF THE NATIONAL SENTINEL CLINICAL AUDIT OF EPILEPSY-RELATED 
DEATH
Comparing care provided to those with learning disability and those not
Audit records with significant missing information are usually omitted from the 
relevant tables.
Table A1 Sentinel Audit (specialist care): overall standard of care in people with and 
without learning disability
No learning 
disability 
N %
Learning 
disability 
N %
Total
N %
Care adequate 48 41.7 18 27.7 66 36.7
Care inadequate 59 51.3 39 60.0 98 54.4
Major error in care 3 2.6 1 1.5 4 2.2
Care unclear 5 4.3 7 10.8 12 6.7
Total 115 65 180
Table A2 Sentinel Audit (specialist care): death avoidable or not in people with and 
without learning disability
No learning 
disability 
N %
Learning 
disability 
N %
Total
N %
Death unavoidable 42 36.5 24 36.9 66 36.7
Death potentially 35 30.4 24 36.9 59 32.8
avoidable
Death probably 12 10.4 4 6.2 16 8.9
avoidable
Circumstances 26 22.6 13 20.0 39 21.7
unclear
Total 115 65 180
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Documented history o f  seizures available
Table A3 Sentinel Audit (specialist care): seizure frequency noted at last 
consultation in people with and without learning disability
No learning 
disability 
N %
Learning 
disability 
N % N
Total
%
Seizure frequency 86 74.8 49 76.6 135 75.4
documented
Not documented 29 25.2 15 23.4 44 24.6
Total 115 64 179
Table A4 Sentinel Audit (specialist care): clear description of seizures recorded in 
people with and without learning disability
No learning 
disability 
N %
Learning 
disability 
N % N
Total
%
Clear description 99 86.1 52 81.3 151 84.4
documented
Not documented 16 13.9 12 18.8 28 15.6
Total 115 64 179
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Investigations o f  epilepsy
Table A5 Sentinel Audit (specialist care): EEG in people with and without learning 
disability
No learning Learning Total
disability disability
N % N % N %
Had EEG 80 69.6 47 74.6 127 71.3
OK for no EEG 13 11.3 2 3.2 15 8.4
No EEG, but needed 13 11.3 13 20.6 26 14.6
Need for EEG unclear 9 7.8 1 1.6 10 5.6
Total 115 63 178
Table A6 Sentinel Audit (specialist care): neuroimaging in people with and without 
learning disability
No learning Learning Total
disability disability
N % N % N %
Neuroimaging status 97 84.3 39 60.0 136 75.6
satisfactory
Unclear -  no clear 4 3.5 9 13.8 13 7.2
description of seizure
Neuroimaging status 14 12.2 10 15.4 24 13.3
not satisfactory
Need for 0 0 7 10.8 7 3.9
neuroimaging unclear
Total 115 65 180
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Use o f  AEDs
Table A7 Sentinel Audit (specialist care): number of AEDs taken at the time of 
death in people with and without learning disability
Number of current No learning Learning Total
AEDs disability disability
N % N % N %
0 10 8.7 5 7.9 15 8.4
1 56 48.7 19 30.2 75 42.1
2 33 28.7 26 41.3 59 33.1
3 15 13.0 9 14.3 24 13.5
4 1 0.9 1 1.6 2 1.1
5 0 3 4.8 3 1.7
Total 115 63 178
Table A8 Sentinel Audit (specialist care): new AEDs taken by people with and 
without learning disability (in those taking AEDs)
No learning Learning Total
disability disability
N % N % N %
No new AEDs 68 64.8 31 53.4 99 60.7
New AEDs 37 35.2 27 46.6 64 39.3
Total 105 58 163
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Comparing care provided in those with learning disability according to the 
suitability of specialist seen
Table A9 Sentinel Audit (specialist care): avoidability of death according to 
specialist seen
Not
satisfactory
Satisfactory Good Unclear Total
Unavoidable 2 18 3 1 24
Potentially
avoidable
6 13 3 2 24
Probably
avoidable
1 2 1 0 4
Unclear 1 5 3 4 13
Total 10 38 10 7 65
Table A10 Sentinel Audit (specialist care): documented evidence of having seen a 
consultant according to specialist seen
Not
satisfactory
Satisfactory Good Unclear Total
Yes, in last 3 
appointments
8 26 5 1 40
Yes, at some 
stage
2 6 2 1 11
No consultant 
seen
0 6 3 5 14
Total 10 38 10 7 65
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Documented history o f  seizures available 
Table A ll  Sentinel Audit (specialist care): 
consultation according to specialist seen
seizure frequency noted at last
Not Satisfactory Good Unclear Total
satisfactory
Yes 6 31 8 4 49
No 4 7 2 2 15
Total 10 38 10 6 64
Table A12 Sentinel Audit (specialist care): clear description of seizures n
according to specialist seen
Not Satisfactory Good Unclear Total
satisfactory
Yes 7 33 8 4 52
No 3 5 2 2 12
Total 10 38 10 6 64
Investigations o f  epilepsy
Table A13 EEG status according to specialist seen
Not
satisfactory
Satisfactory Good Unclear Total
EEG status 
satisfactory
7 30 9 3 49
EEG status not 
satisfactory
3 7 1 3 14
Total 10 37 10 6 63
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Table A14 Sentinel Audit (specialist care): neuroimaging status according to
specialist seen
Not
satisfactory
Satisfactory Good Unclear Total
Neuroimaging status 
satisfactory
6 26 4 3 39
Unclear -  no clear 
description of seizure
2 3 2 2 9
Neuroimaging status 
not satisfactory
2 6 2 0 10
Need for
neuroimaging unclear
0 3 2 2 7
Total 10 38 10 7 65
Use o f  AEDs
Table A15 Sentinel Audit (specialist care): number of AEDs taken at the time of 
death according to specialist seen
Not
satisfactory
Satisfactory Good Unclear Total
0 1 3 1 0 5
1 4 9 3 3 19
2 4 18 2 2 26
3 1 5 3 0 9
4 0 1 0 0 1
5 0 1 1 1 3
Total 10 37 10 6 63
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Table A16 Sentinel Audit (specialist care): use of new AEDs according to specialist
seen (in those taking AEDs)
Not
satisfactory
Satisfactory Good Unclear Total
No new 
AEDs
4 21 3 3 31
New
AEDs
5 13 6 3 27
Total 9 34 9 6 58
Comparing care provided in those with learning disability according to whether 
or not a consultant was seen. (In six audit files it was not possible to establish 
whether or not the patient had ever seen a consultant.)
Table A17 Sentinel Audit (specialist care): death avoidable or not, according to 
whether a consultant was seen.
No consultant 
seen
Consultant
seen
Total
Unavoidable 2 19 21
Potentially 3 21 24
avoidable
Probably avoidable 1 3 4
Unclear 2 8 10
Total 8 51 59
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Table A18 Sentinel Audit (specialist care): use of AEDs according to whether a
consultant was seen
No consultant 
seen
Consultant
seen
Total
0 0 4 4
1 2 15 17
2 4 21 25
3 1 8 9
4 0 0 0
5 1 2 3
Total 8 50 58
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